var title_f38_59_39856="Vertebral flexion teardrop fracture";
var content_f38_59_39856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexion teardrop fracture of the cervical spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39856=[""].join("\n");
var outline_f38_59_39856=null;
var title_f38_59_39857="Repair median episiotomy";
var content_f38_59_39857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of a median episiotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 589px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. 2nd degree median episiotomy B. The vaginal epithelium to just outside the hymenal ring is reapproximated first. C. The perineal body and bulbocavernosus muscle are then reapproximated with intermittent or continuous sutures. The perineal skin can be reapproximated with a continuous running subcuticular suture D. Completed repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39857=[""].join("\n");
var outline_f38_59_39857=null;
var title_f38_59_39858="Nasolacrimal duct probing";
var content_f38_59_39858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasolacrimal duct probing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 387px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGDAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDx4yNvJJJYeuada75ZOSeD0pzLwF2dRwe+a07C0YqpCkD+I+ldRi3Ynsd6yDAPHGK2pLjjy0O0e1MxDEgWPBY8fU0kduRnu3fBxVLQxbuPhiTlpixx0JNTrJK0eIlO0+npTVhC7mdt5JyAR0qeCJpfunbkZxjNNWQmzLv7J5mJYkcdMda5u5t7ixvRPbK/B7nHHvXeLCMDczsQMVWvtP8AtCMAAvpmpcOZDhVcHdGx4C1xblERyQ9em2c4KjIORxXgFqJtG1BJ0GcH5l9RXr/h/VoryCJkb7y5xmvHxNN05Hu4esqsbnXxyDA4JzVjlhzwMdM1k20vzZHT61bS54I5561yNnXESRijEcj0xVG4Z1JHOD1yau3MwCbVcFu/esy8fC5BOTxiotc0bKt22BwDx3zXMa1MI7Zy2c9637idgu3jHU1wnjfUo7axkkLKoUetCjeSSFzJK55wb+aLxeZ7bG9X28HqO9R+MFmN2XfbkEH8T1qhJOqoLgIVdTuyB1B610GqhLvS4bsgMJEIIznDLxn8sV6b91pnHdTTI/D2oH+3YYWQt5PA2+pFeqREuyfMCT3ry7Q4hB4rQ+bbTZjjY+QdyDKjj6jvXq1urMTkAeikV6ND4TxcX8bEijdwzckKemcYqzsIjZsbTjI5z+HFMjYZQM4BBwR1q1HukgZkGMEZK9q12ONsryJhFXcdjfeA7U8kZKkEY74PT+dOMfmZbkZ6EkYPH5U0SN5eAGwOozjPvjrRfUOgxkSNAWxtYkLmldVjYZKjbyMg1E6AqRtXB6Etx+dSMspyu0fKcHHamncQuWKI+Dhj1/z/AEpcYYFmUcdMj/P504Hei4AZVPPJ5+nr+FQhirqMcsPlA/lj/GgCWOMFSQ4Rs9faopUYhjEQVUnDEYJ/DrVlWk8xZA3IGDlgMcdCe1MDyBmXhcn5gAD2/M0CKwt5C6lTl1/hK5x+XFRhXGeOSc8f5/lVp3lZypVUZc8AdR64pih1JAJBByWzxj2P+FNDISViwWi256HueKF3bfmGFznFSyEu/mJu5HOePxz3/CledNsQST589CMA/hTQFeIb9pQsAAQMc5/pTkUhAT83YkDpVjc45Rgdp56ZH0HSo5286UMSV4BOBn9BwKYXGDDDZjnqDyaQmNwFA2t3wO31pZJlbcY33Bcc9fw9qr8M43DjnnO786BlhAu84Iz3yc5p24hgcA9iAP5GqxGZQytkfnTclCGyGO7oecfhTAtKysoDINnfPOKZGod8LhQDgc5NMEiO5LZ3g8beRUnkjcSdpGfqadhXEELKxLhgRxxUZt97ZCjHOTVmJmO7JIBHKnmkBBAyQwx+P5UJBcSyhYXUYGSCwHTPeip7aVTLES20KR1PJ5or5jP3TVSHOr6d2vyTOvDXadjzO0s0H+sTJx74rVjQKhCIAPamuEjXaDljVmFOARhSffNfQWIbIIYVA+YEkc4Hap0Un7pzjkcGra22Cd3yknOfWpFUcA5wBz3FCRDkQJE80TOy/SpoY4o2IcknrxTo9o3c5447VLb4BYsgI460yWQqNzgKMDtjvTro+UcgktjuelDykyggnJOB2xVTUjsQ8nPfFFwsRXVol5GchvMPcGo/D17LpF6Lck+WehzwKuadCXUb3IHuOtSX1pFLbtGO3JPrWFakqkbM6KFd0pXR3+l3scsYZzkY5FaLSIEyARXkmj6y9hOLS4LIxOF3Gu6hvxLbKFJ6da8SrTcHZnvUqimro3WuBghSM1VuJDsHzDPUn0qlHIeSjcY/Kqd9cBImXeOeuTWKdzZyG6ndqEcg/N1/CvL9Sj/t7XEtS2+2hYtIw6Z9K3Nf1Keac2OnIWnYYZ+yA9zVvRdHGl2CRoyszEkuepJ75r0MJh23zs8/F4lRjyLchvNGtJ7DygnlqBjAA5FcxBbvbLe6azjysedGCoPA4Ir0DajIFVlO0n5T1rE1i2MEqXQ3YQ4YgcFSMH6cGu6tS54HBh67hPXZnH+AYhcawZkQhFY5wOvPrXrSIzBl2MS3KjIxXFeAbWLTp72DdukjkIBY8sK7LzWKrGGHuB0xz1Fb0laJjiZOU2P8sgruKBj1BGcVKq8b0bBJ5Ycg89qiVkc7WAKkYOSSAeMdOalKo2NrEvu/h6nn16GrOZjyQCqKHbeDhSRu6fkaaREdgkCqe6hjtzjv3/KnqisGAJVlPzLj1HcdfyqJYdwDEjapHzHGemMZ/h/GgljQsW2XKRYDcE5GePX+lKIoPNYq8apg5AUjB9h/WntCdpOSORtBI549P4vrTRs3DbGoBznMvfH97t9KYDTGoYZKkqc/LJ79z/hTolBJ24G7uGAGc9u5/GpWjRkLBMcZ+6PzA/rTCuLlAc7jk4yGb15PTH0pWsA6ISgjaoDA4AYAk8fkKjjhO6QxhmkyN2FwBxzk9fyqUohVS6koxwoyQAc9vX8acsK/MrSOTFjcwBz19P4frQ9wRA0LKV2x7fdhnP09RTXY7geS+7gDkj39BVn5VVnhl6AAbsj169/xFRvCS7cjOcjcM9s8Afzpp3HYryEtLuZsnPTGec9z/hTFZCPlVQcZLKeD/jUzwqhc4USEkkEZb67Rx+NRrHjcMY2nkg5Pfqegq0IR9hADB15/iAx/3z/WkYBXWNJcAZ27uCeemBTcIzMSxA9FyF6eppuGU7NoVM/wnYOT70XCwssT/IO7HhcZP/1vxpksLK65OQeNgYnt6Cpug6rjgY6DGT26mkdmKfNnacdTgHj0HJp7rUZCpChEMQDEnhqbIwjiZnKgHkZ/wFTgfMd5/dY7cDP86rTxRvgRsnTBy2wfSmNCxPHIOBtQegwD+FPOxFZUlY+4G0CoIVkG54xlRwSO350Bx5YPQd8DJP4mjyBovK74UKNydCRxUiLGFJ2Ee44FZ8MxSTaSN498mrJZiN258DqRyapEtFiBQbhB2yCaKitpx5yhdvLDPcmivns6oKpOLdturZ00HZM5kW2XMnVe2KkZVjA8r5hipJm2lQi/KMAjpTJmG8eWvJHKivaaRmLFJIGBznjNOkmILDZ1HQHNS2wBj2lW3juadHDGAx6H0osIitwJNw+5z3qwVkk4jPC+tIGCRb1GQT3bmoI5GMpJc4PQ56UtgWpZKKGjbkY6571nXsivM65+bP3WqVZVDPlt5bPWqkEQMzyHk54AOaGxo0oUUQIX+99OPzqZ5IkTBZuRknrU0MYWBFQbgVyRjOKaQQQxiG0DAOP1pCuY+pWsGokZHAGdx4qG2utXs4xDabLiFM8McN9K2Wt3dGzgHPYdas2VmiFt8e52A5BwevasqlKNTdGtPESp/CzNbWNQjiy9jLu9mFRyDVL+HcoS2Q8ks25wPpXSPZxyIgGQ/JKjt/n2p1paqC6vt9cHP5VisJTTvY2eOqNWuYFlpiWVuWBYuclpCclj71dtY3GCN27sOPWtiWEJk5XgHjbwB9e9A2klBncy/d27e/8AnpXTa2xzOo3qzLeCVypfAkbOR6DPf0qDULM3OmyoHBHI25zzjoK21jMjMFUdlI67eeOO34UySLyg2Y1G08Meh45+n409yec4DQj5OuxLOu1p4fLYBeQ6cfngA12qQlWwcADG4Ae1cxrES6XrsUiqI189ZkZuOD8rcfiDXaEERq2wFpMFWx1/z71NPROPY1ryu1LuRDlQmD5ZOeRz0/P+lNijd2Z9zBn4Y4wDz09KlbzSzZ4ZVKkjnt/npxUZzlQNxck8evT8K0Oe5cEGFO4MdpHO37gz/wCO/rUarFtUclCQFyT8xz69/wAaRpWc7wNuOcMC3fsOo+pqwxbzJSQQSp3AtyRnu3Q/SjqJkBTdu4IPG7nO0e/p+FSqmTEhQszcp0yQR2Hf8aAuwKzAY42HkAHPQDqPxqJ1MeG8pScjdgn3HPr+FGpIohZPvKxHRhnGOO57fTpQ1uvmEGFxkkjHTH+72+tOSY+Wu0g46dRnB7f/AF6dM6rC5Rv3hwRjgLx375+lAyLy/lXy2OwnlicgjPQt3+lPVAko+VlLkbVVzxz3X/GlaQn90Vly4J5AyeO3b+tIJnExlMh5G3rgdup6n6UDHmQom8MxKNgnIyPz4FMICKfmADDc3y4B4/vdfypXnaSQRkfulBwGXrz/AHe340xSxZVbBYjA3dV6++FosFyOZQgMgkKjkYyVAH061GWMjYZyG3cLs6H2A71ImCjKVO7o2D0JH949KZsWJXLbsemdoPTkHr+FWrgRSgb2DYaTI25HzA4/IUSNmQGM/vemVHmnp37CpgELqGB2NyRj68Adfzqu7Rk+WcqMbhuyTwPRaY0DbmkBGGZiMheSOe57fhUkRIlG5cHIGEXJ6d27UxkzEnmD73G5uoP0FR4QYALbcrne5JAx2A/lVIQ5hEJgQMOSc45x+NKISMIF3HnlBk9+pNNVcxxgbXGf4ht+nFPlSQAq7YU9A/8AQCkMrpEUZdmWl6/dzj69qiyN53R7iT94c4/DpVnLlQrhANoGScA++OpowzL5ZkB9d3yqv4dadtR3IHjR2aRmCtgcnk/lTzAVTdGH9SOx/CnSf6sCdTs6Ag7R+VNy6IrwzHb0K9PwosFxIHKXUcjxqBkDHSipIZHEqGSMhGI+bAGefeivGzSEnONpW072N6TVjjJ7wyyADjBz7GriyN5+TkjHQVnxqFkGOCenvVsO4lUgYI7A5zXqEs0I5GTAXOO3eoluFDE7j6etVmQuWGSO2B24ojtSAnPU44PFBGhO8/mRsuSoAzyKZGJMoGYFAOq1ZeMR8BQzAYPHFRyyNErgRggDbn/61KwX7DWxbgylVPHr0p+mgyy7kiwpG7JHIqi1o0wWWVmVR1XPaujsIFhhAk5G3g54ApDbsi6IsDeZvlUdqmW2YRlCzYKgk44HNTxKXBXyUXaDtU45HrirKRMqSeZtCDbt+UkZz2PUU72MWyrCkaIMoGQY6nJX6en41NByDIobc3K7R/Dn0qRFOx0YbGGCQx5PPr/F9KBCwX53VFwdu77oH9D7VIriOHy25FI9FGRwfTrTgriaJgV5UjIOO3Y/h3qYqHJePAdSw+Y5J6c5H8qbgGQKWJctj7uM9eo9KWwIjVWZGB3FiCAQOemcAd/rSDMk52Kisc8Kpx1Hb196tRooSIYLAnkhsBvl/wDHajkdSQoX5yMJ82COAcBh2+tIZAkIjAbA3BuOcgc9j2/GlCNNkktnJCnOSTj9asPI29wm1XPBIUA43dMdx70hSRXCq2EVwqhQcE8jA9KG7Acv4u05bq1jmWNikLkNgEhSwwD65BOa0fDokudLgeVW+0qm2Xf97Ktg5Pf6Vdv7aS6tLmE5yyFdwfBHHb16VQ0SJLeVoZNzRyxrOC5yFcHDj65Gfxqb+96m696l6GgIo0kGI94k45AXHB/75pzQ4w7IvA9ucjsP4qskETFWXLA5DFvmxkjJ9fpT0UbSfMUBguQRnJ5/74rS5zlBoXHULGrAspY4Xt36/hTsMHkJYcggnbk9Qfu/1qzI5J6xnahwfLDADb0x/F9aZMuYcLGNjg8EgdgfvdvoaBkRQgES8lN2FBz3/vf0qMMq4eQDg8ELnPzdMfwn3qdzvO7Yu9CQWK7Rjjjb/WkURkNhd2QWx0ZefXv06U7iEKsz/wCpILE5HBON3Ut3HtSiAISAp3sMoO54P3T2pzRxhsBEC44bkLuz2HrQAgiLFssoG/OffhuaEBEqHlUClhhmG0gDj+L/AOtSmBmfcxx16qC+MA/KO49+tSBEJjMUsiyEDZkcrwfu+o+tNBRMsZGYDcCDkKeB/F/CfaqeoEM0BVWBYEEkZCkDGQfvd/pUBhfYAQgBbCk5A69AOv51fkdTGDlmBY8HPHTt/WiTgERkswyxGQxxnufT9aE7AZzLL8iKGyDgYIJz9B0/GkBdXC7zkD+IbivHTngfSrjWwdOFXIwxxlVIz69WqGIkpwoEJHO4/L37dTTT0GMYnZ86rtyOV/kT3/pTFEXlllUgDGCn7sdOhPf61M6RqR5nllwBgFfm7cgdB9ajCp5ql9wlPAHDvnnt0FPcZGsbiFfLZSGOfL3bV/8Ar1GXMcPzbvL3DIXCg/j1p7wsQW3hpeCqjlscdOwqF1IdllVlmzkgp5h69c9B1qrgERVQ0kfA6Hae+O5NWEEjNmPp97EfHY9WNZ0o8twshbqMZOT/AN8jpVxZQUYyOnp+8PzYx/dFO4WLARtpMigY67D/AOzVELXzpSycN0XAwfxY1KCPOAuNy45TzD/JRUrQq2HkXCnnc54Ax6DtTFcyzG6yLsyW6Ejn9TT03Pu3KCVJywIOT9auzxgKCC2MZG/oT7CmmM+U27bgg8Hp+VIdyukUbTqQ20g5G5S1FWmidQN+Tn+82Bj6UV4mbYmVGcVHsb0dUzz+3RvOIjxtB4yK1La2baAwG7d1NWLC1KsAyj0//XWvFCnmfMVAA4HPWvZin1M5yMuCxBYk5JHLcdqfP5aqdgbaRwB61oXKYkwGCjH4YqlIWLEAAKwyMHrTSsRe5UlYNMwXA3cfjT4LASA/NlSefU1Zs1DrIfLDbHw2V5/Or5VFD7nYEEMMEHjpSauHNYrJbLCm3B6fKzDBq9bK8qZL/IV+bdxnpVFnB3qnIQZPJHf9a04CoC4YElAVbG3jjqOhqRMsrbnaVVehOOBu/wAMVOyoWY5kMZHzEOBzn17/AEodWe62mBWXJIRAcYx1x2oywVmKkLnGQQQenHPGfpWYCBVeAFVYngg9R9707fWmtEpbAQYLEAlvmPy9ux/GrIliSNBIZYxt4DYBJ3dM96VzELc/LJsLYZSRjkUtRFcq4ZlXAUZVgg4zgHle596c0ZJDEqSMcZ9+x9fapTcRK43BOON5OSo246jp+NIlwglYrGsmxOeMlhxzz1pajGxgqVKDkuAyj7wGSMn1FQCE+X97ML4X7vHQj5geg+lSSTJvDhGEYl/hHAOfzFNfzTJtYbslSpL/AHjk8A9z9abQWJAhABPzEIcAnAPAPB7DjpTpXHnyNiTHUhTz1B/Ec1XIO4fOA+05G3/Z7r3P0pqRu6SEyKFUEnKna3IHXqD7UrAO2BnVQUHGGxwG5Iwvp9ayXQ2N+7+dKEV1b5RkKkgwwH0YL+dbEkR+2KJGYnGSW4Iw3XPf6VR1GEyRITuMbnyGXAHyuuAxHbDBT+FTPa/Y2oW5uV9TUYx+bIG2BfvY28E5H5NTt4CrhRgkZycOBu6Me9MhY3MMZZXEhUKRuwwYYDAc8jINSCJQBIQip0c8so+foB2PvVJpq6MpKzsyFmhQliUwBgjsTz/3zULssq/dHltgA4wynb6fxVYW2wwBRN4J2gjJxzyfWnoIxC2VARmQ4C/e+Xqf7tVfURXKxeWzPIflOCp+6eB3xnPtTZBFGQizK4+bY5XPf07fWrDJviDAJlcYOwHGV7etNMaiLau3YpJ2gDAOR37H2pXuBBI7MrtvXcGIPPTkH73f6UpVgX2yxNg5BII7/pVuaLbHMNqNJ8xLFRkjI6j+tNt4twC/I2TlQOQPm9e/0NVcCphhGhLwIHO1hg/QZ9fwqQL+6ZRKhYEjPXjHbtj681OgV3UyqCDwf4WOCcZ/u/UVBsGBJsTCDjIyOnoPvD3ouMc6lAqqEkUg4CtgYI/vdfwqOUjHzRLySCMlVB47DnNS+UomXzADuYtnOXHGflPTHsaSSKNpT5cbnqrFTgdM5LHv7VQiFwQMOZA4xjncRhuy9vrUTgDBEh3g5IAy/fqei1M6om7hgR3PCgZ9epprRZjVcRGLPAYFQRk546n6UILEJVtjeXvIKnOzv05Le3pRF948khiB8nCjk9SecUnlEH94pZgCyKxJ4wMYUfzp5YCQJku4G4GQbsd/ujgdataBa4RzB1UlV2+ucKD9e/8AWleRZt5MknzDgr8i8t+oqJQshHlqTKyfKVIycHoF6DpUUwU3W0ktnkbhuYEHP8PFCY7DmRJHZPlxnA8o7B36k9arCMFwsGDgn7qbB1xncetT3Kqzq0x+bOMu2eeeiims0jne5yy/89Gz37KKYDFYoF5YnoWHr/vH+lSK/PGVJYDEXzE8eppGyypvIPAIEoOB9FFT+WAu5xnndy+xR1HCelUAnBTejs7DBOBluvQntUsMrNIcFhuzuK8nGPWoV3CI/uw6jBDbtqjp0HerDIqqXCgcH7xKrS6iYrEfL90BQeg3kjPc0VHMG8lRJuZD0OdoPPTFFeDnFKM5xu+htRbSZUggUN83yk+lW/JCr8uTnj3FMH7qMNt56g9hSSTkMAAC3XjivdMHdlW8BIO0Hjg96qxQtjdIOcEgZz+laEqKUJduSMkHis5pOpORjjBOcGlcaEWZ4kWKPCs31BpwR5YX34IbAK446+tS2luA7SyhipBLLnd9Dz0q3I8NmmWePcgI3EYAG2hspK+xXithHlZXG4MCDnOQRWgbm2t4QZGiiXhWDEBTnoOenHNeda54ufzDFpW55CB+8PReMGuY+yz3btLdzPI5bJ3nj8BXJUxUYbHpUMrnV1loe1J4n0IBojqUOwtyu/lmxg4PYfjT7PV9Nu5GWLUbdyhILFsKDjoqnqfevHo9LhUZaEHnIz0qZdKhfOFUSd8D+tcrx0ex2/2IraSPcUj3uZBLuO0gEFWYnjg57U1rUIxE2OCPunBXr92vFrSOe1d/s93c27kYbZI3IqwXvlw0d9d/c2giU5Ap/XYdjL+xJ30kewxJEZdu6NC3fOAMj+LsTmoJXtFIEjhYlPQvxk4+Y/l0ryKKCb5Q91dbVOQPMJA/WrK6YJFLFpJBnLEsetJ4+C6FxyKT3keo3V3p0UpElynynerswBbnv7Uj6hpyPE0lxbgMoJG4APyc7R2+teZrpKksGTdkYBzk49z6VPDpMW04QEZxuIyBWTzGPY1WRd5HoH9t6UoH+mW/B2KRJynGMCoZPFGlRTSeZdQBdrL9/dtJ9u5yK5KPRrUjYkC7s4Z8YB+lSpo8bOGWBBkEEnvUvMl2KWRw6yZ0MnjDSoJFKSbyDux5e5SeuT/hVGbxVpc9vKjSTEuSA6pggg5BJ9KrNpCOAhjDn+HauM1GdHidFUGPkfNx0PYAVDzFvSxrHJqUdbsvHxbCp8yYOx1CFbiMRqeAflcD0+YE/jSp4utNxzDcL8uAwXIH0H4dTWPJp6Lp8AYK0mnXRC5GP3Uw/kHH61rxWCAFVjVW6ncAT+VOWOlTSSFHK6VRty3uPi8UW8h3Pa3WSxfAjzz6n17+gq7F4jsm5LSxk4O148E46ZP0qmtgwJ3fMSD84OOD2qRLQ7izlSQM5J5b8alZlPsU8noEyeJtPjV1VnAAGMRntkfLUkXiXT2VMysm7ORsPU9/f8ahjtIwwBiSNB6c8ilGnjCsyFFcnnHAH9Kf9pSXQh5LR7sunxHpsjP512obJUjaQT06+nTtUg1rTBl1vLcKrcFc4JyDwO9Zo0vYgddjoudwYDiqr6ZC0bbY02McnanKg9qtZi+xDyWn0bOlXVrASxhL+12nnmTqM5+b0+lOWaGSNWW4THAXBHAwRwP61yk+i2rKhjVJTjccL1Hv6VE2lp5X7qLb2BQ449KpZilujN5GukjsRDlGWMI4zuKDGGyuOT/hTzaqqx7oRIOnA+UfLz9a4RLCeBF8m6mjYdi/TrjA71Yt9Q1y3iRhcpMckZkTJIx69q2jjqb30OepktWPwu51MsSnBAkR1JAI5J6cemKHDCX96zb8kE4DN17tXP8A/CV3lu5+02G6PuYpM5+px1qxb+MdJlkSKV/LONwEq7V65IJ7muqFeEtmcFTA4invE0/JcYG1kXkMwfA6d29aJ4mUfKkhhbqSvy5wOp6n61Pb6haXgj+y3FvMNpYfMCcAdAvrz3qYAsFIGGyVUr8zYC88dq1TOVpx3RnSxhiMxr8o4JXZz7LVOWJlhVXLqHy2W55x2C1vD55Aki7m3Hg8njHBPaoTblj+7iKgMN3ksU7Hqf61S01FzGJcwmEFiu6MqGIUhNp4/E0ifKGZciR17r5f4ZPNX5LdS7uh2s2MAJgnI/vGqdykvnbsFjjLgANgf7xq0O6YkUjcqUJIydykDn3c09HhkJaJ1DA7tqDex69zxVWMQN8pclsnn/WH/AUqyPGQrDdk7cFgRj6LVXuOxdTcQBJsDDDA4Lt2x7CrEcv3lfIkyRlhvJ/DoKgilfyVjTqASVHyD6c81LDPuV1eP5VPSM4B465NFiWIFXedqgHI++29jz+lFTxIrZWNmy5Hyx/cHPc0V5eYxblGyv8Ad+ppTehnzy/u9yg7gOQOBTbZGkf5lPAHApILQmZS/QD7ueRV43UVvCXlkCKnRjxx9a9Mi19ESGJAnzIOeMKaxfJXzyzgAIMntnntVLU/G2m2G/yS1xIrE7RyBXJ6h4q1LVIz9miWCMjGcc1zzxEIdTro4CtUex0+v+JbbT7Pyy/70hgEQctzxmuEvr6/1wsskrx2hbcsWe1FpY75mlm3u7Hqeua1fIMcWUXcPSvMr4xvRH0OEy2FLV6szbawSIADAUDpir8EChdxGAc496sxxlUwU3cdxUsUeMErx/dxXnyqtnqqCRBDG2doG5T1BFWYYmYEBMOP4hzU0SHzARu68qPSn/cZW7nhhnFZOVy7FZYBlAQefU1OlqmAzA5Jxx0qcwKIMqpJLZ47VIqKinyizHqv9c1Dkx2IjamPAUIM5JJ6VKEUOqrlsjt3qTyiT87Bwecf0q5b2+wARQ8tyT2xUuRXKVI13R8x4A454zVu2tQFyFG3PQk9PWpWi3y4IwAOQTxmnpiJflJwxG5utRcfKOVmPARs54AHSpREmfmLZxwB90VICHQhyxJH3ycZFPjVFKlipT0HUmmS0M2hio+Ygd89BT2jQIFRWEROR/tVL5gKbNnv9aIVUFnjOTgYB5C0JktFWG0S7uJLNVIN5C0BJU9fvJ/48KbahNkUvllXK4J5znvWlbOlvqEM8+GeGVXzk5q9rNlFYa1ewQx7Y3cSrnphhkY/OtW7wS7GSXLUfn/X6mdGqOcRkYHBAGfyzViGNVYhoyX4AA+6PrUyK0kaxLG52g/c43D+tJFbCLcG3SA8jB4X6+9SkW9RLq3AKs+0sCSQmen1p63LiPaxVSRhUbstKJGjKgiOPcMe+PepGjBiQqkbhjlMkZx/hVE27ld/NMn3SVPOAeD7AelRqzOXk8so3QADC/iDWgYBHb+YvzsfvYHQegqvIkjEbgNo4246ntTTfUaRTdXWQEjyywBXaefeq9xbupIkkZQP4WU1pG3ReWVo1bsgyAaaUlbYhBJzksc5NLqMzWhKoNiFz1LDnmq09tKJSNkhQLkbD1rRlRCzMI5PmPLgY/KoZoSYXMMj+XnqBk4+tO4GFNbhnxsmwoIyvAz71mahpsU3lyHCc4Hp+frXT3MGYkJkxGeNuM4+tVlspVDxBEdDhkOOp9qpTsDijmTo0UoPkN5crHIZGw3uaqDWNY0oNGL6R4lJzvXgj3NdNKgfLSBY3AwdozyOOKy9RsvPWQOybWGJAldmHxcqcrnFiMJCtGzQyD4g6jp7xx6paJcRsTl4jtI9CR0zzW3pvj/Sbvf5xkt3Ulf3oOAemRjivPbyM2MktncksGOFYsAOnGT6+hrnbu1ks7hlkKMVfJEp4xnpX0lNwqxU4bHzFbC+zk4zWp9EwX9heCL7PdLL0xzkAAY4Ap1xCrs4k2ny14Yn6AYA6187Wcz27RyQzNbyjlfIz0yeCfWuosPGmqacinc00kYJdZVA4x1z/Sr5FucssO+jPUp4Y3kHmIsmXO1WG0DtwBVfyGRVeN2jYc9lUjH5muYsviJYskYukNtJu4J5Gccgn05rqLC8stRVXsbtJScfMrZPTG3J4z1NLlZm4zjuiGRJfMLM8SIRktgKfwJ5/SnRXKbRuJlXoA4LH8O1bC2e6bIK5ySpHzEr9T0qncWI4SQ7mwMAksRxnB7Ug5l1ESRG27nIIIOJGz37AUVVW1MOFaYwLkZ55b8hRXDjKlSMly/r+hrCKZjeIfGFjprvHFJ5tyOiL/U1wmoapqWvzr50hSIn/VqeMVSsrPzgZJSS7EsWbnNa1omzjr9K46+LlLQ+lwuXQp6talSHSlgIYncf4gB0rUjjCqNpxjuB1pScKM8/TrUkQZkGRxnpXnym3qz1Y00tiZI8rlSBnqBTwCp47npRCcAqEIHr61OkCqCy/MfesHI1SHCMsUXBP41a8g8IGYZOOOwpIFO8hOQp5UNVkFA+5myowAF5IFYtlWIjEVOF3FsDINDxCS4Gfu4GRVlF3L2y3IGccUMAJEOPvcY96nmGRjC98YHAAHPNSPE2QYyOfT6daddRqznapBVBjA7Ulqiqw3M5CjilcomQNM23yypA+9jHPtViNJyduUVSRlsZ/KoQSuDlmLDJBPSr9uwYgAkn19qGBFFbZYksxGey1OERpU2oH2np60RqWm3M3yAZxnHFWkjbdvVQoPUZ5NSO5GVkOMIM54BOcU0KRkkKVJwFHT61cWQorBVTcR820dB6UiAO4BUbMcL15p7k3IraGMyFclznp1GfanyRGN2UIoVj6Dt9KtRsgVigMYXgdBj1pY5d24xFQAOCx5ye9NIlvqQPCrHfIvXg47Y9aoWerS6jrc8F1EXuIIkhUg8sFJ+b64IrWiPmKS0QO3/a5P1rnpbe4j8TtfRAqhUeZkHjPHX8q2g9GjKVrpnVRKSMoysq/c7Ee31pywyhG87ehHYd6ZaMwCyhhgnO0859s1ZluQ7vuTg/eIyc+hpIGVtglReHdM8IcZFRnaDENgfJIBzjB7cVO7fNlVUADj/61V2VSzD5cFgRzyPxpbDRPJMI0KvJ0GCvOfoKrvIC64UxlTgjOS1PkTBYhm3HByDnI9KhlYkjqxPoO3+NPUasSeZHOS2xhtP3QDnPuKhnnxHskIYg9TxgUhfCHymwc/wjp7nNJIwBCEAMMAZ7mjUNB7EjcFDADgZA4461Wcyx4AddhGDwOPr70XO623sS7oD8rN6f54qvJd+YdpYgso4KdvpQh8vUjfOXKxqzr19DULSfPuMRVG4Gx920+1SkCMt5iPsJ2sOxX2qgLVIogFVywBwykg4o2KsiVzHjYhRxnKgjqKgu1gQMpQpJuyNoxj656055IQgikV89x1/WopJV8xjtfZ2Uc8UJu+hLRz2sWMF7A6qFLFcElcZx/XpXNT27TSR2V2+QqnyZm6DjhGP4da724mhlIkMSncApUD73vXPa1ZRzQgAFSSc5PbtXqYPFyoS8jhxeEjXjrucJdWkltOZJAu0HmJm689iKV4hOFJmikdFyp2sd3HC/WtaQGVBZ3KBZYhtgcHjbz1rAnja3kYTcIjfcLHn0ZfXrX0SnGUVKOzPm5U5Qk4S3RbWMqrFo2jVmKsqRgtGQRyQe1RmW4spN8Ek0WTuV48DIyecZ4prXj3RM+xGnYkyPg4cccY/Cp7UIUIeNoxv+U+QH2k54OT0ppKRN2jptL8faxYohuc3sJPBZhnHQ/Su20v4haNeJ5Vzvt2wC3m9CD1X/AAryCWGWOXymgBVuFPkbSScHpmqojKx4dA/PKlMEf40zKVKEt0fSen3tjdxq1nPHMgwTsIIxyeneivnnSZ7mznjksrma2bPzeXxnrRXBi6EqjTjp94oULbM6K3j2R4yB254q5FGoTgjn+VRIVlbC8/hzV7GwKMZx0FeBNn20UQqASONx6cVKAFYglgAO1SBFDAqMHuBTlZsHH3T7c1m2aJCxsuPlBx3zVlRtYuxOD0HaolfDA4I7DPerkcW4DJz6+1ZSdi0FtnOSuBnhi2KsQsTs+T5N2PTIqOHawK7d2c8e1Wo0BQbjhk42jms2NonlTaSSp4A4ApuwiQsq7cKMgmg7nbexChRgL1zUsY3L8xwAMgkdSKiwD2JM26PkkcgjtQY1QcDIPzHb2p0LAtnAb5iD/sj6VNGERSW7/d+h9qAsyAKZbgPnajD5mPYf41biYF5EViAvG4dDmoo3Xeu4Nt7rjjiriLuix3z+GaBiIF2AgjI6GpLd3YnYSdvp0H1qRYisYVR0GBt708wiLashO3GTzmn6iEEe6IZQ++T1/KpYkCru3Mv06VMhGACm0jgDGBj1pwd32thBGowB6mnoJkMdqyIJflZScnI/WpXYYAZvmPTAzipQGVcjCucZYnIpA5Epwnyn7xHehWJZDtDSYLqjdfm4z6VHZI0088SllV7V8jOcshDD+VaBh85hvTdkYVVbGPUil0KOKDWdPmcZBcxs3QgMCMfrWsH7yMqnwuxCvECPGwCP7HIHrTAWkGFLbiOCDxmp5YhbGaOGY7oXaMccgjtj0pkKHageY+aTnKng1PkUtrkAWSOVwSwZvl9h68U0viNSB+8wc8VYm3K2XcSI5wPUVBIquwjAzgEqFPP4mj0GUoyxAyxRevTPSkEm8sZDtGOCOp/CrFui4EbqS3OcngY+tQFyv3gpOfTrTTKsLIpjRFI+cgbCw4OOxpolkcAhECkkktwM1FIpfc7bzg8Kp6UxY/3Stbyjk5O/Jx+FDY+XQneUsocsWViAMDP4VRmQtKXVlBIx9PbFWJnJWNWh28/w9D71XuIpGkJDHg9SMce9S2VFDI5ZQGBXEZHReefY1DdEnZvLeowccGno0jAsrx/ICD35+lV2X5PmQBWP1waLhbUjkxgsJQVXCsdu7j3FZzhbiUCJihAP3Gxj2wauKMEPMpVc9Y+Mj1qvMWztVdy9mJAI56VcQsVGLK5tpVYoD8zYyR7j61HeLD5hCKJAwKnBwfwzRdXHzFHVI3DfebjAHbNZ8042hWXrxuz0reKIauZ1/ZrPbOqschc++ayhE14vkXXmGdABGmOFGOo9RxyK6GR8kjcrDpgjNZV1aHPmwsyOv8QJJX3r08HinSdnseZjcIqyutzlZ4Xt22lgB944Y4b0K4qX90kqbVjl2jLsC/zdxx+NbcSpeRPb3IRZojzk4J4PK+/TisW6iMEzLxgDAO84I9vavai0480dj5+UXGXLLcthkuYsmMbz/DsY4AAwQc1X2FfmCKx+7zG3B5461DDdPtDtGDEfkAy3B+tTSuLgN5W1nB6Irck/1q009SLNEtuVjlU+WoVjnlCADzRTYz86nIUg4Iy3z8/0oranFSW40dbCduUAx61ajYeYCSQR6HrVXaAy4JbjmrUAy3GcD1NfFS0PsolmPCpuAx2+tSgDIyDwOnSolYbSCGGO2Ke5YjG4dPyrF6miHnLOJAxGOg9qs28uEKBScHjvVSD53UDJ+vT61bhZ4pC3y5+lTLzKRcjPGxSBk9Mc1OQUVgThz61FahAwYtuZWyTjOKss6ozFcksc7ulYsBFz8oUE8ZJqeFG2YywOeB2H0qFVA253Ej0OKsKCTjOSo3bW75pCuTqJFBAAHPX1zShS4QklW5J9OO1PRC67nHl8FiPT3oRfMtSEJwp3lgeopJXC4kDHyXV0wSOAemSasrECwZsHjGA1JEgCqGy2CCD7VNMgJHlnOOSQepq7aDuADruwdi/wjPOatJGY41Z2+brtbv71XRmMjbV3DH3m6Z74qwrMFaRlVpE5wR2pWQXE3vMdgI2ryT2q0zoMb3VgoxhfmGfpUbRx/Z9su0bvmO3jJoJG7OxQoOTjgEU2rK4rk6EyN5gkDA8bCv601zhziRe/GOKmiIlPykLuHAz0/E1IYBHGrAI7nkk54+gp2uiXoyDBCjbwg43f3T3qpMzWjmRnDhSHCPw3BzxWkzlZG4BDrudscfhWdehZWlVkO7AwX6LVJIV7mn4ilVNUa5hwpnVZ0PfDLz+tZlrcPlgAmEJ4bnPqfrV/V44rjRNEumOP3RgYg9lPFZqxx/aWMbopBzjOM05L3r/1qRS/h2fTT7tC1JJFK6FEDAjJXGOKhVYnjXymVGY/MVBHepWKqicY3D7w9qYU8qNxv2kjIHX8KaKILldinzpUPbaB2qncfOD2II2qPT39Kuk/uNygM56Dp+dQSRsrMsqZ3DLbBx9fwpNXGnYoqsm7KBwqnHPc01rjbnOc5x8oqwruYl8kMzjPHpTEJBZZY380jJDKMVNrlqQ1pkPEbMynnEg7UzOFJXcjkcccAfWmvcLACREp2H7uOWqrNdxuoUliO+GwV/CiwXHysIgTGQX/AIlK9ahiujsZY5EZ25OVJFRPISwWJjMqDrnDD/GovORsSGB2KtnfGefyqrBtuStMiCRp7cBcbXIXdgVl3LwKxaFfvDK7n/L/APVUtxqMEshMoeNu5IIrPuow7yS2zK6gc+UQRj1NaRj3C5UnndFKzgR5bcsnVffNZly+cOpAPfP3TVmcSxsygBlYAgZ6VSY+XnchQnqAQVb1rpgjOTG7mZj5W3d3y3UVXe5icOsispHbJz+lS/aI3jypXPUAAE1QuZd27cpU+qGtoownIrXjDO+FAhTkN3qzDHHrNu20+Tcwp++Rn4k9Cg9eORVR3SRMkse5BFUkJtLtJ4GUSowYZPH0r0MLX9m7PY8vF0PaK63GS2zwLJE2Dkhxjdn8KiQmI4UuPm4IBGTXVRNHrdjJcbvKvE2iQdN3XAA9TWHc2fkM6AM5YblZYzg5x69+a9RwuuaOx492nyyI7aVRKArbSSONxH40VBG0kciYTG4hQcYorqw3vJ6DaPQYIkySScZ7GpdpD+g7VEvJ5+6OmKuWyl+eARz0r4aR9miRORjaM05gHjGCM9D61KiKDyQMds0103jO3P161lcoIgA20EEemKtLHvUFgQR6VEsYOGyQ3sKsxOCuTjg8jPJqJFIltxsj2rgdyTUwbdEoAwy5OcdaYoxGWYbu2BSwhmUgPuyORWQyWJWZyFKkkfmaswsy4DKu31xkkYqtbqqviQZZRgHPSr8a7WQMAMpuwO4oYmh2GLRiUnbjH/1qsWwBddg6/Kc9h6VDdBkb5RgZ2jP51ZhHysdighQM9OaFvoK2gscBDbVIw0ZOeemeKmKZhYncWCjB9vU0ltmJuWPCAH6Z6VatwZt0rKATgnPYdBRfUewbXOCw4xjb7k1KgEryErtIYJnpk5pcoGSLIZlP5CjMiFVt2VmJ+716npVK4tyWRVbey5I4BLcZ+ntQPmQMTgr9wAZyfepBaSBGjICyZ3Nz1z2pYgoURuOF/hHGPxoYrEShmBLsvH/jx/wq0RNKVWM7Mryf60jqBKnlKFUd+vPpmpACwO0neVzgdTVLYl66kTgxgpKcN90jHFYupzbkYB+PlGff2FbjNGVbBycc7ucD2rmtTCW8EkrnYyHhCcFj2496G+xUErma2tSyaY8HzMkF0JC7fwhlIK4+oFWLS7WYHOC4PI6GsHThMs2qwNg/bLKSRFHVGUhhj34NW9MuFmt0WWMLLgMpPGT61pUXuqQU/ilGx0ccxxksCB0HvUz3C/aHMj8nA3beD9Kx47kwwl0UHHGCec5xVqOUzRyCTbiLByx4GfT3rKMmU4ms88OCkzIMHICDOPrVFr51fbCrzAr1yML9adIkU0MZXbt2kMq9fxqm8ayzNHGu4gAtg8D0GKvmI5EI9zcFsJIsIALEld35AVCl0oba107sRwAQv545ouo7R1IaN7gBtu1WKoufU9z7Co1sUG5Ui8uNhkw23X8e+PrTXcdkV7lpCf3avLMOxkyM/jzWddNeIAzaUxUfMHilwf1q1OYbYukFuhckDYOfzOeKrS28nz4a3hOOcjOB7GmtNwa7Gba30XnZjtriJ8dGw3PvTHvpZHZjbGTHeNQv54q1HZWEQDtLcTknBMaEYP44zUz2r4Jgt5IsDI8xwc/UDoKttCRWe4NwqFFmTHUBsj8jVS5sVJPyxgschkI3D24xWjNBezBWS6tInAOcgflkd6qeTKkJlI85ySCRjn86Fp1KsijJZzhVG95FUZwCMiqxtjGA6owY/wB9c7vz4roEtUmRSsEKNGvBGQ1RJZoiqwupmBbkYyM/jVKYuXyOYu9JEqmSNPLmHJwuAapS2cyj9/17MO1dXOjyTfxEDpjAOKqXizoApjCjpkjr+FaxqsylSicvPbl1zH5Tg9HHHTtWTNuLkNtHuK6i8tl2kmNxuPWPjFZU1pE7FXZlZOzAce+a6YTOWrTbMe2nktp0njUZB5BPDexrqFnh1fTYisKvcIu0puYc88HHfjIPeudurYo3yHOOv1plpdSafdJNHu2g/vEB4YV6WFxPI+WWzPJxWG51dbouT2Ukl4NkCrISCqICeuP8aK3HEN3BDew7nMnTD5foR82OhGPxor26MY6tI8vma0NmNcKSPXFXUVkUEPge1YyTvI27A5PQVdhnk+XcB9K+EnE+2izRDYJfuTjJ706OYFwB97pjtVVmYEvyPY1H57bgQMH1rLluaXL5dUY4bn6ZFEcoIy3JGOgqhcSSpDnG4MeMdqInbG2QZI6kdKTjpcE+hvrImCU3YIBx1pkMmHwUKqT2ODWYsjo4RPmU8Bl7VJFKzsA23PSo5Crm4HDspVRjPJJxV1SgmKsSR7dDzWNDIfLVGUEg9farXzKrFCWYvlR7Cs7Aam/ejovQnPzDOPx7VZQgqvmnPQkLzk9KowyhyV4U57cVdiKhcKcfLk8dPahaC1JYJMLhgBubGe9PQkFckhSOvWoiyqH4425wegqZD+5XcMEfyoew7E0ceXLn/VAYyRk+9TLHtRcYLc9D0otWcRAMwPfBFKCwU7xyR2pqwnuWoYGDHLZ2YC88njqan37Yy5X5wM57GoYt1unAXPHI60THdICxKxjkjPem+5G5JHOG8pMAPk8HoDTZfMZVMg2MWOPQ468+lVmUkSAKrc5wRhqkmmVoApjO1CCTnrVJiHyEuWDKvIyoBwCB1xXM6vEjzGQjcF5ycmtvUSTJGXXAXOST649KzNQGZi6klSmCue9TI0iYOmhbXxBZXErhl88K64/hPykfkao2amz1GexuAQsMzRR7vZj3qx4hkNvaBIEUyA8t/d961NbiE19BcyY8u9tknU9MtgK345FdCd6WpG1ZPuv6/UcURioGOGzzRCuMyNF8pPAz196bFvWRFPJKHr2qdiNo2YXaPm/KuZaGrFG9CZrhsQkEhcc5+vrSoZJbclkEQccBTg7R1LGmqhd4y5yhGQgOentVuOQpGZJurnPAwPp9KtEyIAVSPdKpiskXau7gk+oqnLcAxCOygkiJP3UJ+cdyxqxOpuN6uS7KMgkEiMeuPWn2dulsA2x9yr0Y9Pr9au5JT+zyQTRFEgYsuRAF4J9W/wDr0sNq0kqmdY5ZR90qflQ1qxWYCOMKDI+703D0/wDrVYhT920FspQLyx28gd6Qmyi8CG42hfMkRQCSBgA8dKSS0McbM5GZOCijt9O9X9oQjygAzcHPBUetRSAlf3IYDJ/ef3vxpabgmzEMUtxMfOVIoFOBmMAD0qRbK3RDmON+7MF59zmtKadHh2IkZ6Hpnmq13bm4Pzn5sgBV6Gh6bFLXcxbjT7diknzlGGV3MQMVG9rGp2wWvmE87x91R610PlW8UMSMm+TsTzj2xVS5lhHmq7uCeFRF/pT1C5z1xpm5w8hO3HROMVnS6XBDja74wTtLE4FdHOY/LR4UY/Nlv4R+VUroqIyESIHqXJHNXGTQNXOfksIuMSuSTnhv6VRntNjPtc8/3hxW+y/JkQoHI+9jHNV3s4ssZVMuOQz/AHc+mK2jNrchwOMv441fBDAkYBVcDFZVxAwyChXA53c13lxbjaSyLhuoHA/DNYd/p6jquc8ls11U6pyVaLepjeHbw2F6UlcpbTsqSkdQM9RRTpYCm3aVZCcjPaivcwWKpRharJr0PIrYPmldHRwWxiULyQD16VeidmUD09aih3KhDHcMdTxUkUYLZTIbupHFfNTdz6CMUW7bzJGxu3VFdMY8E4U9CCM5qWJSRux5b+gqVh9qRkkRVI6Gsb63NbFaOXzI/LdCVzwQACKWIhGwrYOe/cVE5AHl8qwPalJBPoRxg1VhFlWjYORlduNw96lRysy5KegPQGq+dwBIO4cHHekaX5uSp244qbFGnHIUlAC5PbnpWpG4YKSqhiCeDWIG3HsTnJYGtGHKMjS4AC8c+tYSRUTWhkInAXBPVgKuxyFkZRjzM5x261kRTs5I6HHOO/tWhallyTtxjBOP5Vnsy2i7Gu7AJ68c/wAqnjDDIAYgnJGagj27R12Z6g1PCBuLKwIOccdaCS/DKHITaARySR+XNKjlFAOSckVDG7Y5BwSCxqe2JLyDywytyM8c9sU7kNFmObeeSvp6GlYiQ+ae3Bye30qJWcSMTglR0607e5IGwcD5h0NUmTYfCmE3RqS2eCe9LGrABCFGMqcjI+lPiUBiqBhGOdpHQnv9Kjc4JEp+Y8HaOg/xqhFXUbcLbs8eBIq7WXrgE9ayboMjkA8t3POK1ZZQ6SAhtudvTlvqKzrtyHGFB2jgkUpFRMO/gEykDaDjDcY4p1pd/aNAtbSRMy2U7BJPRG7fmKmuUEysF4yBn1qnFCyRzOm3CspwD0GcZNVSe8fIdS2j7M0Y2+cM3O0YGKmhGcc8p8xGOKjhiDDBIB4NXFiLkkEnHB+lZJXKkwMe8L8nzntSOHIBZcleFG7gfhUwDLznOBgDNWUjDRrnghsYBq9iLoqwWe/nLYHGM9R6GrapGWVM9MsT6mposD5WB2nOSOwpkoj2ttxlfu+9MlsjRyCXAJIbjIzUkCMN7ZwT+ZpCYxGpIwcdjimps5y+MA8nuaVrAxozLKzSIrcfdHY1Gm9lAcgKDlV6UySYiU87UJByKfH/AKxwFXJGFy2aNytiBtnnKLdQRu+ZwOBn1NJcKrSspYqRySOKaZURVRim3ccn1puEysm/K9Nv/wBaqsA51SGASWw3MRksv8PtVRo5HV2jGz+8W5arrYlIGQqdcEY5qIRmN2MpyP8APFAJ2KdxGPlaZDhVG0nn9Kz72HzQ3lIqgkYkzkn2Arafcu8BArZ5BBOBULxR7hsGw9cnpQtykzKazTzFLDfL3bvVO4iXqFUd+vOa2XjTc5VhgfeJ6VQubVFO88g8hATkfhVK49DAu0kjiIZF2+uckViXaAMHwST6V1Utvb+WzbRv7ZGKqXNkzKnKoDzg/MTW0J2M5xucVKqySjj5+6gf0orobixBcEFlbswFFevhJRlF3/U4qlN3I442GccDnB/xq0UyoJyuOSRWo9kMK3Ud/wDGmy2Z2qRjaeOBXjOomdiVikrHbt3K3fLdqRJvlVX+Vvzq0bNA4VwEHqKcbQCQEgEdiO9S5IsqSgDDKpLYxVeTDEEH5T145zWlJGpkUHK/0NVJLcKxwTgHr0pxYmiNRhBuXaSOCO9MOwFQcAt1DCpHPA3KT2BqNkCjLKGbqBTQEvmsVwcYU4PHatK3m8xFUHgMNprIDMcluh6VoWhztVwPK68dRUTWhUTYicF+QCx4A/rWlFjYrcdeMdjWRbNiTgcEYwRn8a045P3Cq2AueB71zyKLkzBVwpGSfSrVoWBUn5T0GR1qkWJYZIBx2FWYXOMnnGMc9Ki+o7OxpWyPJI559CM1YiwSA/TcQB1/HFU4mckbR8/cir/mjcCSA3IwAOnSqvch3BVjWIeWMMDg5HXnvVneplZmjLLngZwMVACykrvGACuAOasQgvGEaNSQOdxOAapMhoi3h3OwYBAJHQ026VmYKRswPvBs5+lLIiKGZeg4BPY0sobyVXJAHrzVCKsm4KWUgMvXdzWXd4DjY5yR0J61pXTFFVSd7AYyvrWZKg3A/KM9c8Z/GlJ9C0V3ZXjDADuKisoI2k1JApBFqXHGfukHmnycsFHy9wKgSSWK4cRyCMSRNG+X2gqQcjNVRtzkVU+Rl62dSq/JlevHr/hV6IMwyNpPU98Vk6YvmQoGPGAODzW2nyhRxjGMd6SdgaFVGb5io2+/Wn52OG6cevUUjMoHGeuSahkl2nb1HqBT8xJXJhIzZxj/AOtURc+XtAUerelMMnBxlvXtmoHZfl8xfu8jHOaB2FeQkKBhxjp6U1Jgowy7iex6VVaYeZ8zYUDtTPNLs3zgqTxgdKLXLsW/PRgwcNk9PTNJukBwUIRfuntmqpuI8lncMcYBJHWrO+KMEKQyFQQo55ppWWomNkKkp5eM4znHep3IIznkjOCO9NdY+BGTgDPIxmnqGBJywBHQ1ewh2A8al90ZA5bGc/4UwEMMsuWIyKsSkT7o+NgGTg4zxSMQqL5DFsAZBHQU9tARWKlQWeTBK8474qqVMjllO5yOlXOPL3lQxJwM9KGR/kIAKihIbKMvzgCQHAxjBquUbzSrLtwPxb0rUuFUsgxszjIB4JqvJFHvyCxOMYz/AJ5oC5kOijzCxfng5Gc1QniXafJUsMc54/KtyWDygVPL56YqncbNjBl2hunHFNMDAKlrhQyFgccjtRV6aMRlVdx+Pb8qK9DCv3Xt83YiS1LEVuC2RyOvJ61aWMg7QAcipEWNl4OT1B9ac7dACeO3vXjNu5pYrPB0RgrYNQmAZOGBA/OtDAYlgAPp1zTTtPzAYAPORmkmw2M2a38xtxU+9Qvagj58+prUlkBYArx19KiZfM+6MVSbAxriFVHysCR2PNUZSwDcY+grXmXy3JHAz0I6Vm3YDcgsT9K2gwKeDjg5B5qxbyuRzwOnrVJy6kqvyjOaWJjuBySQcECtnESZvWshUkkgsfu5PFaMUwbAH3lxWHA5Cg7flA4z1q9ayYAckjJ5JFc04Fo2iAzOcHJxjnPNWrfOWUgAkYrPs5CkxIOMZxkVdtym5c53MwPTgDvWDLTNqCRkfCv04O3gZzVknYBtUZ6Hv/8ArrOtcebwobqWwcfjWoHAIUZVcDcB1zihaohuz0LMZCqij3DD1FWUjYr+7wwxhiOR+FVYCDtWM4kx8oOck1JvYj51w7dgeM1SXUhse6CRedoxjkDpUF1vDE7yHIHTggUsjBItnOD1OOv4VExEzqVZcngHPeqJKkg2uyyF9v3uPpUMqxuv3T8oz81WnZvOYgAA96rXLJswGAGcEds+9KxSZnS/cJG7eVySMACsbVJB5WHXkkfNwOPpWrclUQtIGbI3YA6Vg6qcW0hI6YIz/WqgrSTLavFmro0hMZXP3TjaBjmtpyc5yPfJwa5O0uUS4ZQwXequuG46dK0jeop5dAp75pzjaTREfeSZqvchdowWIOSM1D545yxA781hy6qB/wAe+ZHB+8F6Gqkk1xMhGR65zjNJJlqJrXGqLEx2nO33qh/bDuSsKOzHoaqRWo2hmO7gnBORUsCFDkqAScDB7VdkVoSCW4nyWzGoPORnmp0hZt+XY4PQccVNFuMh8zjccjNWFjGW5X+tHLchyZFDZRkK7JuIPJz/AEq6mnp1JdHxwD0yadAi5JPAOAMdzV2NGd2IBLLxwcVUYkObI47QNuZZAvTv1FSfZCFZtx49yfyoFvJ5Z2/Mw6A9qHhaMDIYE/dHbNVyC5vMjiilBZ1Y46DJ/SnxNKS5KBgD9KeEKDIPB5IqnJKXLHleemck0WsUnzE4O52wpwDk/X2qYBhCWV1JPHHOKoyyybG2BeMEZ7/WoPOdugJJ6nNNIdrl2WQgbSBtHcdagkIySoGfU9RUAklchivyL155p4Jk4HQDkjpTtYHEhmnyMLySecVVuJN+3eCv0Oc+9WJFxMwXcV7DFQSsSu0DHv6UrWBIpvArTBgnO7uetFTRllaMEcbhz2or18toOrGX9fqiJ6E0QVWUFdpH61OSpx8vIHesyGTD9S2ParasHC/eODXz7RZZGxM4XA9aeoJBUAHvgd6hSVd+SvPQdqnAyAMHH1pW0E7kUkfzAEZJ6YFVJ/lDKwLN61oyZxlRx0zVSRMJuJz35osCM+5RfLLMAHHGKx7htyZJGAeorXD79xPfg8VTvkWMbtvPt0rWA2raGFMhZyRznv2qBD8/J79asXIO4EY56dazZpCk/wA5G4dvauyGqMpaGtDOm7D5Pqa1IJQUCrgADnvk+tc9aTq+QTkDtmtC3k2gnHTt6VlUgXGR0EFxjG1ue4xWjb3CbyGXKgfrXOW87B93Oeo29a1IZgd+3cW68npmuWUDRO6OgtZ8jChlJAAx0NaMRzxtBRQOQeaw7N+VzHyeP/1VqWjLtUovzA/d7H61lcTNWKX5FKSfOcAkDpVjzS7Mrffxtz90Gs+Odh/CAw44OAc1ZWZAVJ3FgMkYxg+lWiGi1xgBlJ5wSB0PoKqiMB3J4YdFx+dSfaC0CnOCvAGOv40TnbJyFYqvDe9O9ydUVJZHkcgDAH8IBqlcnZH9zd3yorQcSMvmbcKcDOe9Zt2wDlOY2Oc56fSjzLiZ1zK+UVlxkdW6Gs3VIxJbyBhxj14H+NakiBWGSv55rL1QDMgIP1HcU43vc1sc/PNO1pZXMEZCqWtyRyMrzz+dKoxta5kMhY/dzgVlT3slpZ3cQaMwmcShSfmGeD/So4dSiwCrpXdKDlqjlpy5bxZ06TRJho4/u9cdPypr323OOhHGB3rJiuhwRKoH1HNPE/y7RIrHryKx5LPU6FNF+O7O9jzwOcmiK6LsCONpyue9ZTyYBBPJ6AVGLhsbA3C9iK0ULi9ojqkvAUBPBz171ct7pFBJbr1A7VxsVxJJIrLnCjjtW3YyOsj54Xb2o9mJyR1scqs43EAAZyRVuKUZJVDwcZJxk1y8V42TuLcgAkVrWzGQFmJCZHOcU1Cxka73O3BPyc8HORiq812ruV+U5HUnFVri42qhUjbnkbc4qi8yliz7eOAoH8qdmCSZekumAUAZ4+93qnHOpY7gcj2xVY3Mm/sQenHSlNwFXDJnJwSOpNQ0zVWRceYcc4A4Ge9LyyhidqnpVCO9UvsUrzxUxuNn3scdMVNgLcfTk8njmpMBe65B596pGVmT724dSAOBTWn3IhZvYEULQLFq5dgCM4z3A7VUnUSB1wCBwDzipGlRlySSe+e9VmmAb5SQPTFKxcUEZ2lEADHNFOiTdIC4GeOlFehg/acr5Pyv/wC2smSMu2QhiGwDnnPatFHAGAQeKjhTeOFbJ4BqwsRYdAMj16V5jjfcz5hI5Mgjbg/WgykH72R7d6etu/Rmy3qBjNORCcAHgenWp5UWncfFIGKHDZPv0qS4VZFIHGOwHWogmOOeaV328DH4HmoKtqZV1CyPlNyn0rNufNIG/OPTPWtu4Ocgnbjvisq9gdlGzgLzmrWhTMKZWSQ/MQOtZd7IuQT1B/Otq4iJkJb7vrmsW+VQrE44PfnNddJnPVWgyCeNcHAHbA5Ga0Ipwc9emCMVznm4bbkYzkGr0c+GU8AE1rKBhGp0Oggm2Oh6jrwa0orsGTIVcjk4PWubt7glsnscfWtGCUZGQMn0rmqUzphI6m3uflxlgCfmA/xrVtpmVj2Jxg4FctBK2MH+HuOlbME3ypkjK9hXFKNjS50NtMz5Kj5hnnd96rwCyRhVwJcZPfHtWNbXWEwMAHA3d8d6swMA4L703Zw6jPHtRFEs1YdwRFcsQB90nilkV2URyMOo6dc1FA0phLSR8jAD4z+OaZKGL5AI3fMPUCrasiOopRQ7qXLhejE/yrMuCWXBHQdR3/GrzFGI+ZdoBOcn8vrVDaZcgbirfd9c1O5UWVnwSgkT94MYYcfQVFfxcyIvytxyFzmr5RiEL4PHrkfjUkKF+SSA3XDdfqKdrGjkeUa7aOonCMQ5PynAPGeaWDwxZTWwkluHE23ogJOe9df4n03yZWkI+VSDjGM81ev/ABPaaVNe2mk2dqtvNGE83cZCwI6g9ua7oTlKOjOWpBOWiueYXGlXdu5FvvEC95cKfy61UINlmR7uOSUDhATn9a2r+7a4kCKrNLIQiKPvEnoBWHcRhrdppQofpg9q6YXfxGVSMY6RMyXVrhS/zlwnJJ7t/hUP9t3McYMkjBifmOensKcloLiJmlPlwbvvAZJPpWbrsAhkjRQEwOIxyfrXQox2POqTqQi5XNyLxQY4kA+ZgT81XofGji2fIIOPl9jXn+TkjdwOmRTiWZTkg+tP2UTD69VPSbTxisvlxMGUtzkV0mneP9PM8STAAA7QSM14h5jBwynGOnNTqjLPbvcF0VyHyBk7c9R60nRiy1mE+qPoD/hLdKuNv+kKGLYK9MH3pJdThn5FxHHEp2kA8/jXiGuT20WpTLotzPNZOABJOgRycc5A96rJqVwuMytkc5z1qPYK2hvHMUuh7tNqEUcTFSGH94VUGorMwZJCzKOTnGK8YGr3G4kyPn0/rTl1a6CgiRlXPByeKn6uaRzKHY9lF55h4YZXngUq3LllUynaec15IniS5CqTJ84PXHNXLbxDezI8gDukePM2AgIDwCal4dmqzGmz1Rr7bkK+3ucenvTheArlW4Yf3s15zF4jkO3f+8TG0Z46ds9617bXLedVCugb+4xxmspUWjqp4mE9mdmL8gbXBJH93mo5rrzMMN2PUHGKwra/ZWJR9j4K5B7HrU9vcsUxghSQPwrPkOuMrm1BdSkqo5wRn3FFUIZJmZTuAA5zjtRXdg44flftnr8v1FO/Q6mONeChbnvxVqJEIxuBFZVrc7AFJ7ZHpUhvF2EBxuPAyMflXnNHNys03B6Z4PXPNNlVVARep75rNF1IowDu45NPkvPlBQbhjr71PLoaxiyyoXfkYznp2qCVilyNuM449Kz3vir78dfahrgO2SCoP51m15GygWZ2Zs9Rk84GapiKYh+QRnBzU8UiM+ckDsanbGVyC2M8jtUNWEzCvbcrJgKAneuc1GHA+YHkEcHpXd3tsxjVVAOB94dq43WmALiQdM8Gt6MtTCpZo5KciNztGfrxTVmdmUghvpUd/IXceg6GoELPtC8g8HNekloeZKWuhtWzEsOT75rYs5l3Zxwa5uAOCq5JX2PWt62c4BJB59OlY1EdVKTOgtJcqvGFH61rWsnIKEKwII461gWbKOQcYrRtyfM+8MDsO9edUjqdsToLSdtweQEKO57+nFW7G8jA++QSDhewb19qwoyjYALnn8qcNyuFVvlB6Z5rG1jTlTOztbtDZeTMcSzc7wemD1+lSuHjhVJgrn7oljIbBPI/CuWtroIyOTgg8AmrtjfvGzRgqsL5JDgnnsRTT7mbp9jYhWK5VxK8wMY6ADg+tSQQQzIZIiwVGynnMFB45ArHa5M6GZXCkffXqT749KshBJBbxiZTDKco8bDbvx09vxqovyIkrCo0RUNFE2+Jsy5PGe1WoEDyFfKG/cDgDoOtUIiskm3JFwww8eP4/Y55FWbSbyt2dqDgEg9u5p2sxvVaE2t6WLm2Gecjtya8y1TSLq0hlto3byGkEmzYCMj36969Uhuotzhf9WMhc+lZ+oRRybldBg9wMY96uMpQ1iSop6SPGr+yuiN21VZcHrjn2rPura4eDy3hbAPGDxj+teu3OloykgAxntjkVk3mlJuBByeg7VvDFdGhSw8ZbM8qMF1CCRG5f+E4zzWdLYyzTSSXQzJxnjAr1KbTXjIOFyRx3Bqk2nsCCqoD34rpjiUc08DfqeVPpc6SFthbngVG1hKq8IQfSvWmsMITKgZWyPu01dLi+XEYXHB9RV/Wkc0srXRnkKW8mCAmWB9KsW8Dbo/tCkxAjcVxnHtXq0XhyHCxyRZJU7MAdT6mlt/CsMXmCSONgeCWXOPpT+tRMv7Mfc8ovYrYwwi1WZZ9zeaZGGGGflwPXHWqiwt5gUgjPQ17LZ+GLOFgz2cciO/y564+vaqHiXwvDKubC1xLCN2FHGB6+tUsRFkyy6SVzzb+zZWQEtu29QO1Ma1mGV+ZsdBjivUNB00yRDzbVZgByCp4+tXJvCxkmIjtiq9SV5pfWFc2WXq10eOyWkgQ8E59BU8NncPbOYWY7hh0TjIHTPrXqd34Mb70KAP6kYDD39DVNPDFzZ3Pn2Kksud0ZOQR6UfWItGawDTODs4Li5iFokkqokm8Qk8bsYz9a0YNJeVzG4VJR0DA8+4rszotnrFxNKqPbXi4+QA88en1rXisP9Ghjudv2oZCyYxuA9feonX7HTSwiWjODi0i6jOPMlDL3ByK0rD7XbY3FnXODnqK61LcQyeXMCYxxuPX6Gn3VjHtDR4ZD19qxde+51RoKLvErabKsm0vIUPTDCinG2SKReMAEYJP50V6OATlFuNvn/w6NnPuJHdzSTJEMZIqyf3ihd3IOfxrzl/FrqfMjG1h071QuvFt6XLRuyndnjiuP2DZwSx0F1PYo2wSGdc9xTZJTglZEPbANeLyeKdQYkmRhk5470y213U55I4IpXaSRgirnqTQ8M2T/aNNPQ9cluIxyZckdMHpUaXa7hvwRnINc+nhjWrbSru71C9ghlglELWxcGTPXOPSsCTVLq3l2FkcKah4Zo6442NrtHo6XcecJt+uelS2epvJfCLPB6jNeaw69KikMpGfQV1/gaCXUr0XckbrGnC7u5rKpQ5Y3ZosVGeiPRryPGnMwO3cOa8v8QyhTIG2jtnNeh69fCCxZSBtxgDPNeOa/fCR9i5OetTQheRjOfLFsx5SzzAbsYPB9aeqYfCNv9AeBUSK7Dcxw2KmjOAuCRuNeieei5b7W2qoII981sWbMQRngdyOtZFopG3t2JxWzbxkoMDHbpWE9Dro6mlbEknceM9fWtKOVcYLYGazIVKHvj1q4qE844xnPeuSaR3wNOKUlQFzgddo6VKzkkAtkk1Si3IAQxCn0PepY9xHAxx1zk1g4mqLqz7c5OQPxqWAsz4QsGYfLniqMA5UOOB29asho1fKrhRyGz0qGhkrXU1vMyoSGHfHP0p1pcSSSOiGOHcMsjcK30Paq7DeN8jZIOSc80jrkgABgfehWE1c1raYsR5CbGiB3KQOR9e/1qykoVcykRkkMFQZU/jWFBK8Eq+YqvHjoTnj0q5C7Tlnt0ZQvzMG5C88fhTsTymt58fn/uWLKcE7u1TXl2Xk8zzEJPYf1qhbvC8RLShXJ3FCAc/Q0zcW5Rdw6ZpqVhKKuTyXDMuDgEjp61SkkYo4LjOPu+lOZiOACjA8iqzlW3bhhs9RVWT1NEh6LwRhcn5Qu6qXlBpMOT14BGcH0qUqVO5TliMkDtT96upBQZ7kHimtCuUg8lScbW2jnNWYYAQNxAwDnNOWPCgZ5I3AZ6Vct0VQpIMeRgqT+ooJaEtbaNXB3Ky46envWrBbxbWRlUEjbwOtUIeM5OFBwB/erRjyRlshc/KfetEzCcWx/wDZltDs3KyrnB4p40uJpSCoKnvnkCpgjbQWkfgAEHnipwuAMZIHpRcyafcx10VbebzbPETn73o2atLaJlhkbl5J7VoKgfG4kDpntUTpu+8AB0U00xWZUKopKOFKkdD61TltEkVxtAwOGXj61oSxeWoxgE5xjnmovLba2MsR7dqlyKUTCksFS7EwQZ6EBeopl/axybo8HGd3X8ua2JFYoMrnqCc8YqnJHuOAT05GeBUNs0SuZkasm+MruyACT3quYvK37XIRjyvYVoNgFhg8deaqhEUg9h1780XL5SjIqSXAIIJQY64zRUzIFbLdG5OO9FdNHEukmk7f16MiULnz0ykMR1XP5VHkqxGCR2zWxa6TNPJg7ua6Wy8LIY1MowfYZzXoyqRjufMUsJUqbHCxQSuQqITnua29J0W6WWOTy/m/h9q7uy0a2ju4tqAhQc8V0K2ixRrtA3DkCuaeKtoj0aOWpO8mcJa6XdS3cyztJ5rjcSTyacmgM0xBHI6HHX612s6h71JOBlSrYPWlEY3bkAGO9YvESO9YaKVjG0XQIXkiEkYXB+YeldrHJDZxHaSFHAxWOkqQuzJkkdTWXrOpARk7iB7VhLmqMqygiPxZrYwUiOSc49689dzLPubkHJ696l1K8kubhiMZLZx7VACVBKtlycECvQpUvZxsebWq88vIkhZn4ZyFxwM5qRVz8oBIPUU2GLzGUbth74rStINoBUc9M9c1UnYIK5btIQcZWti3AQYUAHv3qvbRFQGI5/StCBAcDHua5Zs9GlCxPGFJBPJPHNWkUMnQEdPSoY42IGDnnp/9epYsqSxycdq5pHVFFmJGAIKfKR1p4AVt2OT70zLPJyWwO1TqrKo746nFZMsUQBsbuSR+Qqyo39WAxwfTFN2kYIOcjtUyfKDkHPsetQ2O43AAOACB1OKjPlggxqetWUA3ZAIYnJ2ng0k8SndhG65GKm6AqyR8lQec8cc0gdw3LOrNwewqysWG34yT2HeoJlMhP8IznANUn0AsRsAPnUFh0OeTVqOZNhUKzkAnA4C+lZaucEZ4AqeKRzjoAMAA8ZoaAtkGQOxVk24zjmq067Rjb8vp6VM8hI4B684pW3SDK7skjr6e9ClYLlOR1AxHuxgZyO9RkkoQo2qvXNWGz87KQcdulRyjIAOOB0rRSGmS2+4SBgw3VfVjIPlXd2Ibn8qyFZ2fjGSeSKtCVw4A5deGIP60DZpJO4RY3AUjhd3WrsMp8wKUO0jOc9KyFuC5WScbtvBarDXCHcmNrADGaadiJK5upOHYyZUEng56irUUuY8ZPJx8h/pWHG5jZcuQiL90j1rTt2WWKPyxtc5LbiMfWmncwkrFnJMrBmK57EVDMwzheVB59qiE7bmV2DBT1Yc05J0dGHBPfsadxNWDYRyTwwzxzTpUKgyo2FxgkHimvMrRMuBz0J/pUW9ZB5QCkfdyBjNLQV2VpWkG9cttPSq8kRB4YEAfnVxiyhVOM5zmovKGNo5LZz9amxaZRaNZIyM7v0GKrNGPNCiLP9a0ZFCru53HOVqnIu4AYCgHj1/KlcpMqSIwGJBllzkY4xRU0iMy7DnK91FFYV1NtcrX4fqNNdTgbawVclRtXOOBWrHahIxgD0wDVpYivYYzzSZKBkHU+1ehKbZhGCRFAwjbGAOe3arLzKyJxnbxmodqr94EMT+dReb838IPTGOgrN6mpYkKFwAQdvv0qGRwFwpJPpmoGbkFWIweeetVLx2DElhmqUbkylYmuLkRx5IzXHa1qLSSAKwCgHgHkVo6xeBY12v144rlZnZ5iw2lu4PeuyjT6s8/E1vsoaR1KDJ6k7u1TQxfOCcN3qsvMpAO1uhxWlbIABGSwX72M10SdjhguZli0Q5Yr1788VsW0BUqGBK9Oneq9tb/ADcY6DAHU/Wtq2tjhQQfc1y1JnpUaY+CNWwCuB7Vfjj2qAvUjkAVJb2r4Hy5BPYVoQ2pBLNjArjnUO+FMphGUYGMAdzUiwnaxPXPTHFaAjjBAPIPOOlQlAzkYxz1rLmua8pHHCzAFXHvigKQeQSw9anWIAZHHt60jj5wQc0rlWFAHBAUkenpUi4PIHHfFMiVWOGPOevtU6Kv3Mg/jxUsVicR5wTgEdQx6/SpSS2Cwx68daIVC4ym73J6Vaii3ZA+8eeT1rNktaFNkC5KhsZ4z2qKchnKhG6delakMDnKEAj0PGKbNbcYKjcPunNF7CuYRR/POV4PqKkMR3bm5A4BAzV2aERgfKCCM/T/AOvUckZVg4B2djjr7VSkOwisoBUFj7Himl3KZbGT0A7U/bnnBB6ZHSkMeRndyeCTzxSQWIf9aFYNtPZcU9yMEgMoAwVUcfnSHbngHC8fIamB3xODwPfPFO4FRvl+VTkeo4oX5SGVzz1JFSeXl/vHcB0HSneUMgkEK3UDmq5irCohkZRnAz+FSCORsec25jwxNQA7T8g+XHPtVtXMirgcN0J707idyyzscE7uMbs8n0FWUZ32gkhe7Hp9KhhZfNUyBTx8wUZIpy+SZMoTgYGGP9KOYixNGQED4APQbec1YEpQLs2hiOc/yFQERgv5Z+U8jdxilMgEYwBz1IoUrEuNx0jM0wLLt45xyKRmRcqQQVPXFAdX3kICAOx/WoNxIBjjGT2anzE8vQfIV3BQ37v1POKiZ0VhsbLnHParaSBj9wHjB4qFdrMW2qcfUYpcwEJBlfcEbGe5/Wq8gAO8ADBweO9WWDbjh/n65FMIMnXhj3z3ovqNIrRsRJ8i7cnkg4op00P74EKQw6kUV24WEJJuSuKSOZkdvmwwAPpUKvsILkmorhwr5zj6VA824FScH1rPluCkWJnV5PlyAOhNVnbkgHg8A+tNMhHHBxVaVyG4J5HQVSiQ52JRIu4gjLdhWfeTYm+UkMByD0p01wYgSRk4yPpWLcXLs7uGA3AjB6CtoQ1OarUsilqEpJ+9hQcCs+QlAdhHTrUkjbuGAI9c9agkwEChi34V2RVjzKkr6sIA7tnnPtxW5YWhcgnOB0PaqFjEZAmDhu9dfpNmwUKwGPzrOrPlRvhqXMT2NkpVQA2fWty0tQDgqT6E0tlZkqDgY7Ctq2t8bRtx0PNeVWqntU4JBBAzAIoHA5p81uwX5V49q1oYcgAYGPXilMIzgjjtxXJzGyMT7MDwQCT3NSm3C85wK11tehA68kUyWPIK8dOgo5h3MaRCpIX/AOtVRlCr/KtqW3wM54B9KzrqMCNlJBPtWkJCuVIck8845ANTIzbtuMCqILJk5IweSKkW4XeGHBxya0cQubcWfLAJBGO1W4hjAyMdM1jW9zzgkY755rSjkHy4OMdCaylGzE2aqYJEZwc/dJ/rVya332/mZAwMcH9KzLaTfjJLc9+xrTikyGXnjsR1pxRhLQy5bTdFvQuG/iINV5Ubbnk47+9bUiB/mGEyOQOhqlcQOFJJIGDgrRy2KU+5lF9p2jOM8qKJgNhJwAeg65q48KMijjrnI6/jUKphRuUlT3qDRMqlMqBgYXoOlByqAfLsBxtY1LtYOSNpJOAOwFNUsBhmG7oNw70xkblQx3kcdQoz+tRmVd23eyp165p7Bi2CVx1B6ComSNTg/N9OlVdDRLGylTtKsW68dKlR2jwQAM5zxkCqykIxYMOvrmlSRy+7ccYxgd6AZZBxJuLlRjIwM5P0pzzsWL4+ZuPTH4VCcbcKPnHrUm1gRsOTn5sGhCJUk4Ej7jzg7jxUxKluDlO/FRLGqj513cevFOeNwQdxwRnAoJuWUCqzMcAHpTkCBDknHbNV0B2YOM555p6pwrEHb2JNG5LLSYAI5Bx70kfy5yT06jsKVRkHCll7MDTmQBQI+pHJIyad7O5FyMKGU8AgHjI61EsRD/dx/smpBvQHccgdB6Uu4uwKnODnPvTAqskom3oQo7DHT60VadXlzvAQk8saK6KSbWiv936iueVz4D5blf1pCw29OPekeQl8YCn1qJyTwcgdyK6LGLkIsu9iHLY6ccUxyWwY+CvU05ApfH8a85x0qKZ2UZcEehP86pIhsq3ZKgBiSRzg1iXeGk+V+v8AD3Fa1wUBEkxXB6ZNZbo0jHcudxwMc1tA5apUcYUBsAYz1qkxMl0PuhR0rTuogigtwwHTHSqVlHmQ4XOTxmtk9LnJNapHQ+HrOKQbm3HHArutPsQqL1x2HSsXQbdYreJgnJ612djEThTzj2rzMRUuz28NTUYk9tbfKCQ2O+K1LeEKoxwDzTraJSeV59qvxQBgCVx3FedJ3Om4tvAHG3jJPNW/sZDYU547irlvAuVVBnPc9627W2UINwBPSrjBPcxnV5TnRYNgEZB65qK4tNn931rqp4EQYj61j36/JhcdeafIkTCq5HN3NrvByQKyZrXIKjGB6CujuIwXAbd7Yqs9lkMQeM+nNZ7HQnbc4+9tgsRbqT1FY8yYXB6etdhqlmdvXkdPc1zt1bMOnQ9iK6KUxtXRSin2MvcAd6vwX4XGCd3vWZJG4GCvP60xZGHG0Z/GtuRMm7R2FnfowUkEAHsOBXRWb+YQ4Y/4+1eZW14UdcOVAPT1rsdHvThSpB2noTWThysUldHXqqtg7MLnJ4qtdKWC4J8s5FWYHIEStggjK454q1OgKIhUAg8HHNBzrRnMXMSwkl2DnHBXNVMErwcqeQPSty+icSMWxjoFqhJDGsg+RjjjCjvWD3OiL0Mm6UzN8u7A7njB/ClZRkYBPGBkdavSKSecAKc/jTTC2cZ6d6TZqjNIYuEOcjsV4FQPuIAKD3OOlalwGd/mGT0xjAqnIF3kHljTuUtSntOf3YGfejzH43Zz7Cp3jO1SMhO3FRFAHPQknjNUFghUq/Dk4PHOaupIfmAwrVCqndwmO+c8/WnrHiUFGA4J5peomiygIwQcripIywAXdsx361AgwozgHvmpVKMCCTzzildkOKJGUYCuQAO605cdBlsf3qagXBccn0xShwzjKsARjAppiaJ48KMGTPOcVJLI/D4ZQeCAaRAgU7l+bHGB1+tI7A7Q7LtUdKuxmkPQrvCsN27svWjywszfu9uf4ak2I/MKqpx2PWqs+wN5YZt3UjPekG48RhgSR3xnNFCIxjwuA3UnPQ5orooqDXviaPJ8hjnHfFRYYMCcBc42+tWGUt7ryAahiQiQjk8966rnOIFALEkDJ4B6mmPycbsL3BGankRgxJ49fUU1IcgN1Pf6UA0ZN6A8oOFKdBtHWpIrYqNxBXvnHSrxtA6/NgndnBGMVNdqEtsttxjOTT5+iMuTqzjdYkHm4yT9aZp6AOvysCxqK7xcXeE+b5q27DT3jVZNnIPAzXU3yo4Ypync6zShtRP4RjpXX6cwIUrz7Zri9PYPtYZDZ6V1ulyZUAsAfQcV5NeLPapPQ6a2U4G7K+3rWlEm3BB6e/FY9o5GMkkVfikAYqxP07Vy2RTZ0drsXDKMtjoDV4zYA2tz6VhW044wcZ7VO1wCuNlapHNNNstT3OG6jHp3qjNc8HeFz6dqjucsNwzjrjNUJnUnGcgU2tC4Kw+UqzY3c9ST0q1CC8WAO3XrWOblQSQ3Aq9Z3wXlyVH8qiO5pO9iO7s2IPB6c8Vzl9Y4bIBOa7qO5t502nqfeqV5YB1JRTk9DScOsRQq2dmecXFsFYk5zWZcQsmT1/Gu31GwYEgIQR196xri0BQ/KeB1q4VGtzo0ZyZUqxJXDVq6RetG4Bxt9h1qK8tWDk7SPfNVYw0bMV6ZzXTdSRFrM9Z0SYSW6Kj/ADY/i6itWTzGXYpD8568iuK8I3i+dCHYn19cegrt22ldyliobnaPyFYrYwqLlZSuR5ZUsBknGKqTQshIkVzkcYOPxq3IgY5lAJznvRcqvykbQoHqahxuOLMhoQMbDlh15zTZQgfY6sc+h4q35e5jgBvx60x4SYtzKqj86xcbm8WUm+6Qi9u9V0ixJk7W5z8vatGNA4OMYGaheJERgnDA8ii1i1IoSqVyqvkE8qWqukJVm+UFcfXNXpLYMFMi7WHfOaXyg0ZZPu4xkU7l3KQBJLYGABgE8UEZG0jnqCatGHauFJJPXinKvl8DHsccCi4mynCjgqGZRnkY5xVrIJPI9N1QSOFcInXPzE1NseQDBG0nqO1DJdxd77yNygj+IdDT02lgSSRnk9PzoMbbug47etSIWYbTHtx37UXJGRowkY5Cg54JzikZwUUgK7LwwqUlQFVm59qNqBGwmB0PNWmQ2NjyNzcBe3tTridTEFVQOfve9NJSPgsWHAAK1FsLMxUfIDwD60wFMzbh5eTg/eXvRUSRqnOeQfug4/GitYT5UJnng6E98mmnhFI6k80UV1nOTRqMr79alZVEigAYIooqJbDQsADYzzyaz/EPFqwHAx2ooop/EZz+FnLaLEj36q6gjJPNdgyKI9oGFx0ooror7nNhvhK9nxOwGcA8V2Gk87fqaKK5a520djoU4BI6gircKLuLY5xRRXG9zboaViflP1FSqzHqehoopogWYkgAngism8GMgdMUUVRUTKDHcxzyOlUHvJ0lAWQgFvQUUVKRZ0unyM6qWPJH0rfsGZlyTk0UUo7mVQrajGjDJUVzl2inAKjFFFTL4jWlsYV2oKtkDg1k3igZAGBkdKKK6KZpI2/CwAmbA6V6SfltwF4BNFFPqzlrdDOckozEnI5zUEY3N82T+NFFZroWtiST5ZmCgAADGBUswDcsATjNFFR1GULn5WG3jPXFEigoCRk4oopGnYrY+dT3IJoZFA4FFFZs0RWUASbR0JwRT5kVSNoxx2ooqgM6bh0x71bhJ8tee9FFMp7F90XK8d6btBMgPbpRRQc5Dc8QZHUVKvMAz3H9KKKGCGhF8txgcHioewPfNFFNiQlyi/bEbHJAJoooqvaSj8LsM//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A small probe is introduced into the punctum and advanced through the lacrimal drainage system until it abuts the obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Paysse EA, Coats DK, Cassidy M. Refinements Volume III/Number 2. San Francisco: American Academy of Opthalmology, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39858=[""].join("\n");
var outline_f38_59_39858=null;
var title_f38_59_39859="FLAIR MRI CADASIL";
var content_f38_59_39859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Brain MRI in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial images of the brain with fluid-attenuated inversion-recovery (FLAIR) MRI in representative patients with biopsy-proved CADASIL show a typical pattern of brain lesions. Note the symmetry of the lesions and their extension into the superficial white matter (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Auer, D, Putz, B, Gossl, C, et al. Differential Lesion Patterns in CADASIL and Sporadic Subcortical Arteriosclerotic Encephalopathy: MR Imaging Study with Statistical Parametric Group Comparison. Radiology 2001; 218:443. Copyright &copy;2001 Radiological Society of North America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39859=[""].join("\n");
var outline_f38_59_39859=null;
var title_f38_59_39860="Lymphoma liver spleen";
var content_f38_59_39860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Difusely enlarged liver and spleen in patient with lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography&nbsp;of the upper abdomen shows a diffusely enlarged liver and spleen. A small nodular focus can be appreciated in the posterior spleen (arrow). The patient had biopsy-proven T-cell rich, B-cell lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39860=[""].join("\n");
var outline_f38_59_39860=null;
var title_f38_59_39861="Decitabine: Drug information";
var content_f38_59_39861=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Decitabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/33/26132?source=see_link\">",
"    see \"Decitabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2930134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dacogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2930138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, DNA Methylation Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2930507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      MDS:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 8 hours (45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) for 3 days (135 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /cycle) every 6 weeks (treatment is recommended for at least 4 cycles and may continue until the patient no longer continues to benefit)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjustment for prolonged hematologic toxicity (ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;6 weeks but &lt;8 weeks: Delay dose for up to 2 weeks and temporarily reduce dose to 11 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 hours (33 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;8 weeks but &lt;10 weeks: Assess for disease progression; if no disease progression, delay dose for up to 2 weeks and reduce dose to 11 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 hours (33 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) for 3 days; maintain or increase dose with subsequent cycles if clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 1 hour daily for 5 days every 28 days (delay subsequent treatment cycles until hematologic recovery (ANC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AML (unlabeled use):",
"     </b>",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 1 hour daily for 5 days every 28 days (Cashen, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2930508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F2930511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic toxicity (ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Delay and/or reduce dose; refer to adult dosing for  recommendations specific to each MDS dosing regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nonhematologic toxicity: Temporarily hold treatment until resolution for any of the following toxicities:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum creatinine &ge;2 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ALT, bilirubin &ge;2 times ULN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Active or uncontrolled infection",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2930518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dacogen&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2930136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2930512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Infuse over 1-3 hours. Premedication with antiemetics is recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2930499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, and lactated Ringer&rsquo;s.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2930140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of myelodysplastic syndrome (MDS)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2930161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of acute myelogenous leukemia (AML), sickle cell anemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dacogen&reg; may be confused with DACTINomycin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2930490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (25% to 27%), pallor (23%), edema (5% to 18%), cardiac murmur (16%), hypotension (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (6% to 53%), fatigue (46%), headache (23% to 28%), insomnia (14% to 28%), dizziness (18% to 21%), chills (16%), pain (5% to 13%), confusion (8% to 12%), lethargy (12%), anxiety (9% to 11%), hypoesthesia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Petechiae (12% to 39%), bruising (9% to 22%), rash (11% to 19%), erythema (5% to 14%), cellulitis (9% to 12%), lesions (5% to 11%), pruritus (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (6% to 33%), hypoalbuminemia (7% to 24%), hypomagnesemia (5% to 24%), hypokalemia (12% to 22%), hyperkalemia (13%), hyponatremia (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (40% to 42%), constipation (30% to 35%), diarrhea (28% to 34%), vomiting (16% to 25%), anorexia/appetite decreased (8% to 23%), abdominal pain (5% to 14%), oral mucosal petechiae (13%), stomatitis (11% to 12%), dyspepsia (10% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (38% to 90%; grades 3/4: 37% to 87%; recovery 28-50 days), thrombocytopenia (27% to 89%; grades 3/4: 24% to 85%), anemia (31% to 82%; grades 3/4: 22%), febrile neutropenia (20% to 29%; grades 3/4: 23%), leukopenia (6% to 28%; grades 3/4: 22%), lymphadenopathy (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (6% to 14%), alkaline phosphatase increased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Tenderness (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigors (22%), arthralgia (17% to 20%), limb pain (18% to 19%), back pain (17% to 18%), weakness (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (27% to 40%), dyspnea (29%), pneumonia (20% to 22%), pharyngitis (16%), lung crackles (14%), epistaxis (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (8%), chest pain/discomfort (6% to 7%), facial edema (6%), hypertension (6%), heart failure (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (9%), malaise (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (8%), dry skin (8%), urticaria (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia (10%), LDH increased (8%), bicarbonate increased (6%), dehydration (6% to 8%), hypochloremia (6%), bicarbonate decreased (5%), hypoproteinemia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Mucosal inflammation (9%), weight loss (9%), gingival bleeding (8%), hemorrhoids (8%), loose stools (7%), tongue ulceration (7%), dysphagia (5% to 6%), oral candidiasis (6%), toothache (6%), abdominal distension (5%), gastroesophageal reflux (5%), glossodynia (5%), lip ulceration (5%), oral pain (5%), tooth abscess (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (7%), dysuria (6%), polyuria (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bacteremia (5% to 8%), hematoma (5%), pancytopenia (5%), thrombocythemia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Ascites (10%), AST increased (10%), hypobilirubinemia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Catheter infection (8%), catheter site erythema (5%), catheter site pain (5%), injection site swelling (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (5% to 9%), falling (8%), chest wall pain (7%), muscle spasm (7%), bone pain (6%), musculoskeletal pain/discomfort (5% to 6%), crepitation (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Breath sounds abnormal (5% to 10%), hypoxia (10%), upper respiratory tract infection (10%), pharyngolaryngeal pain (8%), rales (8%), pulmonary edema (6%), sinusitis (5% to 6%), pleural effusion (5%),  postnasal drip (5%), sinus congestion (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Candidal infection (10%), staphylococcal infection (7%), transfusion reaction (7%), night sweats (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5% (Limited to important or life-threatening): Anaphylactic reaction, atrial fibrillation, bronchopulmonary aspergillosis, cardiomyopathy, cardiorespiratory arrest/failure, catheter site hemorrhage, cholecystitis, fungal infection, gastrointestinal hemorrhage, gingival pain, hemoptysis, hypersensitivity, intracranial hemorrhage, mental status change, MI, mycobacterium avium complex infection, peridiverticular abscess, pseudomonal lung infection, pulmonary embolism, pulmonary infiltrates, pulmonary mass, renal failure, respiratory arrest, sepsis, splenomegaly, supraventricular tachycardia, Sweet&rsquo;s syndrome (acute febrile neutrophilic dermatosis), urethral hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2930167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2930168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: The dose-limiting toxicity is bone marrow suppression; worsening neutropenia is common in first two treatment cycles and may not correlate with progression of underlying MDS; may require dosage adjustment (after the first cycle), growth factor support, and/or antimicrobial agents. Monitor for infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; use not studied in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; use not studied in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2930162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2930163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects, decreased fetal weight, and increased fetal deaths were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should be advised to avoid pregnancy during treatment and for 1 month after treatment. In addition, males should be advised to avoid fathering a child while on decitabine therapy and for 2 months after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2930165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2930166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Dacogen Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $2053.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2930515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     CBC with differential and platelets with each cycle, more frequently if needed; liver enzymes; serum creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dacogen (AR, CL, CN, CO, IL, KP, MY, PE, PH, RU, TH, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2930500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     After phosphorylation, decitabine is incorporated into DNA and inhibits DNA methyltransferase causing hypomethylation and subsequent cell death (within the S-phase of the cell cycle).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2930502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 63-89 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Possibly via deamination by cytidine deaminase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~30-35 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: At end of infusion",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cashen AF, Schiller GJ, O&rsquo;Donnell, MR, et al, &ldquo;Multicenter Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(4):556-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39861/abstract-text/20026803/pubmed\" id=\"20026803\" target=\"_blank\">",
"        20026803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cashen AF, Shah AK, Todt L, et al, &ldquo;Pharmacokinetics of Decitabine Administered as a 3-h Infusion to Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2008, 61(5):759-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39861/abstract-text/17564707/pubmed\" id=\"17564707\" target=\"_blank\">",
"        17564707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Issa JP, Garcia-Manero G, and Giles FJ, &ldquo;Phase 1 Study of Low-Dose Prolonged Exposure Schedules of the Hypomethylating Agent 5-Aza-2&rsquo;-Deoxycytidine (Decitabine) in Hematopoietic Malignancies,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(5):1635-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39861/abstract-text/14604977/pubmed\" id=\"14604977\" target=\"_blank\">",
"        14604977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Issa JP, Rosenfeld CS, et al, &ldquo;Decitabine Improves Patient Outcomes in Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(8):1794-803.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39861/abstract-text/16532500/pubmed\" id=\"16532500\" target=\"_blank\">",
"        16532500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Oki Y, Garcia-Manero G, et al, &ldquo;Results of a Randomized Study of 3 Schedules of Low-Dose Decitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(1):52-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39861/abstract-text/16882708/pubmed\" id=\"16882708\" target=\"_blank\">",
"        16882708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Acute Myeloid Leukemia,&rdquo; Version 2, 2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Myelodysplastic Syndromes,&rdquo; Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/mds.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saunthararajah Y, Hillery CA, Lavelle D, et al, &ldquo;Effects of 5-Aza-2'-Deoxycytidine on Fetal Hemoglobin Levels, Red Cell Adhesion, and Hematopoietic Differentiation in Patients With Sickle Cell Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 102(12):3865-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39861/abstract-text/12907443/pubmed\" id=\"12907443\" target=\"_blank\">",
"        12907443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steensma DP, Baer MR, Slack JL, et al, &ldquo;Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing For Outpatient Treatment (ADOPT) Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(23):3842-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39861/abstract-text/19528372/pubmed\" id=\"19528372\" target=\"_blank\">",
"        19528372",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8855 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39861=[""].join("\n");
var outline_f38_59_39861=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930134\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930138\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930507\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930508\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796000\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796001\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930511\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930518\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930136\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930512\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930499\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930140\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930161\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401603\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930490\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930167\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930168\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299128\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219689\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930162\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930163\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930165\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930166\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322940\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930515\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875344\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930500\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930502\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8855\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8855|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/33/26132?source=related_link\">",
"      Decitabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_59_39862="Procarbazine: Pediatric drug information";
var content_f38_59_39862=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Procarbazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"    see \"Procarbazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/49/5909?source=see_link\">",
"    see \"Procarbazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Matulane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Matulane&reg;;",
"     </li>",
"     <li>",
"      Natulan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"      see \"Procarbazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (refer to individual protocols; base dosage on ideal body weight):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hodgkin's disease: 50-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily for 10-14 days of a 28-day cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brain tumor: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     at hour 1 on day 1; repeat cycle every 2-4 weeks if tolerated;",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1-14 of a treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuroblastoma and medulloblastoma: Doses as high as 100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 2-4 mg/kg/day in single or divided doses for 7 days then increase dose to 4-6 mg/kg/day until response is obtained or leukocyte count decreases to &lt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or the platelet count decreases to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; maintenance: 1-2 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Matulane&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food or after meals; total daily dose may be administered at a single time or in divided doses throughout the day to minimize GI toxicity",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unstable in water or aqueous solution; avoid contact of the drug with moisture",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Hodgkin's disease [FDA approved in pediatrics (age not specified) and adults], has also been used in non-Hodgkin's lymphoma and brain tumors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Procarbazine may be confused with dacarbazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F213741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, flushing, hypotension, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apprehension, ataxia, chills, coma, confusion, depression, dizziness, drowsiness, fatigue, fever, hallucination, headache, insomnia, lethargy, nervousness, nightmares, pain, seizure, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, hyperpigmentation, petechiae, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia (in prepubertal and early pubertal males)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia; hemolysis (in patients with G6PD deficiency); hemolytic anemia; myelosuppression (leukopenia, anemia, thrombocytopenia); pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysphagia, hematemesis, melena; nausea and vomiting (increasing the dose in a stepwise fashion over several days may minimize); stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Azoospermia (reported with combination chemotherapy), hematuria, nocturia, polyuria, reproductive dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic dysfunction, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, falling, foot drop, myalgia, neuropathy, paresthesia, reflex diminished, tremor, unsteadiness, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, inability to focus, nystagmus, papilledema, photophobia, retinal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, epistaxis, hemoptysis, hoarseness, pleural effusion, pneumonitis, pulmonary toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis, herpes, infection, secondary malignancies (reported with combination therapy)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to procarbazine or any component; pre-existing bone marrow aplasia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May potentiate CNS depression when used with phenothiazine derivatives, barbiturates, narcotics, alcohol, tricyclic antidepressants, methyldopa; use with caution in patients with pre-existing renal or hepatic impairment; renal impairment (serum creatinine &gt;2 mg/dL and/or a blood urea nitrogen &gt;40 mg/dL), or decreased hepatic function (total bilirubin &gt;3 mg/dL). Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; procarbazine is a carcinogen which may cause a secondary acute nonlymphocytic leukemia; procarbazine may cause infertility and is potentially teratogenic. Bone marrow suppression may occur 2-8 weeks after treatment initiation; allow &ge;1 month interval between radiation therapy or myelosuppressive chemotherapy and initiation of treatment. Withhold treatment for leukopenia (WBC &lt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or thrombocytopenia (platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), hypersensitivity reactions, stomatitis, diarrhea, or hemorrhage or bleeding tendencies.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): MAO Inhibitors may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: MAO Inhibitors may enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: MAO Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1049551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid food with high tyramine content (cheese, tea, dark beer, coffee, cola drinks, wine, bananas) as hypertensive crisis, tremor, excitation, cardiac palpitations, and angina may occur",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F213678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3415040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. There are, however, case reports of fetal malformations in the offspring of pregnant women exposed to procarbazine as part of a combination chemotherapy regimen. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, and reticulocyte count; urinalysis, liver function test, renal function test",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA, RNA, and protein synthesis; may damage DNA directly via free-radical formation and suppress mitosis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the blood-brain barrier and distributes into CSF, liver, kidney, intestine, and skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver; first-pass conversion to cytotoxic metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (&lt;5% as unchanged drug) and 70% as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/49/5909?source=see_link\">",
"      see \"Procarbazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician of fever, sore throat, bleeding, or bruising; avoid alcohol (disulfiram-like reaction with nausea, vomiting, headache, sedation, and visual disturbances)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 28",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F12807817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL oral suspension may be prepared using capsules, glycerin, and strawberry syrup. Empty the contents of ten 50 mg capsules into a mortar. Add 2 mL glycerin and mix to a thick uniform paste. Add 10 mL strawberry syrup in incremental proportions; mix until uniform. Transfer the mixture to an amber glass bottle and rinse mortar with small amounts of strawberry syrup; add rinses to the bottle in sufficient quantity to make 50 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable for 7 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Matulane&reg; data on file, Sigma Tau Pharmaceuticals, Inc.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Longo DL, Young RC, Wesley M, et al, &ldquo;Twenty Years of MOPP Therapy for Hodgkin's Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1986, 4(9):1295-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39862/abstract-text/3528400/pubmed\" id=\"3528400\" target=\"_blank\">",
"        3528400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez LA, Prados M, Silver P, et al, &ldquo;Re-evaluation of Procarbazine for the Treatment of Recurrent Malignant Central Nervous System Tumors,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1989, 64(12):2420-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39862/abstract-text/2555038/pubmed\" id=\"2555038\" target=\"_blank\">",
"        2555038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12733 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-73EC6B31EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39862=[""].join("\n");
var outline_f38_59_39862=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709348\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213700\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049541\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049534\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213667\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049545\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049537\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049544\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213744\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213741\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049548\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049533\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049532\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299945\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213676\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049551\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213678\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415040\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049540\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049531\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049547\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049539\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049549\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807817\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12733\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12733|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=related_link\">",
"      Procarbazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/49/5909?source=related_link\">",
"      Procarbazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_59_39863="Labetalol: Pediatric drug information";
var content_f38_59_39863=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Labetalol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"    see \"Labetalol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/21/20821?source=see_link\">",
"    see \"Labetalol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trandate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Labetalol&reg;;",
"     </li>",
"     <li>",
"      Labetalol Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Normodyne&reg;;",
"     </li>",
"     <li>",
"      Trandate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-/Beta- Adrenergic Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"      see \"Labetalol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use care with labetalol continuous I.V. infusions; the rate of administration is different for pediatric patients (mg/kg/hour) versus adult patients (mg/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Children and Adolescents: Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Initial: 1-3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 2 divided doses; maximum daily dose: 10-12 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     , up to 1200 mg/day (NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. (intermittent bolus): 0.2-1 mg/kg/dose; maximum dose: 40 mg; use should be reserved for severe hypertension  (NHBPEP, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertensive emergency:",
"     </b>",
"     Infants, Children, and Adolescents: Continuous I.V. infusion: 0.25-3 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; initiate at lower end of range, and titrate up slowly (NHBPEP, 2004). One retrospective study in infants and children &le;24 months of age observed reductions in blood pressure at doses up to 0.59 mg/kg/hour with little additional benefit at higher doses (Thomas, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 100 mg twice daily, may increase as needed every 2-3 days by 100 mg twice daily (titration increments not to exceed 200 mg twice daily) until desired response is obtained; usual dose:100-400 mg twice daily (JNC 7); may require up to 2400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute hypertension (hypertensive emergency/urgency):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. bolus: Manufacturer&rsquo;s labeling: Initial: 20 mg I.V. push over 2 minutes; may administer 40-80 mg at 10-minute intervals, up to 300 mg total cumulative dose; as appropriate, follow with oral antihypertensive regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. infusion (acute loading): Manufacturer&rsquo;s labeling: Initial: 2 mg/minute; titrate to response up to 300 mg total cumulative dose (eg, discontinue after 2.5 hours of 2 mg/minute); usual total dose required: 50-200 mg; as appropriate, follow with oral antihypertensive regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     There is limited documentation of prolonged continuous I.V. infusions (ie, &gt;300 mg/day). In rare clinical situations, higher continuous I.V. infusion doses up to 6 mg/minute have been used in the critical care setting (eg, aortic dissection) and up to 8 mg/minute (eg, hypertension with ongoing acute ischemic stroke). At the other extreme, continuous infusions at relatively low doses (0.03-0.1 mg/minute) have been used in some settings (following loading infusion in patients who are unable to be converted to oral regimens or in some cases as a continuation of outpatient oral regimens). These prolonged infusions should not be confused with loading infusions. Because of wide variation in the use of infusions, an awareness of institutional policies and practices is extremely important. Careful clarification of orders and specific infusion rates/units is required to avoid confusion. Due to the prolonged duration of action, careful monitoring should be extended for the duration of the infusion and for several hours after the infusion. Excessive administration may result in prolonged hypotension and/or bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. to oral conversion:",
"     </b>",
"     Upon discontinuation of I.V. infusion, may initiate oral dose of 200 mg followed in 6-12 hours with an additional dose of 200-400 mg. Thereafter, dose patients with 400-2400 mg/day in divided doses depending on blood pressure response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Dosage reduction may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 5 mg/mL (4 mL, 20 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trandate&reg;: 5 mg/mL (20 mL, 40 mL) [contains edetate disodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trandate&reg;: 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trandate&reg;: 200 mg [scored; contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trandate&reg;: 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with food but should be administered in a consistent manner with regards to meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. bolus: May administer undiluted (5 mg/mL) over 2-3 minutes; maximum: 2 mg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Dilute to 1 mg/mL; undiluted labetalol injection (5 mg/mL) has been administered to a very small number of adult patients who were extremely fluid restricted",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F186254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      2.5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS, Ringer's; most stable at pH of 2-4.",
"     <b>",
"      Incompatible",
"     </b>",
"     with sodium bicarbonate 5% and alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), amikacin, aminophylline, amiodarone, ampicillin, bivalirudin, butorphanol, calcium gluconate, cefazolin, ceftazidime, chloramphenicol, cimetidine, clindamycin, clonidine, dexmedetomidine, diltiazem, dobutamine, dopamine, doripenem, enalaprilat, epinephrine, erythromycin lactobionate, esmolol, famotidine, fenoldopam, fentanyl, gentamicin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, lidocaine, linezolid, lorazepam, magnesium sulfate, meperidine, metronidazole, midazolam, milrinone, morphine, nicardipine, nitroglycerin,  nitroprusside, norepinephrine, oxacillin, pancuronium, penicillin G potassium, piperacillin, potassium chloride, potassium phosphates, propofol, ranitidine, sodium acetate, sulfamethoxazole/trimethoprim, telavancin, terbutaline, tobramycin, vancomycin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, ceftriaxone, furosemide, micafungin, nafcillin, pantoprazole, thiopental, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin, insulin (regular), tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Store at room temperature (refer to manufacturer&rsquo;s labeling for detailed storage requirements); protect from light; protect unit dose boxes from excessive moisture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injectable: Store at room temperature (refer to manufacturer&rsquo;s labeling for detailed storage requirements); do not freeze; protect from light. The solution is clear to slightly yellow.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral admixture: Stability of parenteral admixture at room temperature (25&deg;C, 77&deg;F) and refrigeration temperature (4&deg;C, 39&deg;F): 3 days",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of hypertension alone or in combination (particularly with thiazide or loop diuretics) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of severe hypertension (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Labetalol may be confused with betaxolol, lamoTRIgine, Lipitor&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Normodyne&reg; may be confused with Norpramin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trandate&reg; may be confused with traMADol, TRENtal&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F186253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, flushing, hypotension, orthostatic hypotension (I.V. use), ventricular arrhythmia (I.V. use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, scalp tingling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, nausea, taste disturbance, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculatory failure, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia (reversible), anaphylactoid reaction, ANA positive, angioedema, bradycardia, bronchospasm, cholestatic jaundice, CHF, diabetes insipidus, heart block, hepatic necrosis, hepatitis, hypersensitivity, Peyronie's disease, psoriaform rash, Raynaud's syndrome, syncope, systemic lupus erythematosus, toxic myopathy, urinary retention, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other adverse reactions noted with beta-adrenergic blocking agents include agranulocytosis, catatonia, emotional lability, intensification of pre-existing AV block, ischemic colitis. laryngospasm, mental depression, mesenteric artery thrombosis, nonthrombocytopenic purpura, respiratory distress, short-term memory loss, and thrombocytopenic purpura.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to labetalol or any component; asthma, obstructive airway disease, cardiogenic shock, uncompensated CHF, severe bradycardia, heart block (except in patients with a functioning artificial pacemaker); conditions associated with severe and prolonged hypotension",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and monitor closely in patients with bronchospastic or hyper-reactive airway disease; in general, patients with bronchospastic disease should not receive beta-blockers. Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms; may also reduce release of insulin in response to hyperglycemia; dosage of antidiabetic agents may need to be adjusted. May depress myocardial activity and precipitate or worsen CHF; use with extreme caution and monitor closely, especially in patients with compensated heart failure. Use with caution in patients with hepatic impairment; bioavailability is increased due to decreased first-pass metabolism. May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud&rsquo;s disease; use with caution and monitor for progression of arterial obstruction. Beta-blocker use has been associated with induction or exacerbation of psoriasis, but causality has not been firmly established. Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression. May mask signs of hyperthyroidism (eg, tachycardia); if hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A-V conduction abnormalities may occur; reported incidence less than with propranolol; consider pre-existing conditions, such as sick sinus syndrome, before initiating. Use with caution in patients with myasthenia gravis. In children, two cases of reversible myopathy have been reported (Willis, 1990). Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and MI have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency. Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Labetalol has been shown to be effective in lowering blood pressure and relieving symptoms in patients with pheochromocytoma; however, some patients have experienced paradoxical hypertensive responses; use with caution in patients with pheochromocytoma. Additional alpha-blockade may be required during use of labetalol. Consider diagnostic tests for pheochromocytoma prior to use. Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. Instruct patients to inform ophthalmologist of labetalol use when considering eye surgery.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic hypotension with or without syncope may occur; close monitoring of patient is required especially with initial dosing and dosage increases; blood pressure should be lowered at a rate compatible with the patient&rsquo;s status; cerebral and cardiac adverse effects (infarction/ischemia) may occur if blood pressure is decreased too rapidly. Initiation of therapy with a low dose and gradual up-titration may help to decrease the occurrence of hypotension or syncope; patients should be advised to avoid driving or other hazardous tasks during initiation of therapy due to the risk of syncope. Orthostatic hypotension may occur with I.V. administration; patient should remain supine during and for up to 3 hours after I.V. administration.     Severe hepatic injury, including some fatalities, has been rarely reported with use; periodically monitor LFTs with prolonged use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Tablets may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; avoid use of labetalol products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Alpha-/Beta-Blockers may diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss); food may increase bioavailability",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse events were observed in some animal reproduction studies, labetalol is classified as pregnancy category C. Labetalol crosses the placenta and can be detected in cord blood and infant serum after delivery. It has been shown to decrease maternal blood pressure without significantly effecting placental blood flow. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The pharmacokinetics of labetalol are not significantly changed during the third trimester of pregnancy. Labetalol is considered an appropriate agent for the treatment of hypertension in pregnancy; intravenous labetalol is also used for the management of pre-eclampsia.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, pulse, ECG;",
"     <b>",
"      Note:",
"     </b>",
"     I.V. use: Monitor closely; due to the prolonged duration of action, careful monitoring should be extended for the duration of the infusion and for several hours after the infusion; excessive administration may result in prolonged hypotension and/or bradycardia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks alpha-, beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptor sites; elevated renins are reduced",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 20 minutes to 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 8-24 hours (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; small amounts in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 3-16 L/kg; mean: 9.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via primarily glucuronide conjugation; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 25%; increased bioavailability with liver disease, elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (55% to 60%, primarily as glucuronide conjugates, &lt;5% as unchanged drug); possible decreased clearance in neonates and infants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/21/20821?source=see_link\">",
"      see \"Labetalol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol; may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause postural hypotension;  do not stop medication abruptly; may cause dry mouth. For diabetic patients, monitor serum glucose closely and notify prescriber of changes. Report altered CNS status (eg, fatigue; depression; numbness or tingling of fingers, toes, or skin), palpitations or slowed heartbeat, respiratory difficulty, edema, or cold extremities.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F186182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 40 mg/mL labetalol hydrochloride oral suspension may be made with tablets and one of three different vehicles (cherry syrup, a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush sixteen 300 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"protect from light\". Stable for 60 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated (Allen, 1996).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Extemporaneously prepared solutions of labetalol hydrochloride (approximate concentrations 7-10 mg/mL) prepared in distilled water, simple syrup, apple juice, grape juice, and orange juice were stable for 4 weeks when stored in amber glass or plastic prescription bottles at room temperature or refrigerated (Nahata, 1991).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Labetalol Hydrochloride, Metoprolol Tartrate, Verapamil Hydrochloride, and Spironolactone with Hydrochlorothiazide in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(19):2304-9.",
"     <span class=\"pubmed-id\">",
"      8893069",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, \"Stability of Labetalol Hydrochloride in Distilled Water, Simple Syrup, and Three Fruit Juices,\"",
"     <i>",
"      DICP",
"     </i>",
"     , 1991, 25(5):465-9.",
"     <span class=\"pubmed-id\">",
"      2068828",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39863/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , 2011, National Institutes of Health. Available at  file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf. Date accessed: March 16, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39863/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39863/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas CA, Moffett BS, Wagner JL, et al, \"Safety and Efficacy of Intravenous Labetalol for Hypertensive Crisis in Infants and Small Children,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2011, 12(1):28-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39863/abstract-text/20495503/pubmed\" id=\"20495503\" target=\"_blank\">",
"        20495503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wesley AG, Hariparsad D, Pather M, et al, &ldquo;Labetalol in Tetanus. The Treatment of Sympathetic Nervous System Overactivity,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1983, 38(3):243-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39863/abstract-text/6837902 /pubmed\" id=\"6837902 \" target=\"_blank\">",
"        6837902",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Willis JK, Tilton AH, Harkin JC, et al, \"Reversible Myopathy Due to Labetalol,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1990, 6(4):275-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/59/39863/abstract-text/2206162/pubmed\" id=\"2206162\" target=\"_blank\">",
"        2206162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13403 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39863=[""].join("\n");
var outline_f38_59_39863=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186205\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186206\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053525\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053516\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186176\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186160\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053529\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472669\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186254\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053520\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053528\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186256\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186253\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053534\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053515\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053514\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299562\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186169\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053536\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186172\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186187\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053524\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053513\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053532\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053533\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053522\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186182\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13403\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13403|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=related_link\">",
"      Labetalol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/21/20821?source=related_link\">",
"      Labetalol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_59_39864="Iodine deficiency disorders";
var content_f38_59_39864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iodine deficiency disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39864/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39864/contributors\">",
"     Paolo Vitti, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39864/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39864/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39864/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/59/39864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both insufficient and excessive iodine intake can result in thyroid disease. The term \"iodine deficiency disorders\" refers to the several consequences that iodine deficiency imposes on individuals. Important consequences include goiter, hypothyroidism, and intellectual disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/1\">",
"     1",
"    </a>",
"    ]. When severe iodine deficiency occurs during pregnancy, it is associated with cretinism and increased neonatal and infant mortality.",
"   </p>",
"   <p>",
"    Iodine is an essential component of thyroxine (T4) and triiodothyronine (T3), and it must be provided in the diet. Inadequate iodine intake leads to inadequate thyroid hormone production, and all the consequences of iodine deficiency stem from the associated hypothyroidism.",
"   </p>",
"   <p>",
"    In developing countries, iodine deficiency has been identified as one of the modifiable factors that have an adverse effect on child development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/2\">",
"     2",
"    </a>",
"    ]. It is a global public health problem and, in combating it, emphasis should be placed on diagnosis and correction at the level of the community rather than the individual. The International Council for the Control of Iodine Deficiency Disorders (ICCIDD) maintains a website (",
"    <a class=\"external\" href=\"file://www.iccidd.org/\">",
"     www.iccidd.org",
"    </a>",
"    ) with databases of information about iodine nutrition in different countries and an information reference desk.",
"   </p>",
"   <p>",
"    This topic will review the consequences of iodine deficiency, its geographical distribution, diagnostic measures, prophylaxis, and treatment. Other aspects of iodine and the thyroid, including the adverse consequences of iodine excess, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147486325\">",
"    <span class=\"h1\">",
"     IODINE REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodide is essential for thyroid hormone synthesis. In order for the thyroid gland to synthesize adequate amounts of thyroxine (T4), approximately 52 mcg of iodide must be taken up daily by the thyroid gland. Severe iodine deficiency develops when iodide intake is chronically &lt;20",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33320?source=see_link&amp;anchor=H3#H3\">",
"     \"Thyroid hormone synthesis and physiology\", section on 'Thyroid hormone biosynthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iodine can be obtained by consumption of foods that naturally contain it (fish, seafood, kelp, some drinking water, and vegetables grown in iodine sufficient soil) or to which it is added (table salt). Cow&rsquo;s milk is a source of iodine owing to iodine in cattle feed and the use of iodophor udder cleansers in the dairy industry. Sea salt naturally contains only a small amount of iodine. Dietary iodine is absorbed as iodide and rapidly distributed in the extracellular fluid, which also contains iodide released from the thyroid and by extrathyroidal deiodination of the iodothyronines. Iodide leaves this pool by transport into the thyroid and excretion into the urine.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) recommends 90 mcg of iodine daily for infants and children up to five years, 120 mcg for children 6 to 12 years, 150 mcg daily for children &ge;12 years and adults, and 250 mcg daily during pregnancy and lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/3\">",
"     3",
"    </a>",
"    ]. The US Institute of Medicine recommended minimum daily intake of iodine is similar: 90 mcg daily for children one to eight years old, 120 mcg for children 9 to 13 years, 150 mcg daily for older adolescents and nonpregnant adults, 220 mcg for pregnant women, and 290 mcg for lactating women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/4\">",
"     4",
"    </a>",
"    ]. The iodine requirements are higher in pregnant women due to an increase in maternal T4 production required to maintain maternal euthyroidism. Severe maternal iodine deficiency during pregnancy results in a reduction in maternal thyroxine production, inadequate placental transfer of maternal thyroxine, and impairment of fetal neurologic development. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Consequences of iodine deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147486924\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF IODINE STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A system for classifying iodine deficiency and sufficiency has been developed based upon the median urinary iodine concentration in a population (",
"    <a class=\"graphic graphic_table graphicRef74914 \" href=\"mobipreview.htm?20/54/21355\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/5\">",
"     5",
"    </a>",
"    ]. The most usual survey group is school-age children, but their nutrition must reflect that of the community in order for the data to be meaningful. Mild iodine deficiency is defined as a median urinary iodine concentration of 50 to 99",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    moderate deficiency as 20 to 49",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    and severe deficiency as &lt;20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/6\">",
"     6",
"    </a>",
"    ]. Pregnant women require special attention because their renal threshold for iodine is lower, the needs of the fetus are greater, and dietary salt (including iodized salt) is often restricted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In pregnant women, urinary iodine concentrations of 150 to 249",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    are considered adequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A median average daily iodine intake of 150 mcg corresponds to a median urinary iodine concentration of 100",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF IODINE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine deficiency is associated with goiter and hypothyroidism. When severe iodine deficiency occurs during pregnancy, it is associated with cretinism and increased neonatal and infant mortality. In addition, mild iodine deficiency is associated with thyroid enlargement and learning disabilities in children. Additional factors that can exacerbate the effects of iodine deficiency include coexistent deficiencies of iron,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , and vitamin A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/9\">",
"     9",
"    </a>",
"    ], and the ingestion of foods such as cassava or millet that contain goitrogenic substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diffuse and nodular goiter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goiter is the most obvious manifestation of iodine deficiency. Low iodine intake leads to reduced T4 and T3 production, which results in increased thyrotropin (TSH) secretion in an attempt to restore T4 and T3 production to normal. TSH also stimulates thyroid growth; thus, goiter occurs as part of the compensatory response to iodine deficiency.",
"   </p>",
"   <p>",
"    The goiter is initially diffuse but eventually becomes nodular because the cells in some thyroid follicles proliferate more than others. Therefore, in regions of iodine deficiency, children and adolescents generally have diffuse goiters, while adults who lived in conditions of longstanding iodine deficiency have nodular goiter. Iodine deficiency favoring thyroid follicular cell replication also increases the chance of mutations in the TSH-receptor gene that may lead to constitutive activation of the receptor and TSH-independent growth and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With continued growth of one or more TSH-independent nodules, hyperthyroidism may ensue if iodine deficiency is not extremely severe. Hyperthyroidism is more likely to develop if iodine intake is supplemented, just as it can occur in patients with nontoxic nodular goiters living in iodine-replete regions who are given large doses of iodine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Goiter has traditionally been assessed by palpation, particularly in field studies. In the last decade, ultrasonography, which allows precise estimation of thyroid volume, has become the preferred method of assessment. In regions of iodine deficiency, the median thyroid volume at any age is considerably larger than that in regions of iodine sufficiency. For subjects living in iodine-sufficient regions, thyroid volume measurements standardized for age, sex, and body size are now available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/12\">",
"     12",
"    </a>",
"    ]. The volume in subjects living in the United States is smaller than that in Europe, many regions of which have a lower iodine intake than in the United States.",
"   </p>",
"   <p>",
"    For many individuals, iodine-deficiency goiter is only a cosmetic problem. In some, however, particularly older adults, the goiter may be large enough to cause compression of the trachea or esophagus, or delay recognition of coexisting thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/46?source=see_link\">",
"     \"Clinical manifestations and evaluation of obstructive or substernal goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism due to very low iodine intake is now extremely rare. Adults have the typical clinical manifestations of hypothyroidism and usually a goiter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .) For the developing fetus or infant, untreated maternal hypothyroidism due to severe iodine deficiency is a catastrophe because thyroid hormone is essential for normal maturation of the central nervous system, particularly its myelination. For the first 12 weeks of gestation, the fetus is completely dependent upon maternal thyroxine. During the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation, fetal TSH appears and the fetal thyroid is capable of concentrating iodine and synthesizing iodothyronines. However, little hormone synthesis occurs until the 18",
"    <sup>",
"     th",
"    </sup>",
"    to 20",
"    <sup>",
"     th",
"    </sup>",
"    week. Thereafter, fetal thyroid secretion increases gradually. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Thyroid function in the fetus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothyroidism during these critical periods of development leads to permanent mental retardation which, in its most severe form, is known as cretinism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .) In a randomized trial and several population-based studies of women living in severely iodine deficient regions, iodine supplementation to women prior to conception or during early pregnancy was associated with substantially better neurologic and developmental outcomes in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cretinism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to mental retardation, cretinism is accompanied by other neurologic and somatic defects. This has led to cretinism being subdivided into neurologic and myxedematous types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurological cretinism is characterized by mental retardation, deaf mutism, gait disturbances, and spasticity, but not hypothyroidism. It is thought to result from hypothyroidism in the mother during early pregnancy, but a euthyroid state postnatally.",
"     </li>",
"     <li>",
"      Myxedematous cretinism is characterized by mental retardation, short stature, and hypothyroidism. It is thought to result from iodine deficiency and thyroid injury predominantly late in pregnancy and continuing after birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two syndromes overlap considerably [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/16\">",
"     16",
"    </a>",
"    ], and attributing them to specific developmental periods is undoubtedly overly simplistic. Both can be prevented by adequate maternal and infant iodine intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147486588\">",
"    <span class=\"h3\">",
"     Neonatal and infant mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe iodine deficiency increases neonatal and infant mortality, an effect that can be reduced by up to 50 percent with correction of severe iodine deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/17\">",
"     17",
"    </a>",
"    ]. The mechanism of this benefit is not known, but multiple factors are probably involved. Hypothyroid or retarded infants may suffer more birth trauma and be more prone to infectious diseases and nutritional deficiencies typical of the poor rural communities in which iodine deficiency is so prominent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147486650\">",
"    <span class=\"h2\">",
"     Subclinical neurological defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal iodine nutrition in the pregnant woman is required for a full development of the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/7\">",
"     7",
"    </a>",
"    ]. The potential adverse effects of mild to moderate iodine deficiency during pregnancy are uncertain. Minor neuropsychological defects have been described in children born to mothers exposed to mild to moderate iodine deficiency during pregnancy. These defects may be detected by appropriate neuropsychological tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the results of randomized trials of iodine supplementation to pregnant women with mild to moderate iodine deficiency have reported mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/19\">",
"     19",
"    </a>",
"    ]. In some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] trials, iodine supplementation resulted in smaller thyroid volumes and lower thyroglobulin concentrations in mothers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    newborns compared with controls. However, there was no effect on maternal or neonatal thyroxine concentrations in the majority of the trials. In addition, there are no randomized trial data on child development or other long-term outcomes.",
"   </p>",
"   <p>",
"    In two observational studies of women with mild to moderate iodine deficiency and mild hypothyroxinemia, neurodevelopmental outcomes were better in children whose mothers received iodine supplementation (200 to 300 mcg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    daily) early in pregnancy (prior to the 10",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation) compared with children whose mothers did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The better outcomes noted in the observational studies may be related to improvement in maternal hypothyroxinemia. Both mild and severe maternal hypothyroxinemia have reportedly been associated with a higher risk of expressive language delay in newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/27\">",
"     27",
"    </a>",
"    ]. Severe maternal hypothyroxinemia also predicted a higher risk of nonverbal cognitive delay. It is possible that iodine supplementation in women with iodine deficiency severe enough to cause maternal hypothyroxinemia may improve neurodevelopmental outcomes, but this has not been assessed in randomized trials.",
"   </p>",
"   <p>",
"    An increased auditory threshold may be another clinical manifestation of iodine deficiency. As an example, in a study of 150 school-age children in Spain, 38 percent had a goiter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/28\">",
"     28",
"    </a>",
"    ]. In this subset, there was an inverse relationship between auditory threshold and urinary iodine excretion (ie, the more iodine deficient, the higher the auditory threshold). Thus, iodine repletion in children may be important not only to prevent goiter, but also to prevent changes in auditory threshold. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intellectual disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine deficiency also appears to have adverse effects on growth and development in the postnatal period. Children and adolescents in regions of iodine deficiency are at risk for some degree of intellectual disability. A meta-analysis of studies relating iodine deficiency to cognitive development suggested that iodine deficiency alone caused an average loss of 13.5 IQ points in affected subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/29\">",
"     29",
"    </a>",
"    ]. Developmental studies in iodine-deficient regions have many limitations, including an inability to distinguish between the persistent effects of fetal iodine deficiency and the ongoing effects of iodine deficiency in childhood and adolescence.",
"   </p>",
"   <p>",
"    Even in developed countries, marginal iodine sufficiency may lead to intellectual compromise. In Jaen province, Spain, schoolchildren with urinary iodine concentrations below 100",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    had lower IQ scores: 96.4 versus 99.0 in schoolchildren with urinary iodine concentrations greater than 100",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intellectual disability resulting from the effects of iodine deficiency on the central nervous system during fetal development is not reversible. In contrast, the additional impairment caused by continuing postnatal hypothyroidism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iodine deficiency may improve with appropriate thyroid hormone replacement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iodine supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/31\">",
"     31",
"    </a>",
"    ]. In a trial of iodine supplementation or placebo in 310 children in Albania, iodine supplementation significantly improved thyroid function (prevalence of hypothyroxinemia was reduced from approximately 30 to &lt;1 percent) and performance on cognitive testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Socioeconomic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;People in iodine deficient communities are typically less educable and less economically productive. Correction of the deficiency has resulted in dramatic improvement in school performance, agricultural output, and per capita income.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GEOGRAPHIC DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report from the World Health Organization showed that between the years 2003 and 2007 there was substantial progress in reducing the frequency of iodine deficiency (",
"    <a class=\"graphic graphic_figure graphicRef79246 \" href=\"mobipreview.htm?19/43/20151\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/6,33\">",
"     6,33",
"    </a>",
"    ]. Data were available from 130 countries covering 92.4 percent of the world's 6 to 12 year population. Approximately 31.5 percent (264 million) of school-aged children (corresponding to an estimated general population of about 2 billion individuals) were iodine deficient (defined by a daily iodine intake &lt;100 mcg). This represented a 5 percent decrease in prevalence in school-aged children since 2003. The largest decreases occurred in South East Asia and in the Western Pacific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/33\">",
"     33",
"    </a>",
"    ]. The Americas region was the only region which remained stable with a prevalence of 11 percent.",
"   </p>",
"   <p>",
"    In spite of this progress, iodine deficiency remains the world's most prevalent thyroid disease. Inland regions, especially relatively \"young\" mountainous areas (eg, the Andes, Alps, and Himalayas), are particularly iodine-deficient. However, iodine deficiency also occurs in some island communities (eg, Azores) and coastal cities (eg, Manila and Bombay), perhaps because fish, a good dietary source of iodine, is not widely eaten. European countries lacking specific iodine prophylaxis programs are also mildly iodine deficient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/34\">",
"     34",
"    </a>",
"    ]. The prevalence of iodine deficiency in Europe was reduced by 30 percent from 2003 to 2010, but 44 percent of school-age children still have insufficient iodine intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/35\">",
"     35",
"    </a>",
"    ]. In a 2009 survey of schoolgirls aged 14 to 15 years living in the United Kingdom, which has long been considered iodine sufficient, median urinary iodine excretion was 80.1",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    consistent with mild iodine deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/36\">",
"     36",
"    </a>",
"    ]. Only a few countries appear to have sustainable iodine sufficiency at the present time: the United States, Canada, Norway, Sweden, Finland, Switzerland, Austria, Bhutan, Peru, Panama, Macedonia, and Japan.",
"   </p>",
"   <p>",
"    Iodine intake in the United States has remained stable since 2000, with a median urinary iodine excretion, a measure of iodine nutrition, of 160",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    (1.3",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/37\">",
"     37",
"    </a>",
"    ]. Among women of reproductive age, the median urinary iodine excretion was 139",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    with 15 percent of women having levels &lt;50",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"    Iodine nutrition in the US is mainly achieved by silent iodine prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/38\">",
"     38",
"    </a>",
"    ]. A systematic survey of US food iodine sources since the early 1990s suggests that the average US iodine intake is currently sufficient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF IODINE NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine nutrition at the community level is best assessed by measurements of urinary iodine, thyroid size, and serum TSH and thyroglobulin. The urinary iodine concentration indicates current iodine nutrition, while thyroid size and the serum thyroglobulin concentration reflect iodine nutrition over a period of months or years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Urinary iodine excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent or more of ingested iodine eventually appears in the urine. Measurements of urinary iodine concentration in randomly collected urine samples have proven to be as useful as measurements of urinary creatinine and iodine and calculation of the iodine:creatinine ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/41\">",
"     41",
"    </a>",
"    ]. The results from random samples also correlate well with 24-hour urine collections. As a result, iodine nutrition is often defined by the urinary iodine concentration in randomly collected urine samples. Mild iodine deficiency is defined as a median urinary iodine concentration of 50 to 99",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    moderate deficiency as 20 to 49",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    and severe deficiency as &lt;20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef74914 \" href=\"mobipreview.htm?20/54/21355\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neonatal serum TSH screening for hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In regions of iodine deficiency, the frequency of supranormal TSH concentrations (&gt;5",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    in blood spots collected as part of neonatal screening programs is higher than in iodine sufficient areas and roughly correlates with the severity of iodine deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/42\">",
"     42",
"    </a>",
"    ]. Transient neonatal hypothyroidism is also more frequent. For this reason, WHO has established that the results of neonatal blood TSH screening can be used as convenient indicators for iodine intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serum thyroglobulin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum thyroglobulin concentration is a sensitive measure of thyroid activity and hyperplasia. In iodine-deficient infants and children, serum thyroglobulin concentrations are high more often than are serum TSH concentrations. Although a nonspecific test, since any type of thyroid stimulation or injury raises the serum thyroglobulin concentration, the values correlate well with the severity of iodine deficiency. In one study, the serum thyroglobulin level was better than thyroid volume measurement by ultrasound as an indicator of iodine nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thyroid size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid size is a sensitive marker for iodine deficiency because goiter, although not the most severe consequence of iodine deficiency, is the most clinically evident. Assessment by palpation is too crude to be anything more than qualitative except in severe deficiency, but ultrasonography is precise, quantifiable, and easily performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid radioiodine uptake is increased in iodine deficiency because of both thyroid stimulation and the low iodine pool size, but is not a practical field test. Serum T4, T3, and TSH concentrations are within their respective normal ranges in most children and adults with iodine deficiency; thus, these tests are not sufficiently sensitive for diagnosis of the disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS AND TREATMENT OF THE COMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine deficiency is a global public health problem and, in combating it, emphasis should be placed on diagnosis and correction at the level of the community rather than the individual. Achieving sufficient iodine nutrition in the population would eliminate the need for specific supplementation during pregnancy and lactation.",
"   </p>",
"   <p>",
"    For the general nonpregnant, nonlactating population in the US, iodine supplementation above what is obtained from iodine fortified foods is not necessary. For pregnant and lactating women in the US, the American Thyroid Association recommends supplementation of 150 mcg of iodine (in the form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    ) daily during pregnancy and lactation, which is the dose included in the majority of prenatal vitamins marketed in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/8\">",
"     8",
"    </a>",
"    ]. The Institute of Medicine recommends iodine intake at 220 mcg daily for pregnant women and 290 mcg daily during lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H59356473\">",
"     'Pregnancy and lactation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59356759\">",
"    <span class=\"h2\">",
"     Iodization of salt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodization of salt is the preferred method of increasing iodine intake in a community. Salt iodination is legally mandated in many countries. Salt is a dietary necessity and often the only one that communities cannot provide for themselves. Adding iodine during the packaging or processing of salt is an efficient means for distributing iodine on a mass basis. It is technically easy (and can even be done manually) and the cost is low, although the accompanying changes in salt processing may increase the price to the consumer. The usual \"dose\" is between 10 and 50 mg of",
"    <span class=\"nowrap\">",
"     iodine/kg",
"    </span>",
"    salt (sodium chloride) as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    or iodate.",
"   </p>",
"   <p>",
"    The optimal amount to be added for a particular country or region can be calculated from the daily per capita salt consumption, the amount of iodine consumed from other sources, and any losses of iodine between production and consumption.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     Potassium iodide",
"    </a>",
"    is added in the United States, Canada, and many countries in Western Europe. However, in hot tropical climates or suboptimal conditions of purity or storage, potassium iodate is preferred over potassium iodide because it is more stable. In Finland, iodization of animal feed resulted in a five- to sevenfold increase in the average individual's iodine intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of salt iodization programs relates to sources of salt within a country. Some countries, such as Congo, Nigeria, and Zimbabwe, import all their salt, making control of iodization fairly simple. In other countries with numerous scattered salt deposits and a complex distribution system, implementation of salt iodization has been more difficult. A determined international effort towards eliminating iodine deficiency by the year 2005 has resulted in major progress with about 70 percent of households worldwide using adequately iodized salt. In Denmark, the use of iodized salt resulted in a 6 percent and 14 percent reduction in thyroid gland volume in patients from areas of mild or moderate iodine deficiency, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59356766\">",
"    <span class=\"h2\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternatives are needed when salt iodization is impractical or delayed. Effective options are iodized oil (Lipiodol), iodized water, and iodine tablets or drops. In addition, alternative methods of food iodine enrichment are currently under study. Hydroponic experiments were carried out to investigate the possibility of enriching the iodine uptake by spinach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/46\">",
"     46",
"    </a>",
"    ] or other vegetables such as tomatoes and potatoes.",
"   </p>",
"   <p>",
"    Lipiodol, developed as a radiographic contrast agent, contains 480 mg",
"    <span class=\"nowrap\">",
"     iodine/mL.",
"    </span>",
"    A single oral dose of 0.5 to 1.0 mL provides an adequate amount of iodine for six months to one year; intramuscular administration of the same dose provides an adequate amount for two to three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/47\">",
"     47",
"    </a>",
"    ]. Iodized oil is more expensive than salt iodization and requires direct administration to each subject. If given intramuscularly, it requires skilled administration and has a risk of infection if improper technique is used. Its main advantage is that it can be implemented promptly. It has been especially valuable for women of childbearing age and children in regions of severe iodine deficiency.",
"   </p>",
"   <p>",
"    Water is another occasional iodization vehicle because it is a daily necessity like salt. The technology can be as simple as adding a few drops of iodine to standing drinking water. Addition of molecular iodine (but not iodide or iodate) carries the additional benefit of sterilizing the water. Other methods of iodide administration include oral administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    solution every two to four weeks and daily administration of tablets containing from 100 to 300 mcg potassium iodide. The latter is particularly recommended to meet the increased needs for iodine during pregnancy and lactation, and it can be routinely incorporated into prenatal",
"    <span class=\"nowrap\">",
"     vitamin/mineral",
"    </span>",
"    preparations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59356473\">",
"    <span class=\"h2\">",
"     Pregnancy and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consuming an adequate amount of iodine during pregnancy is important for fetal development. In regions where &lt;90 percent of households use iodized salt (",
"    <a class=\"external\" href=\"file://www.iccidd.org/\">",
"     www.iccidd.org",
"    </a>",
"    ) and the median urinary iodine concentration in children is &lt;100",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    the WHO recommends iodine supplementation in pregnancy and lactation (250 mcg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/3\">",
"     3",
"    </a>",
"    ]. In pregnant women, urinary iodine concentrations of 150 to 249",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    indicate adequate iodine intake.",
"   </p>",
"   <p>",
"    In the United States, women who do not consume dairy products or iodized salt may have lower urinary iodine concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/48\">",
"     48",
"    </a>",
"    ]. The American Thyroid Association recommends that women from the US receive a supplement of 150 mcg of iodine (in the form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    ) daily during pregnancy and lactation, which is the dose included in the majority of prenatal vitamins marketed in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/8\">",
"     8",
"    </a>",
"    ]. The Institute of Medicine recommended minimum daily intake is somewhat higher: 220 mcg for pregnant women and 290 mcg for lactating women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking reduces iodine in breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In Denmark, mothers who smoke have reduced iodine in their breast milk (26",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    versus 54",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    in nonsmokers despite identical urine iodine concentrations), and their infants have reduced urinary iodine concentrations (33",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    versus 40",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    in nonsmokers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/49\">",
"     49",
"    </a>",
"    ]. Smoking cessation efforts are important in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sustaining iodine sufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular monitoring of iodine nutrition is essential for sustaining iodine sufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/51\">",
"     51",
"    </a>",
"    ]. Iodine deficiency has recurred in some countries with initially successful programs after a regular follow-up program was abandoned. Potential contributing factors include a decrease in salt intake, a reduction in the use of iodine salts in the baking industry, and undoubtedly other unidentified commercial and environmental factors. In some countries that have mandatory programs of salt iodization, inadequate quality control has caused major fluctuations in dietary iodine intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59356843\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine repletion in the doses used for iodization of salt and in prenatal supplements has few adverse effects. Iodine administration may result in hyperthyroidism in patients with endemic goiter or in patients with nodular goiters containing autonomously functioning tissue. In contrast, iodine administration may induce or exacerbate hypothyroidism in patients with underlying autoimmune thyroiditis. In regions of iodine deficiency, both hyperthyroidism and hypothyroidism have been reported after the introduction of iodine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. The evaluation and management of patients with iodine-induced thyroid disease is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excessive iodine ingestion during pregnancy may also have adverse effects on fetal thyroid function. Sudden exposure to excess serum iodide inhibits organification of iodide, thereby diminishing hormone biosynthesis; this phenomenon is called the Wolff-Chaikoff effect. The fetal thyroid gland is particularly susceptible to the inhibitory effects of excess iodine during the third trimester, which can result in a prolonged inhibition of thyroid hormone synthesis, an increase in TSH, and fetal goiter.",
"   </p>",
"   <p>",
"    The tolerable upper intake amount for iodine, as established by European and US expert committees, ranges from 600 to 1100 mcg daily for adults and pregnant women &gt;19 years age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39864/abstract/4,56\">",
"     4,56",
"    </a>",
"    ]. For adolescents 15 to 17 years, it ranges from 500 to 900 mcg daily and for younger children, 200 to 450",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147486289\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iodide is essential for thyroid hormone synthesis. Iodine can be obtained by consumption of foods that naturally contain it (fish, seafood, kelp, dairy products, some drinking water, and vegetables grown in iodine sufficient soil) or to which it is added (table salt). The World Health Organization (WHO) recommends 90 mcg of iodine daily for infants and children up to five years, 120 mcg for children 6 to 12 years, 150 mcg daily for children &ge;12 years and adults, and 250 mcg daily during pregnancy and lactation. (See",
"      <a class=\"local\" href=\"#H147486325\">",
"       'Iodine requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A system for classifying iodine deficiency and sufficiency has been developed based upon the median urinary iodine concentration in a population (",
"      <a class=\"graphic graphic_table graphicRef74914 \" href=\"mobipreview.htm?20/54/21355\">",
"       table 1",
"      </a>",
"      ). Pregnant women need special attention because their renal threshold for iodine is lower, the needs of the fetus are greater, and dietary salt (including iodized salt) is often restricted. In pregnant women, urinary iodine concentrations of 150 to 249",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      are considered adequate. (See",
"      <a class=\"local\" href=\"#H147486924\">",
"       'Classification of iodine status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iodine deficiency is associated with goiter and hypothyroidism. When severe iodine deficiency occurs during pregnancy, it is associated with cretinism and increased neonatal and infant mortality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Consequences of iodine deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iodine nutrition at the community level is best assessed by measurements of urinary iodine, thyroid size, and serum TSH and thyroglobulin. The urinary iodine concentration indicates current iodine nutrition, while thyroid size and the serum thyroglobulin concentration reflect iodine nutrition over a period of months or years. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Assessment of iodine nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iodine deficiency is a global public health problem and, in combating it, emphasis should be placed on diagnosis and correction at the level of the community rather than the individual. Iodization of salt is the preferred method of increasing iodine intake in a community. The usual amount is between 10 and 50 mg of",
"      <span class=\"nowrap\">",
"       iodine/kg",
"      </span>",
"      salt (sodium chloride) as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      or iodate. Alternatives for when salt iodization is impractical or delayed include iodized oil (Lipiodol), iodized water, and iodine tablets or drops. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prophylaxis and treatment of the community'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consuming an adequate amount of iodine during pregnancy is important for fetal development. In regions where &lt;90 percent of households use iodized salt (",
"      <a class=\"external\" href=\"file://www.iccidd.org/\">",
"       www.iccidd.org",
"      </a>",
"      ) and the median urinary iodine concentration in children is &lt;100",
"      <span class=\"nowrap\">",
"       mcg/L,",
"      </span>",
"      the WHO recommends iodine intake in pregnancy and lactation (250 mcg daily). In iodine replete countries like the US, supplementation with 150 mcg of iodine (in the form of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      ) daily during pregnancy and lactation is usually adequate. This is the dose included in the majority of prenatal vitamins marketed in the US. (See",
"      <a class=\"local\" href=\"#H59356473\">",
"       'Pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/1\">",
"      Zimmermann MB. Iodine deficiency. Endocr Rev 2009; 30:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/2\">",
"      Walker SP, Wachs TD, Gardner JM, et al. Child development: risk factors for adverse outcomes in developing countries. Lancet 2007; 369:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/3\">",
"      WHO Secretariat, Andersson M, de Benoist B, et al. Prevention and control of iodine deficiency in pregnant and lactating women and in children less than 2-years-old: conclusions and recommendations of the Technical Consultation. Public Health Nutr 2007; 10:1606.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board Institute of Medicine. Dietary reference intake. Washington, DC: National Academy Press, 2001.",
"    </li>",
"    <li>",
"     ICCIDD, UNICEF, WHO. Assessment of iodine deficiency disorders and monitoring their elimination. Geneva, World Health Organization, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/6\">",
"      Andersson M, Takkouche B, Egli I, et al. Current global iodine status and progress over the last decade towards the elimination of iodine deficiency. Bull World Health Organ 2005; 83:518.",
"     </a>",
"    </li>",
"    <li>",
"     Delange F. Optimal iodine nutrition during pregnancy, lactation and the neonatal period. Int J Endocrinol Metab 2004; 2:1. file://ceecis.org/iodine/04a_consequences/01_preg/Delange_2004.pdf (Accessed on September 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/8\">",
"      Public Health Committee of the American Thyroid Association, Becker DV, Braverman LE, et al. Iodine supplementation for pregnancy and lactation-United States and Canada: recommendations of the American Thyroid Association. Thyroid 2006; 16:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/9\">",
"      Zimmermann MB, Wegm&uuml;ller R, Zeder C, et al. The effects of vitamin A deficiency and vitamin A supplementation on thyroid function in goitrous children. J Clin Endocrinol Metab 2004; 89:5441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/10\">",
"      Kopp P, Kimura ET, Aeschimann S, et al. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab 1994; 79:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/11\">",
"      Tonacchera M, Agretti P, Chiovato L, et al. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab 2000; 85:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/12\">",
"      Zimmermann, MB, Molinari, L, Spehl, M, et al. Updated provisional WHO/ICCIDD reference values for sonographic thyroid volume in iodine-replete school-age children. IDD Newsletter 2001; 17:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/13\">",
"      Cao XY, Jiang XM, Dou ZH, et al. Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. N Engl J Med 1994; 331:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/14\">",
"      Pharoah PO, Connolly KJ. A controlled trial of iodinated oil for the prevention of endemic cretinism: a long-term follow-up. Int J Epidemiol 1987; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/15\">",
"      Qian M, Wang D, Watkins WE, et al. The effects of iodine on intelligence in children: a meta-analysis of studies conducted in China. Asia Pac J Clin Nutr 2005; 14:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/16\">",
"      Boyages SC, Halpern JP, Maberly GF, et al. A comparative study of neurological and myxedematous endemic cretinism in western China. J Clin Endocrinol Metab 1988; 67:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/17\">",
"      DeLong GR, Leslie PW, Wang SH, et al. Effect on infant mortality of iodination of irrigation water in a severely iodine-deficient area of China. Lancet 1997; 350:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/18\">",
"      Aghini Lombardi FA, Pinchera A, Antonangeli L, et al. Mild iodine deficiency during fetal/neonatal life and neuropsychological impairment in Tuscany. J Endocrinol Invest 1995; 18:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/19\">",
"      Zimmermann MB. The adverse effects of mild-to-moderate iodine deficiency during pregnancy and childhood: a review. Thyroid 2007; 17:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/20\">",
"      Pedersen KM, Laurberg P, Iversen E, et al. Amelioration of some pregnancy-associated variations in thyroid function by iodine supplementation. J Clin Endocrinol Metab 1993; 77:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/21\">",
"      Glinoer D, De Nayer P, Delange F, et al. A randomized trial for the treatment of mild iodine deficiency during pregnancy: maternal and neonatal effects. J Clin Endocrinol Metab 1995; 80:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/22\">",
"      Liesenk&ouml;tter KP, G&ouml;pel W, Bogner U, et al. Earliest prevention of endemic goiter by iodine supplementation during pregnancy. Eur J Endocrinol 1996; 134:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/23\">",
"      Romano R, Jannini EA, Pepe M, et al. The effects of iodoprophylaxis on thyroid size during pregnancy. Am J Obstet Gynecol 1991; 164:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/24\">",
"      Antonangeli L, Maccherini D, Cavaliere R, et al. Comparison of two different doses of iodide in the prevention of gestational goiter in marginal iodine deficiency: a longitudinal study. Eur J Endocrinol 2002; 147:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/25\">",
"      Berbel P, Mestre JL, Santamar&iacute;a A, et al. Delayed neurobehavioral development in children born to pregnant women with mild hypothyroxinemia during the first month of gestation: the importance of early iodine supplementation. Thyroid 2009; 19:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/26\">",
"      Velasco I, Carreira M, Santiago P, et al. Effect of iodine prophylaxis during pregnancy on neurocognitive development of children during the first two years of life. J Clin Endocrinol Metab 2009; 94:3234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/27\">",
"      Henrichs J, Bongers-Schokking JJ, Schenk JJ, et al. Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study. J Clin Endocrinol Metab 2010; 95:4227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/28\">",
"      Soriguer F, Mill&oacute;n MC, Mu&ntilde;oz R, et al. The auditory threshold in a school-age population is related to iodine intake and thyroid function. Thyroid 2000; 10:991.",
"     </a>",
"    </li>",
"    <li>",
"     Bleichrodt N, Born MP. A metaanalysis of research on iodine and its relationship to cognitive development. In: The damaged brain of iodine deficiency, Stanbury JB (Ed), Cognizant Communication Corporation, New York 1994. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/30\">",
"      Santiago-Fernandez P, Torres-Barahona R, Muela-Mart&iacute;nez JA, et al. Intelligence quotient and iodine intake: a cross-sectional study in children. J Clin Endocrinol Metab 2004; 89:3851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/31\">",
"      van den Briel T, West CE, Bleichrodt N, et al. Improved iodine status is associated with improved mental performance of schoolchildren in Benin. Am J Clin Nutr 2000; 72:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/32\">",
"      Zimmermann MB, Connolly K, Bozo M, et al. Iodine supplementation improves cognition in iodine-deficient schoolchildren in Albania: a randomized, controlled, double-blind study. Am J Clin Nutr 2006; 83:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/33\">",
"      de Benoist, B, McLean, E, Andersson, M. Iodine deficiency in 2007: Global progress since 2003. IDD Newsletter 2008; 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/34\">",
"      Vitti P, Delange F, Pinchera A, et al. Europe is iodine deficient. Lancet 2003; 361:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/35\">",
"      Andersson M, Karumbunathan V, Zimmermann MB. Global iodine status in 2011 and trends over the past decade. J Nutr 2012; 142:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/36\">",
"      Vanderpump MP, Lazarus JH, Smyth PP, et al. Iodine status of UK schoolgirls: a cross-sectional survey. Lancet 2011; 377:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/37\">",
"      Caldwell KL, Miller GA, Wang RY, et al. Iodine status of the U.S. population, National Health and Nutrition Examination Survey 2003-2004. Thyroid 2008; 18:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/38\">",
"      Pearce EN. U.S. iodine nutrition: where do we stand? Thyroid 2008; 18:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/39\">",
"      Murray CW, Egan SK, Kim H, et al. US Food and Drug Administration's Total Diet Study: dietary intake of perchlorate and iodine. J Expo Sci Environ Epidemiol 2008; 18:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/40\">",
"      Haddow JE, McClain MR, Palomaki GE, Hollowell JG. Urine iodine measurements, creatinine adjustment, and thyroid deficiency in an adult United States population. J Clin Endocrinol Metab 2007; 92:1019.",
"     </a>",
"    </li>",
"    <li>",
"     Bourdoux P, Thilly C, Delange C, Ermans AM. A new look at old concepts in laboratory evaluation of endemic goiter. In: Towards the Eradication of Endemic Goiter, Cretinism, and Iodine Deficiency, Dunn JT, Pretell EA, Daza CH, Viteri FE (Eds), Pan American Health Organization, Washington, DC 1986. p.115.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/42\">",
"      Delange F. Neonatal screening for congenital hypothyroidism: results and perspectives. Horm Res 1997; 48:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/43\">",
"      Vejbjerg P, Knudsen N, Perrild H, et al. Thyroglobulin as a marker of iodine nutrition status in the general population. Eur J Endocrinol 2009; 161:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/44\">",
"      Lamberg BA, Haikonen M, M&auml;kel&auml; M, et al. Further decrease in thyroidal uptake and disappearance of endemic goitre in children after 30 years of iodine prophylaxis in the east of Finland. Acta Endocrinol (Copenh) 1981; 98:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/45\">",
"      Vejbjerg P, Knudsen N, Perrild H, et al. Effect of a mandatory iodization program on thyroid gland volume based on individuals' age, gender, and preceding severity of dietary iodine deficiency: a prospective, population-based study. J Clin Endocrinol Metab 2007; 92:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/46\">",
"      Weng HX, Yan AL, Hong CL, et al. Uptake of different species of iodine by water spinach and its effect to growth. Biol Trace Elem Res 2008; 124:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/47\">",
"      Benmiloud M, Chaouki ML, Gutekunst R, et al. Oral iodized oil for correcting iodine deficiency: optimal dosing and outcome indicator selection. J Clin Endocrinol Metab 1994; 79:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/48\">",
"      Perrine CG, Herrick K, Serdula MK, Sullivan KM. Some subgroups of reproductive age women in the United States may be at risk for iodine deficiency. J Nutr 2010; 140:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/49\">",
"      Laurberg P, N&oslash;hr SB, Pedersen KM, Fuglsang E. Iodine nutrition in breast-fed infants is impaired by maternal smoking. J Clin Endocrinol Metab 2004; 89:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/50\">",
"      Pearce EN, Leung AM, Blount BC, et al. Breast milk iodine and perchlorate concentrations in lactating Boston-area women. J Clin Endocrinol Metab 2007; 92:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/51\">",
"      Dunn JT. What's happening to our iodine? J Clin Endocrinol Metab 1998; 83:3398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/52\">",
"      Martins MC, Lima N, Knobel M, Medeiros-Neto G. Natural course of iodine-induced thyrotoxicosis (Jodbasedow) in endemic goiter area: a 5 year follow-up. J Endocrinol Invest 1989; 12:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/53\">",
"      Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyroid 2001; 11:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/54\">",
"      Pedersen IB, Laurberg P, Knudsen N, et al. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin Endocrinol Metab 2007; 92:3122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39864/abstract/55\">",
"      B&uuml;low Pedersen I, Laurberg P, Knudsen N, et al. Increase in incidence of hyperthyroidism predominantly occurs in young people after iodine fortification of salt in Denmark. J Clin Endocrinol Metab 2006; 91:3830.",
"     </a>",
"    </li>",
"    <li>",
"     European Commission HaCPD-GSCoF, Opinion of the Scientific Committee on Food on the tolerable upper level of intake of iodine, European Commission, Brussels (2002).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7828 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39864=[""].join("\n");
var outline_f38_59_39864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H147486289\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H147486325\">",
"      IODINE REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H147486924\">",
"      CLASSIFICATION OF IODINE STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONSEQUENCES OF IODINE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diffuse and nodular goiter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cretinism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H147486588\">",
"      - Neonatal and infant mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H147486650\">",
"      Subclinical neurological defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intellectual disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Socioeconomic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GEOGRAPHIC DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ASSESSMENT OF IODINE NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Urinary iodine excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neonatal serum TSH screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serum thyroglobulin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thyroid size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROPHYLAXIS AND TREATMENT OF THE COMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59356759\">",
"      Iodization of salt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59356766\">",
"      Other options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59356473\">",
"      Pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sustaining iodine sufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59356843\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H147486289\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7828\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7828|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/43/20151\" title=\"figure 1\">",
"      Degree of public health significance of iodine nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7828|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/54/21355\" title=\"table 1\">",
"      Classification of iodine status",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/46?source=related_link\">",
"      Clinical manifestations and evaluation of obstructive or substernal goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_59_39865="Use of assisted reproduction in HIV and hepatitis infected couples";
var content_f38_59_39865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of assisted reproduction in HIV and hepatitis infected couples",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39865/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39865/contributors\">",
"     Stephanie J Estes, MD, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39865/contributors\">",
"     Elizabeth S Ginsburg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39865/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39865/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39865/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/59/39865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing proportion of couples seeking fertility services have medical issues that need to be addressed. This topic will discuss fertility treatment for individuals chronically infected with HIV or hepatitis C virus, as these individuals can transmit the infection to an uninfected partner during the process of conception. Counseling these couples about the safest methods for avoiding viral transmission to their partner involves discussion of adoption, child-free living, and use of donor sperm, in addition to natural or assisted conception with their own gametes.",
"   </p>",
"   <p>",
"    Recommendations for reducing the risk of viral transmission during fertility treatment have been published by the American Society for Reproductive Medicine (ASRM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/1\">",
"     1",
"    </a>",
"    ]. The basic principles underlying these recommendations are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduce viral load in the infected partner(s)",
"     </li>",
"     <li>",
"      Reduce the non-infected partner&rsquo;s exposure and susceptibility to the infection",
"     </li>",
"     <li>",
"      Discuss the available scientific evidence and risk reduction strategies with both the patient and partner to provide a basis for informed consent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We are not able to make an absolute recommendation for the best procedure for helping serodiscordant couples conceive because there are inadequate data to prove that any technique is significantly safer than any other and choice of treatment is based upon available resources and results of standard infertility tests, which are also part of the decision making process. We evaluate and treat these patients on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis; purpose of treatment; risks, benefits, alternatives to the suggested treatment; and the risks of no treatment must be discussed and documented.",
"   </p>",
"   <p>",
"    Risks include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The transmission to partner (new virus or different strains of virus)",
"     </li>",
"     <li>",
"      Transmission to the child",
"     </li>",
"     <li>",
"      Side effects of infertility treatment on the underlying disease process",
"     </li>",
"     <li>",
"      Complications that pregnancy may cause to the patient's condition",
"     </li>",
"     <li>",
"      Psychosocial implications of the child acquiring the infection",
"     </li>",
"     <li>",
"      The parent(s) becoming unable to care for the child due to parental",
"      <span class=\"nowrap\">",
"       illness/death",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benefits of assisted reproduction technology (ART) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreasing the risk of transmission to the partner compared with unprotected intercourse",
"     </li>",
"     <li>",
"      Decreasing the possibility that the child will be infected",
"     </li>",
"     <li>",
"      Early intervention with",
"      <span class=\"nowrap\">",
"       prenatal/intrapartum",
"      </span>",
"      treatment that can reduce transmission to the child",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, alternatives such as adoption, not having children, and donor sperm if the female is unaffected or surrogacy if the female is affected should be discussed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased longevity and quality of life have led HIV-infected individuals to think about long-term plans, such as childbearing. In a group of serodiscordant (male HIV-infected) opposite-sex couples, 70 percent of the couples expressed a desire to have children in the future if their fertility treatment was successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/4\">",
"     4",
"    </a>",
"    ]. Predictors of couples&rsquo; desires for additional children if fertility treatment was successful were: younger age, shorter relationship duration, being childless currently, and having the male partner diagnosis of HIV known prior to when the couple met. Thus, an understanding of overall fertility desires in this patient population is important, in combination with a discussion of various methods by which pregnancy can be achieved.",
"   </p>",
"   <p>",
"    Infected men and women may seek assistance in pregnancy planning so they can avoid unprotected intercourse with an uninfected partner when the couple is attempting to conceive. One survey reported that 12 percent of HIV serodiscordant couples concerned about transmission of HIV to their partner would still be willing to have unprotected timed intercourse if no other alternatives existed for achieving pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/5\">",
"     5",
"    </a>",
"    ]. Ideally, these couples should have an alternative to unprotected intercourse because even partners with undetectable plasma HIV levels can transmit HIV in semen, female genital secretions, and rectal secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the risk of transmission appears to be very low when the HIV infected partner is receiving maximally suppressive HAART (highly active antiretroviral therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Natural conception in serodiscordant couples'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Factors affecting the risk and rate of male to female and female to male HIV transmission during sexual intercourse are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=see_link&amp;anchor=H4#H4\">",
"     \"The stages and natural history of HIV infection\", section on 'Viral transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Managing HIV-infected patients with childbearing desires involves a multidisciplinary approach, ideally including maternal-fetal medicine specialists,",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    specialists, neonatologists, pediatricians, psychiatrists, social workers, and reproductive endocrinologists. A team of providers knowledgeable in this area should review each case, including the couple's ability to tolerate the fertility evaluation, treatment, and pregnancy.",
"   </p>",
"   <p>",
"    Access to an institution that can care for pregnant patients with HIV and the child delivered under these circumstances is also a prerequisite to beginning fertility treatment. In addition, the program's staff should have training in how to process specimens and separate freezing facilities for",
"    <span class=\"nowrap\">",
"     gametes/embryos",
"    </span>",
"    from HIV infected clients.",
"   </p>",
"   <p>",
"    HIV-infected couples seeking fertility treatment should undergo the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15557532\">",
"    <span class=\"h3\">",
"     Medical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical status of both partners should be evaluated, appropriate preventive therapies should be initiated, and any problems that can be treated should be addressed by their primary care provider",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HIV specialist before initiating fertility therapy. An overview of the evaluation and management of HIV-infected adults can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26474?source=see_link\">",
"     \"Primary care of HIV-infected adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15557539\">",
"    <span class=\"h3\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluating the need for antiretroviral and other medical therapies should be part of the initial assessment. Some issues that need to be addressed by the",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    specialist are: should the patient be started on antiretroviral therapy if",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    is not already taking these drugs? Is",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    on the optimum regimen? Should an HIV negative female partner of an HIV infected male receive prophylactic antiretroviral therapy during ART?",
"   </p>",
"   <p>",
"    For male and female HIV infected individuals starting infertility therapy, common goals are to reduce the viral load to an undetectable level and document stable CD4 counts over a period of time. Typically, this will require antiretroviral therapy, including HAART.",
"   </p>",
"   <p>",
"    Although routine semen analysis may not be significantly different between HIV-infected and uninfected males, as AIDS worsens semen parameters show decreased concentration, motility, and number of morphological normal sperm, and increased round cells with more viscous semen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/9\">",
"     9",
"    </a>",
"    ]. There is likely a positive correlation between total sperm concentration and CD4 count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/10\">",
"     10",
"    </a>",
"    ]. A retrospective study describing observations from 10 years experience providing fertility care to HIV positive men reported 76 of 181 such men (42 percent) had an abnormal semen analysis with at least one parameter in the subfertile range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of antiretroviral therapy does not adversely affect semen analysis. Antiretroviral therapy may be useful from a fertility, as well as a medical, perspective. Some experts believe it may improve the outcome of sperm",
"    <span class=\"nowrap\">",
"     washing/intrauterine",
"    </span>",
"    insemination (IUI) (see below), while others so not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/9,12\">",
"     9,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15557546\">",
"    <span class=\"h3\">",
"     Preconceptional evaluation and counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The couple should receive preconceptional evaluation and counseling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15557553\">",
"    <span class=\"h3\">",
"     Fertility assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before undergoing time-consuming, expensive, and involved treatments such as IUI or IVF, we assess factors that could affect outcomes, even if the HIV positive patient or their partner is not known to be infertile. This assessment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Semen analysis. Leukocytospermia should be evaluated. If present, it may increase the risk for transmission of HIV. Semen parameters affect the choice of treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=see_link\">",
"       \"Evaluation of male infertility\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of ovulatory function and ovarian reserve. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=see_link\">",
"       \"Evaluation of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of fallopian tube patency. HIV-infected women are at risk of infertility from tubal disease, given the increased prevalence of other sexually transmitted infections in HIV-infected individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/13\">",
"       13",
"      </a>",
"      ]. However, if IVF is planned, tubal patency evaluation is not necessary.",
"     </li>",
"     <li>",
"      Assessment of the uterine cavity. Uterine evaluation is performed if clinically indicated. Hysterosalpingography, sonohysterography, or hysteroscopy is performed before IVF to ensure that there is no abnormality that might interfere with pregnancy, such as a submucus fibroid or uterine septum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Female and male infertility factors are addressed, as appropriate.",
"   </p>",
"   <p>",
"    Infertility issues occur in both HIV-infected women and men. A review of age-specific fertility rates (ASFR) from demographic and health surveys revealed a decreasing fertility rate among HIV-positive women compared to HIV-negative women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/14\">",
"     14",
"    </a>",
"    ]. ASFR is calculated as the total number of births in the 36 months preceding the survey divided by the sum of woman-years at childbearing age during that 36 months multiplied by 1000 for every five-year bracket. The ASFR ratio (defined as a ratio of ASFRs of HIV-infected women divided by ASFRs of HIV-uninfected women) for each five-year bracket group from 15 to 49 years old was: 1.2, 0.77, 0.71, 0.65, 0.59, 0.53, 0.47.",
"   </p>",
"   <p>",
"    In addition, semen testing in HIV-infected men, especially those using HAART, has revealed a lower ejaculate volume, decreased sperm motility, and increased abnormal sperm morphology compared to controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15557583\">",
"    <span class=\"h3\">",
"     Counseling and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receive counseling about the psychosocial factors involved in pursuing fertility treatment and are evaluated to make sure they understand and accept these risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Optimal candidates for fertility services",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experts have suggested the following criteria to guide clinicians in selecting HIV infected patients who seek assistance with conception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High motivation for childbearing",
"     </li>",
"     <li>",
"      Well-controlled HIV with a stable CD4 count",
"     </li>",
"     <li>",
"      Undetectable virus in the serum and the semen (&lt;50 to 100",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"     </li>",
"     <li>",
"      Antiretroviral medication adherence of &gt;90 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HIV-infected male and HIV-uninfected female",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal when the male is infected is to prevent transmission of infection to the female partner and the fetus. Options include use of donor sperm, IUI using prepared (washed) sperm from the infected male, or IVF (with ICSI) using prepared (washed) sperm from the infected male. The male partner should be receiving antiretroviral therapy, and oral periconception pre-exposure HIV prophylaxis (PrEP) is an option for the female partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Donor insemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the couple elects to use donor sperm, they should be informed that donor sperm samples are quarantined for at least 180",
"    <span class=\"nowrap\">",
"     days/six",
"    </span>",
"    months after the date of donation to allow testing and retesting of the donors for communicable diseases, such as HIV. Donor insemination is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11433?source=see_link\">",
"     \"Donor insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     IUI with processed sperm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even when there is no detectable virus in the male's serum, the semen may contain a high viral load and transmission to a partner can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/6\">",
"     6",
"    </a>",
"    ]. The risk of female seroconversion is likely to be substantially reduced by utilizing medically assisted reproduction. In couples with a normal fertility evaluation, intrauterine insemination (IUI) with specially processed sperm is a safe and effective approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, if semen analysis is abnormal, then IVF may be the best treatment option. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that HIV is carried in the seminal fluid and white blood cells and that spermatozoa do not carry the virus because they do not have the necessary viral receptors, but this is controversial. Most authorities believe that the sperm do not have HIV on their surface or in the cell. However, it is easy to contaminate a sperm preparation with microscopic quantities of semen. Sperm washing prior to IUI eliminates the round cells, seminal plasma, and the majority of immotile sperm. Sperm are isolated by sequential density gradient and swim-up techniques and are then tested by PCR assays for the presence of HIV RNA. Using this method of sperm preparation, less than 1 percent of sperm samples from HIV-infected men test positive (typically, these \"positives\" are \"low level\" positive tests).",
"   </p>",
"   <p>",
"    A Cochrane Review noted, however, that there were no relevant clinical trials identified in the literature to determine the benefits and risks of sperm washing to prevent HIV transmission in the setting of attempted conception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/22\">",
"     22",
"    </a>",
"    ]. Our current information base is derived from observational studies which demonstrate a need for further research with a multicenter randomized trial in this area. As there have been no documented transmissions of HIV through any processing methods currently used, it is unclear how randomization to treatment other than sperm washing could ethically be performed.",
"   </p>",
"   <p>",
"    The goal of IUI is to place \"virus free\" sperm into the uterine cavity near the time of ovulation. If PCR assays are negative for HIV, the sperm are transferred into the uterine cavity via a flexible catheter. Using this protocol over several thousand cycles, there has been a zero rate of seroconversion in female partners and no documented births of HIV-infected children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, couples should be counseled that the risk of acquiring HIV from insemination with prepared (washed) sperm from an HIV-infected partner has not yet definitively been proven to be zero. We may be approaching assurance of a transmission rate of zero with the advent of nested PCR, which can detect a single HIV viral copy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     IVF with ICSI",
"    </span>",
"    &nbsp;&mdash;&nbsp;IUI has been the traditional medical approach to achieving conception in discordant couples because of convenience and low cost. Since this approach still leaves the potential for thousands to millions of sperm and possible remnants of HIV from the seminal fluid to come into contact with the female partner, the use of IVF with intracytoplasmic sperm injection (ICSI) has had growing appeal, even when there is no evidence of female or male infertility factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/25-33\">",
"     25-33",
"    </a>",
"    ]. IVF with ICSI is used as a first-line approach when there are insufficient sperm for IUI or, theoretically, to reduce exposure to the virus.",
"   </p>",
"   <p>",
"    The combination of sperm wash, nested PCR, and ICSI potentially has several advantages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It provides the least sperm and",
"      <span class=\"nowrap\">",
"       seminal/prostatic",
"      </span>",
"      secretion exposure (a single sperm for each oocyte)",
"     </li>",
"     <li>",
"      Sperm samples negative for disease are already available to the patient for future cycles if sperm are cryopreserved",
"     </li>",
"     <li>",
"      The sperm wash is performed prior to the cycle so cycles are not canceled because of a positive result on PCR testing",
"     </li>",
"     <li>",
"      There is no need to recover large numbers of sperm to achieve adequate pregnancy rates post wash (as in IUI)",
"     </li>",
"     <li>",
"      Pregnancy rates are more than three times higher than for IUI",
"     </li>",
"     <li>",
"      A higher pregnancy rate decreases the number of attempts and exposures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy rates after ICSI in serodiscordant couples are similar to those in HIV-uninfected couples undergoing ICSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/11,23,34,36,37\">",
"     11,23,34,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No seroconversions in over 700 cycles have been documented using the IVF with ICSI approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/23\">",
"     23",
"    </a>",
"    ]. Nevertheless, as with IUI, prevention of HIV viral transmission cannot be guaranteed. Even though IVF with ICSI theoretically reduces the female's exposure to the virus, there are several reasons that it is not the standard technique for all HIV discordant couples. For example, pregnancies conceived by IVF are associated with increased risks of multiple gestations, congenital anomalies, preterm delivery, low birth weight, and the complications associated with these outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the process of IVF, which involves ovulation induction, egg retrieval, and embryo transfer, is not a risk-free surgical procedure and is costly. Potential complications include bleeding, infection, and damage to bowel, bladder, blood vessels, and other internal",
"    <span class=\"nowrap\">",
"     organs/structures.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .) Thus, although minimizing transmission of the virus is a major concern in decision-making with these couples, it is not the only concern.",
"   </p>",
"   <p>",
"    There is a theoretical risk of HIV contamination of the oocyte or embryo during IVF procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/38\">",
"     38",
"    </a>",
"    ]. &nbsp;After",
"    <span class=\"nowrap\">",
"     IVF/ICSI",
"    </span>",
"    because of paternal HIV infection, no births of HIV-infected children to uninfected mothers have been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HIV-infected female and HIV-uninfected male",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal in this situation is to prevent transmission of the virus to the male. Pregnancy rates are similar to those in HIV-uninfected couples undergoing ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/37\">",
"     37",
"    </a>",
"    ]. The female partner should be receiving antiretroviral therapy, and oral periconception pre-exposure HIV prophylaxis (PrEP) is an option for the male partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     IUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;IUI using the male partner's sperm will avoid exposure of the male to his partner's vaginal secretions. If IUI is unsuccessful or if there is severe male factor infertility, then IVF can be performed as per usual protocols. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25351?source=see_link\">",
"     \"Procedure for intrauterine insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a low cost, low resource alternative approach to IUI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The time of the luteinizing hormone (LH) surge, which signifies impending ovulation, is determined using an ovulation predictor kit",
"     </li>",
"     <li>",
"      When the LH surge is identified, the male ejaculates into a condom without spermicide",
"     </li>",
"     <li>",
"      A syringe (without a needle) is then used to aspirate the semen in the condom",
"     </li>",
"     <li>",
"      The syringe is inserted into the vagina and the semen is released near the cervix",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     IVF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like IUI, use of IVF prevents contact of the HIV-uninfected male with the HIV-infected female. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If IVF is performed, HIV-infected women may have a clinically varied response to ovarian hyperstimulation. One study reported that only the CD4 cell count of HIV-infected women had an effect on the occurrence of ovarian resistance to IVF stimulation medications and that increased amounts of gonadotropins were needed to result in ovarian hyperstimulation in HIV-infected women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple gestations are more problematic for HIV-infected women because these pregnancies are at higher risk of preterm delivery. Prematurity due to multiple gestation, and possibly related to HAART (particularly those containing protease inhibitors), together with obstetrical complications increase the risk of maternal-to-fetal HIV transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/40\">",
"     40",
"    </a>",
"    ]. For these reasons, single embryo transfer is desirable in this population (especially in women &lt;40 year old) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link\">",
"     \"Strategies to control the rate of high order multiple gestation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Natural conception in serodiscordant couples",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study of HIV-uninfected women who had timed intercourse with HIV-infected partners reported that 4 of 92 (4.3 percent) seroconverted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/42\">",
"     42",
"    </a>",
"    ]. No seroconversions occurred within the first three months following conception, but two women seroconverted in the third trimester and two seroconverted postpartum; all four cases arose in couples reporting inconsistent condom use. Other studies have reported seroconversion rates of 0.01 to 0.41 percent per act of unprotected intercourse in monogamous, heterosexual, HIV-discordant couples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/43\">",
"     43",
"    </a>",
"    ]. The rate was highest in partners of men with a high viral load and genital ulcers.",
"   </p>",
"   <p>",
"    A mathematical model developed to calculate the cumulative annual risk of transmission of HIV determined the risk of female to male transmission was 0.0022 versus 0.0043 for male to female transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/44\">",
"     44",
"    </a>",
"    ]. The model assumed the couples had 100 sexual acts per year and the HIV-infected partner had a viral load of 10 copies per mL. The rate of transmission may be lower in patients treated with antiretrovirals and who have a viral load below 400.",
"   </p>",
"   <p>",
"    Natural conception would reduce costs associated with assisted reproduction and improve autonomy of couples who are attempting to have children. Theoretically, oral periconception pre-exposure HIV prophylaxis (PrEP) could be an effective therapy to decrease HIV transmission for couples who choose to conceive naturally (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. A case series (n = 53 couples) described successful use of timed intercourse combined with two dose pre-exposure",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    prophylaxis of the female partner of monogamous males under fully suppressive HIV therapy (HIV-RNA in plasma &lt;50",
"    <span class=\"nowrap\">",
"     cp/mL)",
"    </span>",
"    for at least six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For serodiscordant couples attempting to conceive, the Centers for Disease Control and Prevention (CDC) consider the use of PrEP one of several safe and effective options for reducing the risk of HIV infection in the HIV-negative partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/19\">",
"     19",
"    </a>",
"    ]. However, it is prudent to continue to recommend safe sex practices and assisted reproduction techniques until more information is available.",
"   </p>",
"   <p>",
"    Assisted reproduction techniques can also help to overcome subfertility, if present, in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Seroconcordant couples",
"    </span>",
"    &nbsp;&mdash;&nbsp;If both partners are infected, the couple may be concerned about acquiring a new viral strain of the disease from their partner. It has been hypothesized that ART may be useful in these couples to decrease the risk of transmitting a different or mutated strain to the partner. If a female partner has a unique viral mutation, then IUI would reduce the risk of transmission to the male partner. If the male partner has the unique mutation, then sperm washing or donor insemination may be used to reduce the female's risk of acquiring the mutated virus.",
"   </p>",
"   <p>",
"    However, most couples do not know the subtype of HIV that they carry. Moreover, there are no data to document the magnitude and clinical implications of transmission of genotypically divergent strains through sexual intercourse or ART between HIV-infected, subtype discordant partners. Thus, these issues are of theoretical interest, but do not influence ART treatment recommendations at this time. Most such couples attempt to conceive naturally. If infertility issues arise, they are addressed in the same way as in uninfected couples.",
"   </p>",
"   <p>",
"    Of note, one series reported lower ongoing pregnancy rates when both partners were seropositive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/48\">",
"     48",
"    </a>",
"    ]. This may have been related to a very high rate of age-related cancellations or to chance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Legal and ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general consensus in the medical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/49,50\">",
"     49,50",
"    </a>",
"    ] and legal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/51\">",
"     51",
"    </a>",
"    ] communities caring for individuals infected with HIV is that these individuals should not be denied access to infertility treatment or treatment to decrease the risk of infection in an uninfected partner when the couple is attempting to conceive.",
"   </p>",
"   <p>",
"    Physicians should have the right to assist infertility patients with HIV in their reproductive goals without blame if a child is affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/52\">",
"     52",
"    </a>",
"    ]. After appropriate evaluation, however, some patients may not be candidates for ART and the physician is not legally bound to provide treatment.",
"   </p>",
"   <p>",
"    In couples with",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    assistance in conceiving children is supported by the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognosis of patients with HIV has markedly improved with antiretroviral therapy allowing HIV-infected patients to be considered along a continuum of chronic disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=see_link\">",
"       \"The stages and natural history of HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perinatal transmission has decreased significantly with medical interventions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"       \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"       \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ART appears to allow HIV discordant couples to decrease the risk of viral transmission to the unaffected partner.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, opponents to offering infertility treatment to these individuals make the following points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The parental prognosis is uncertain; it may not be in the best interest of the child to be born to a parent who may not be available to provide long-term care for that child.",
"     </li>",
"     <li>",
"      There is a risk of the child acquiring HIV from the parent. This risk is lower than before medical and surgical interventions to prevent perinatal transmission were instituted, but it is not zero.",
"     </li>",
"     <li>",
"      The toxicity and risk of antiretroviral therapy are thought to be minimal, but these issues have not been completely elucidated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"       \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Theoretically, development of drug resistance may be increased by giving prophylactic regimens of antiretroviral agents to prevent perinatal transmission to many women who would not be considered for drug therapy in the absence of pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Legal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bragdon versus Abbott and the American Disabilities Act (ADA) suggest that individuals with HIV can be classified as disabled and are entitled to medical care unless there is objective scientific evidence available that a \"significant risk\" with the proposed treatment is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Under the ADA, \"no individual shall be discriminated against on the basis of disability in the full and equal enjoyment of . . . accommodations of any place of public accommodation\" which includes the \"professional office of a health care provider.\" Handling specimens from HIV-infected patients does pose a risk to the health and safety of others, but this risk can be reduced or eliminated by universal precautions and separated storage facilities. Therefore, HIV-infected status is not enough to justify withholding infertility treatment.",
"   </p>",
"   <p>",
"    Harm may also be thought of in the terms of \"wrongful birth\" and \"wrongful life.\" Wrongful life occurs when the child claims that negligence has occurred and that no life would be superior to the current life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/3\">",
"     3",
"    </a>",
"    ]. Wrongful life is similar to the ethical principle of nonmaleficence (first do no harm). Parents may claim wrongful birth against a health care professional who does not fully inform them of the possibility that the mother may have a child with a disease. This underscores the importance of an extensive informed consent process that allows for patient autonomy in the decision to proceed with treatment with the understanding of the possibility of transmission of HIV to the child. If both partners are infected, then reasonable life expectancy for at least one partner should be documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/16\">",
"     16",
"    </a>",
"    ] and the welfare of the child should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists Ethics Committee has stated that there is an ethical obligation to provide ART to couples where one or both partners are infected with HIV while respecting both the patient's autonomy and fetal beneficence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Ethics Committee of the American Society for Reproductive Medicine (ASRM) has indicated that health care professionals may be legally and ethically obligated to provide requested assistance with reproduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/49\">",
"     49",
"    </a>",
"    ]. Such therapy may be denied by healthcare professionals who provide care at institutions that lack expertise for treating HIV and for HIV-infected couples who refuse the recommended testing and treatment. However, a blanket statement of not offering care is no longer acceptable.",
"   </p>",
"   <p>",
"    In 2010, the California Department of Public health mandated that all fertility centers provide appropriate fertility interventions to HIV infected individuals seeking infertility care, or refer the couple to a center that offers such services.",
"   </p>",
"   <p>",
"    As discussed above, opponents to providing ART to HIV serodiscordant or seroconcordant couples have cited the seriousness of the disease, the availability of reproductive alternatives, and the best interests of the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/56\">",
"     56",
"    </a>",
"    ]. These arguments have been refuted, based on the following principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autonomy &mdash; Autonomy reflects the choice of the patient, after all information is provided, to continue with infertility treatment despite one or both partners being HIV-infected. When considering HIV, it is helpful to point out other disease processes for which we do not deny access to infertility",
"      <span class=\"nowrap\">",
"       evaluation/treatment.",
"      </span>",
"      Many couples with autosomal recessive diseases, such as cystic fibrosis and Tay-Sachs, have a 25 percent chance of transmitting the disease to their child. These diseases may also lead to child mortality, but have a higher risk of transmission than HIV, and yet we allow these couples to proceed with infertility treatment after appropriate genetic counseling. Moreover, women with chronic diseases such as diabetes and heart disease, where the pregnancy may have an effect on the mother's health, are not prohibited from engaging in infertility treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beneficence &mdash; Beneficence is the health care provider's obligation to promote the health of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      patients. Physicians can help patients decrease the transmission of HIV virus to their partner and can assist in providing a couple the psychological well-being that comes from the joy of having a genetically related child. The benefit of a supportive medical environment may encourage a woman to obtain medical and prenatal care and take precautions to prevent transmission to her child.",
"     </li>",
"     <li>",
"      Justice &mdash; The principle of justice refers to the battle between the right to reproduce and the possibility of an affected infant who may suffer and whose care has economic and social implications for the society in which he lives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/16\">",
"       16",
"      </a>",
"      ]. Physicians cannot claim to be simply the \"technical agents\" who perform the procedures to achieve conception without acknowledging the risk of transmission of HIV to the child. The risk is best justified by the low rate of perinatal transmission (less than 2 percent with appropriate precautions), which is lower than the general population risk of congenital malformations of medical, surgical, or cosmetic significance (3 to 5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HEPATITIS C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the same principles discussed above also apply to couples discordant for other chronic, potentially serious infections where horizontal and vertical transmission can occur. Hepatitis C (HCV) is an example; among men chronically infected with HCV who have given three or more semen samples, about 50 percent of semen samples contain HCV RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/57\">",
"     57",
"    </a>",
"    ]. Thus, the potential exists for transmission to the female partner and fetus, and this risk should be discussed with these couples.",
"   </p>",
"   <p>",
"    Factors affecting the risk and rate of male to female and female to male hepatitis C transmission are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\", section on 'Sexual or household contact'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Society for Reproductive Medicine (ASRM) has published recommendations on reproductive issues in women and men with hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/1,58\">",
"     1,58",
"    </a>",
"    ]. The medical status of both partners should be evaluated, appropriate preventive therapies should be initiated, and any problems that can be treated should be addressed by their primary care provider",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infectious disease specialist before initiating fertility therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Counseling and evaluation of couples in which one partner is HCV positive should include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Confirm HCV status with RIBA and obtain viral titers",
"     </li>",
"     <li>",
"      Test partner for HCV status",
"     </li>",
"     <li>",
"      Vaccinate patient and partner against HAV and HBV, if nonimmune",
"     </li>",
"     <li>",
"      Check HIV status",
"     </li>",
"     <li>",
"      Obtain liver function tests and gastroenterology consult",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with peginterferon-alpha and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    should be considered prior to fertility treatment to decrease viral load. The disadvantage of this approach is that the initial length of treatment is approximately 48 weeks and then pregnancy should be avoided from six months after completion of the treatment (for either partner who underwent treatment) because significant teratogenic effects at low doses of ribavirin have been consistently observed in animal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/1,58\">",
"     1,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fertility potential should be evaluated, as discussed above for HIV-infected patients (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Initial evaluation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     HCV-infected male and HCV-uninfected female",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with HIV infected men, couples in whom the male partner is HCV-infected may undergo donor insemination, IUI with prepared sperm (washed), or IVF with or without ICSI with prepared (washed) sperm.",
"   </p>",
"   <p>",
"    Density gradient centrifugation and sperm washing is performed followed by reverse transcription and nested PCR to confirm absence of virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/24\">",
"     24",
"    </a>",
"    ]. Of note, HCV associated with cryopreserved semen or embryos can survive exposure to liquid nitrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IVF with ICSI using washed sperm has been used successfully as a means of decreasing the risk of male to female HCV transmission, similar to the situation when the male is HIV-infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. One group has questioned the need for ICSI in these couples and the need for testing seminal plasma for HCV RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/57\">",
"     57",
"    </a>",
"    ]. They feel semen treated with density-gradient separation and successive sperm washings essentially eliminate the risk of HCV transmission, suggesting that ICSI (with frozen sperm from the semen sample that underwent PCR evaluation) is unnecessary. This opinion is based on their experience with 58 serodiscordant couples who underwent ART and produced 28 newborns, all of whom tested negative for HCV RNA in blood. Others have also found that 0 percent of semen samples contain HCV RNA after density gradient preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     HCV-infected female and HCV-uninfected male",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serodiscordant couples in whom the female partner is HCV-infected are candidates for IUI therapy to decrease the risk of female to male HCV transmission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25351?source=see_link\">",
"     \"Procedure for intrauterine insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In HCV-infected women undergoing IVF for treatment of infertility, significantly increased gonadotropin doses, decreased ovarian response, and more cycle cancellations can be expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/60\">",
"     60",
"    </a>",
"    ]. The number of pregnancies per cycle is similar for uninfected women and HCV-infected women, suggesting that ovarian stimulation and maturation of follicles are affected in such patients, but fertilization, implantation, ongoing pregnancies are not affected.",
"   </p>",
"   <p>",
"    The risk of vertical transmission correlates with maternal viral burden. The risk of transmission was 36 percent when HCV RNA titers were greater &ge;1 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and 0 when titers were &le;10,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    There is a 5 to 10 percent risk of transmission with unknown viral titers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39865/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28923069\">",
"    <span class=\"h1\">",
"     HEPATITIS B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual transmission of hepatitis B between serodiscordant couples can be prevented by vaccination of the seronegative spouse. After vaccination, natural conception can be attempted. ART is reserved for treatment of infertility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serodiscordant couples are evaluated and managed on a case-by-case basis. There are inadequate data to prove that any management approach is significantly safer than any other. In addition, choice of treatment is based upon the available resources and results of standard infertility tests, which are also part of the decision making process. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased longevity and quality of life have led HIV-infected individuals to think about childbearing and to seek assistance in conceiving so that they may avoid placing their partner at risk of infection or potentially acquiring a new viral strain of the disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general consensus in the legal and medical community is that couples or individuals who are HIV-infected should not be denied access to infertility treatment or treatment to decrease the risk of infection in an uninfected partner when the couple is attempting to conceive. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Legal and ethical issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients seeking assisted reproduction services should have high motivation for childbearing, well-controlled HIV with a stable CD4 count, undetectable virus in the serum and the semen (&lt;50 to 100",
"      <span class=\"nowrap\">",
"       copies/mL),",
"      </span>",
"      and antiretroviral medication adherence of &gt;90 percent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Optimal candidates for fertility services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the female is HIV-uninfected and the male is HIV-infected, the risk of male to female transmission is likely to be substantially reduced by utilizing medically assisted reproduction. In women with a normal fertility evaluation, we suggest intrauterine insemination (IUI) with doubly processed sperm as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If unsuccessful or for couples with a known female factor infertility diagnosis, in vitro fertilization (IVF) with ICSI can be performed. Donor sperm is an additional option. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'HIV-infected male and HIV-uninfected female'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the female is HIV-infected and the male is HIV-uninfected, intrauterine insemination using the male partner's sperm will avoid female to male transmission from unprotected intercourse. In women with a normal fertility evaluation, we suggest intrauterine insemination (IUI) as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If IUI is unsuccessful or if there is severe male factor infertility, IVF or donor sperm insemination can be performed as per usual protocols. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'HIV-infected male and HIV-uninfected female'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Natural conception with periconceptional pre-exposure HIV prophylaxis (PrEP) in serodiscordant couples can be considered. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Natural conception in serodiscordant couples'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the female is HCV-uninfected and the male is HCV-infected, similar principles to HIV serodiscordant couples apply. We suggest IUI with specially processed sperm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). IVF (with or without ICSI) and donor sperm are other options, depending on patient-specific factors. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hepatitis C'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'HCV-infected male and HCV-uninfected female'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the female is HCV-infected and the male is HCV-uninfected, IUI therapy will decrease the risk of transmission to the male partner. IVF or donor sperm can be utilized when indicated. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'HCV-infected female and HCV-uninfected male'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/1\">",
"      Practice Committee of American Society for Reproductive Medicine. Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion. Fertil Steril 2013; 99:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/2\">",
"      Steyaert SR, Leroux-Roels GG, Dhont M. Infections in IVF: review and guidelines. Hum Reprod Update 2000; 6:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/3\">",
"      Elster NR. HIV and art: reproductive choices and challenges. J Contemp Health Law Policy 2003; 19:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/4\">",
"      Gosselin JT, Sauer MV. Life after HIV: examination of HIV serodiscordant couples' desire to conceive through assisted reproduction. AIDS Behav 2011; 15:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/5\">",
"      Klein J, Pe&ntilde;a JE, Thornton MH, Sauer MV. Understanding the motivations, concerns, and desires of human immunodeficiency virus 1-serodiscordant couples wishing to have children through assisted reproduction. Obstet Gynecol 2003; 101:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/6\">",
"      Williams SG, Schmidt DK, Redd SC, et al. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/7\">",
"      Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/8\">",
"      Barreiro P, del Romero J, Leal M, et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/9\">",
"      Nicopoullos JD, Almeida PA, Ramsay JW, Gilling-Smith C. The effect of human immunodeficiency virus on sperm parameters and the outcome of intrauterine insemination following sperm washing. Hum Reprod 2004; 19:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/10\">",
"      Dulioust E, Du AL, Costagliola D, et al. Semen alterations in HIV-1 infected men. Hum Reprod 2002; 17:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/11\">",
"      Sauer MV, Wang JG, Douglas NC, et al. Providing fertility care to men seropositive for human immunodeficiency virus: reviewing 10 years of experience and 420 consecutive cycles of in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2009; 91:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/12\">",
"      van Leeuwen E, Repping S, Prins JM, et al. Assisted reproductive technologies to establish pregnancies in couples with an HIV-1-infected man. Neth J Med 2009; 67:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/13\">",
"      Kalu E, Wood R, Vourliotis M, Gilling-Smith C. Fertility needs and funding in couples with blood-borne viral infection. HIV Med 2010; 11:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/14\">",
"      Chen WJ, Walker N. Fertility of HIV-infected women: insights from Demographic and Health Surveys. Sex Transm Infect 2010; 86 Suppl 2:ii22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/15\">",
"      Kehl S, Weigel M, M&uuml;ller D, et al. HIV-infection and modern antiretroviral therapy impair sperm quality. Arch Gynecol Obstet 2011; 284:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/16\">",
"      Williams CD, Finnerty JJ, Newberry YG, et al. Reproduction in couples who are affected by human immunodeficiency virus: medical, ethical, and legal considerations. Am J Obstet Gynecol 2003; 189:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/17\">",
"      Douglas NC, Wang JG, Yu B, et al. A systematic, multidisciplinary approach to address the reproductive needs of HIV-seropositive women. Reprod Biomed Online 2009; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/18\">",
"      Carosi G, Nasta P, Fiore S, et al. Women facing HIV. Key question on women with HIV infection: Italian consensus workshop. Infection 2009; 37:168.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults. August 10, 2012. file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a2.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/20\">",
"      Politch JA, Xu C, Tucker L, Anderson DJ. Separation of human immunodeficiency virus type 1 from motile sperm by the double tube gradient method versus other methods. Fertil Steril 2004; 81:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/21\">",
"      Savasi V, Mandia L, Laoreti A, Cetin I. Reproductive assistance in HIV serodiscordant couples. Hum Reprod Update 2013; 19:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/22\">",
"      Eke AC, Oragwu C. Sperm washing to prevent HIV transmission from HIV-infected men but allowing conception in sero-discordant couples. Cochrane Database Syst Rev 2011; :CD008498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/23\">",
"      Vitorino RL, Grinsztejn BG, de Andrade CA, et al. Systematic review of the effectiveness and safety of assisted reproduction techniques in couples serodiscordant for human immunodeficiency virus where the man is positive. Fertil Steril 2011; 95:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/24\">",
"      Meseguer M, Garrido N, Gimeno C, et al. Comparison of polymerase chain reaction-dependent methods for determining the presence of human immunodeficiency virus and hepatitis C virus in washed sperm. Fertil Steril 2002; 78:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/25\">",
"      Sauer MV, Denison R, Rankin T, Solomon S. Roundtable discussion. J Acquir Immune Defic Syndr 2005; 38 Suppl 1:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/26\">",
"      Sauer MV, Chang PL. Establishing a clinical program for human immunodeficiency virus 1-seropositive men to father seronegative children by means of in vitro fertilization with intracytoplasmic sperm injection. Am J Obstet Gynecol 2002; 186:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/27\">",
"      Gilling-Smith C, Smith JR, Semprini AE. HIV and infertility: time to treat. There's no justification for denying treatment to parents who are HIV positive. BMJ 2001; 322:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/28\">",
"      Semprini AE, Levi-Setti P, Bozzo M, et al. Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet 1992; 340:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/29\">",
"      Ohl J, Partisani M, Wittemer C, et al. Assisted reproduction techniques for HIV serodiscordant couples: 18 months of experience. Hum Reprod 2003; 18:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/30\">",
"      Pe&ntilde;a JE, Klein J, Thornton M 2nd, et al. Successive pregnancies with delivery of two healthy infants in a couple who was discordant for human immunodeficiency virus infection. Fertil Steril 2002; 78:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/31\">",
"      Loutradis D, Drakakis P, Kallianidis K, et al. Birth of two infants who were seronegative for human immunodeficiency virus type 1 (HIV-1) after intracytoplasmic injection of sperm from HIV-1-seropositive men. Fertil Steril 2001; 75:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/32\">",
"      Marina S, Marina F, Alcolea R, et al. Human immunodeficiency virus type 1--serodiscordant couples can bear healthy children after undergoing intrauterine insemination. Fertil Steril 1998; 70:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/33\">",
"      Marina S, Marina F, Alcolea R, et al. Pregnancy following intracytoplasmic sperm injection from an HIV-1-seropositive man. Hum Reprod 1998; 13:3247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/34\">",
"      Garrido N, Meseguer M, Bellver J, et al. Report of the results of a 2 year programme of sperm wash and ICSI treatment for human immunodeficiency virus and hepatitis C virus serodiscordant couples. Hum Reprod 2004; 19:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/35\">",
"      Mencaglia L, Falcone P, Lentini GM, et al. ICSI for treatment of human immunodeficiency virus and hepatitis C virus-serodiscordant couples with infected male partner. Hum Reprod 2005; 20:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/36\">",
"      Melo MA, Meseguer M, Bellver J, et al. Human immunodeficiency type-1 virus (HIV-1) infection in serodiscordant couples (SDCs) does not have an impact on embryo quality or intracytoplasmic sperm injection (ICSI) outcome. Fertil Steril 2008; 89:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/37\">",
"      Santulli P, Gayet V, Fauque P, et al. HIV-positive patients undertaking ART have longer infertility histories than age-matched control subjects. Fertil Steril 2011; 95:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/38\">",
"      Gilling-Smith C, Nicopoullos JD, Semprini AE, Frodsham LC. HIV and reproductive care--a review of current practice. BJOG 2006; 113:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/39\">",
"      Coll O, Suy A, Figueras F, et al. Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART. AIDS 2006; 20:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/40\">",
"      Scavalli CP, Mandelbrot L, Berrebi A, et al. Twin pregnancy as a risk factor for mother-to-child transmission of HIV-1: trends over 20 years. AIDS 2007; 21:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/41\">",
"      Ohl J, Partisani M, Wittemer C, et al. Encouraging results despite complexity of multidisciplinary care of HIV-infected women using assisted reproduction techniques. Hum Reprod 2005; 20:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/42\">",
"      Mandelbrot L, Heard I, Henrion-G&eacute;ant E, Henrion R. Natural conception in HIV-negative women with HIV-infected partners. Lancet 1997; 349:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/43\">",
"      Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/44\">",
"      Vandermaelen A, Englert Y. Human immunodeficiency virus serodiscordant couples on highly active antiretroviral therapies with undetectable viral load: conception by unprotected sexual intercourse or by assisted reproduction techniques? Hum Reprod 2010; 25:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/45\">",
"      Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS 2010; 24:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/46\">",
"      Lampe MA, Smith DK, Anderson GJ, et al. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011; 204:488.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/47\">",
"      Vernazza PL, Graf I, Sonnenberg-Schwan U, et al. Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS 2011; 25:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/48\">",
"      Manigart Y, Rozenberg S, Barlow P, et al. ART outcome in HIV-infected patients. Hum Reprod 2006; 21:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/49\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Human immunodeficiency virus and infertility treatment. Fertil Steril 2010; 94:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/50\">",
"      American College of Obstetrics and Gynecology. ACOG Committee Opinion No. 389, December 2007. Human immunodeficiency virus. Obstet Gynecol 2007; 110:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/51\">",
"      Phelps JY. Restricting access of human immunodeficiency virus (HIV)-seropositive patients to infertility services: a legal analysis of the rights of reproductive endocrinologists and of HIV-seropositive patients. Fertil Steril 2007; 88:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/52\">",
"      Pennings G. The physician as an accessory in the parental project of HIV positive people. J Med Ethics 2003; 29:321.",
"     </a>",
"    </li>",
"    <li>",
"     Bragdon v. Abbott, in 524. 1998, U.S. 624.",
"    </li>",
"    <li>",
"     The American with Disabilities Act. One hundred and first Congress of the United States of America, second session, Washington DC on Tuesday, the twenty-third of January, 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/55\">",
"      Frodsham LC, Smith JR, Gilling-Smith C. Assessment of welfare of the child in HIV positive couples. Hum Reprod 2004; 19:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/56\">",
"      Zutlevics T. Should ART be offered to HIV-serodiscordant and HIV-seroconcordant couples: an ethical discussion? Hum Reprod 2006; 21:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/57\">",
"      Bourlet T, Lornage J, Maertens A, et al. Prospective evaluation of the threat related to the use of seminal fractions from hepatitis C virus-infected men in assisted reproductive techniques. Hum Reprod 2009; 24:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/58\">",
"      Practice Committee of American Society for Reproductive Medicine. Hepatitis and reproduction. Fertil Steril 2008; 90:S226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/59\">",
"      Levy R, Tardy JC, Bourlet T, et al. Transmission risk of hepatitis C virus in assisted reproductive techniques. Hum Reprod 2000; 15:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39865/abstract/60\">",
"      Englert Y, Moens E, Vannin AS, et al. Impaired ovarian stimulation during in vitro fertilization in women who are seropositive for hepatitis C virus and seronegative for human immunodeficiency virus. Fertil Steril 2007; 88:607.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7394 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-B86BBD9DD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39865=[""].join("\n");
var outline_f38_59_39865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15557532\">",
"      - Medical assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15557539\">",
"      - Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15557546\">",
"      - Preconceptional evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15557553\">",
"      - Fertility assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15557583\">",
"      - Counseling and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Optimal candidates for fertility services",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HIV-infected male and HIV-uninfected female",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Donor insemination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - IUI with processed sperm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - IVF with ICSI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HIV-infected female and HIV-uninfected male",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - IUI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - IVF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Natural conception in serodiscordant couples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Seroconcordant couples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Legal and ethical issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Legal issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ethical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HEPATITIS C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HCV-infected male and HCV-uninfected female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HCV-infected female and HCV-uninfected male",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28923069\">",
"      HEPATITIS B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11433?source=related_link\">",
"      Donor insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26474?source=related_link\">",
"      Primary care of HIV-infected adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25351?source=related_link\">",
"      Procedure for intrauterine insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=related_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_59_39866="Overview of the risk equivalents and established risk factors for cardiovascular disease";
var content_f38_59_39866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the risk equivalents and established risk factors for cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39866/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39866/contributors\">",
"     Peter WF Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39866/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/59/39866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/59/39866/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/59/39866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease (CVD) is common in the general population, affecting the majority of adults past the age of 60 years. In 2012, CVD was estimated to result in 17.3 million deaths worldwide on an annual basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/1\">",
"     1",
"    </a>",
"    ]. As a diagnostic category, CVD includes four major areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease (CHD), manifested by myocardial infarction (MI), angina pectoris, heart failure, and coronary death",
"     </li>",
"     <li>",
"      Cerebrovascular disease, manifested by stroke and transient ischemic attack",
"     </li>",
"     <li>",
"      Peripheral artery disease, manifested by intermittent claudication",
"     </li>",
"     <li>",
"      Aortic atherosclerosis and thoracic or abdominal aortic aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CHD accounts for approximately one-third to one-half of the total cases of CVD. The lifetime risk of CHD was illustrated in a study of 7733 participants, age 40 to 94, in the Framingham Heart Study who were initially free of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/2\">",
"     2",
"    </a>",
"    ]. The lifetime risk for individuals at age 40 was 49 percent in men and 32 percent in women. Even those who were free from CHD at age 70 had a non-trivial lifetime risk of developing CHD (35 and 24 percent in men and women, respectively). Similar findings have been reported in a metaanalysis of 18 cohorts involving over 250,000 men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link&amp;anchor=H15#H15\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Lifetime risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite increases in longevity and decreases in age-specific death rates from CVD, CHD, and stroke since 1975 (",
"    <a class=\"graphic graphic_figure graphicRef83599 \" href=\"mobipreview.htm?36/26/37294\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83597 \" href=\"mobipreview.htm?13/58/14254\">",
"     figure 2",
"    </a>",
"    ), CVD and its related complications remain highly prevalent and expensive to treat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. While CVD remains the leading cause of death in most developed countries, with approximately one million Americans annually dying from CVD, mortality from acute MI appears to have decreased by as much as 50 percent in the 1990s and 2000s. The prevalence of CVD is rapidly increasing in developing countries as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many risk factors for cardiovascular disease are modifiable by specific preventive measures. In the worldwide INTERHEART study of patients from 52 countries, nine potentially modifiable factors accounted for over 90 percent of the population-attributable risk of a first MI: smoking, dyslipidemia, hypertension, diabetes, abdominal obesity, psychosocial factors, daily consumption of fruits and vegetables, regular alcohol consumption, and regular physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the established risk factors for CVD is presented here. An overview of the possible emerging CVD risk factors, data supporting the importance of the individual risk factors (eg, hyperlipidemia, hypertension, smoking), coronary risk factors of particular importance in women and in young patients, and estimation of coronary risk in an individual patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link\">",
"     \"Overview of the possible risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hypertension in adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4873132\">",
"    <span class=\"h1\">",
"     CHD RISK EQUIVALENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients without known coronary heart disease (CHD) have a risk of subsequent cardiovascular events that is equivalent to that of patients with established CHD. All patients with a CHD risk equivalent should be managed as aggressively as those with prior CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4874544\">",
"    <span class=\"h2\">",
"     Noncoronary atherosclerotic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncoronary atherosclerotic arterial disease includes patients with carotid artery disease, peripheral artery disease, or abdominal aortic aneurysm. Patients with any form of noncoronary atherosclerotic arterial disease have a 10-year risk of developing CHD that exceeds 20 percent. Concurrent risk factors should be treated aggressively in such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of claudication\", section on 'Risk factor modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=see_link&amp;anchor=H10308274#H10308274\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\", section on 'Medical management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4873275\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance, hyperinsulinemia, and elevated blood glucose are associated with atherosclerotic cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/12-19\">",
"     12-19",
"    </a>",
"    ]. In the INTERHEART study, diabetes accounted for 10 percent of the population-attributable risk of a first myocardial infarction (MI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11\">",
"     11",
"    </a>",
"    ]. The all-cause mortality risk associated with diabetes has been compared to the all-cause mortality risk associated with a prior MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/20\">",
"     20",
"    </a>",
"    ]. While the causes of death are not equally frequent in these groups (CVD death is more frequent after MI, while non-CVD death is more frequent in patients with diabetes), the 2002 National Cholesterol Education Program report designated diabetes a CHD risk equivalent, thereby elevating it to the highest risk category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Diabetes as a CHD equivalent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the importance of diabetes as a risk factor, diabetics have a greater burden of other atherogenic risk factors than nondiabetics, including hypertension, obesity, increased total-to-HDL-cholesterol ratio, hypertriglyceridemia, and elevated plasma fibrinogen. The CHD risk in diabetics varies widely with the intensity of these risk factors.",
"   </p>",
"   <p>",
"    Guidelines published by the National Cholesterol Education Program and the sixth Joint National Committee have provided a framework to treat coronary risk factors aggressively in diabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. There is compelling evidence of the value of aggressive therapy of serum cholesterol and hypertension in patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H1033672373#H1033672373\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Diabetes mellitus as a CHD equivalent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4873282\">",
"    <span class=\"h3\">",
"     Hyperglycemia without overt diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good evidence from observational studies that higher levels of blood glucose and glycated hemoglobin correlate with cardiovascular risk in patients with and without diabetes at baseline. Data on this are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link&amp;anchor=H9#H9\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'CHD before diabetes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link&amp;anchor=H14#H14\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Hyperglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4873605\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased CHD risk in patients with end-stage renal disease has been well described, but there is now clear evidence that mild to moderate renal dysfunction is also associated with a substantial increase in CHD risk. Practice guidelines from the National Kidney Foundation in 2002 and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association task force in 2004 recommended that chronic kidney disease be considered a CHD risk equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The data supporting this conclusion are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESTABLISHED RISK FACTORS FOR ATHEROSCLEROTIC CVD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerosis is responsible for almost all cases of coronary heart disease (CHD). This insidious process begins with fatty streaks that are first seen in adolescence; these lesions progress into plaques in early adulthood, and culminate in thrombotic occlusions and coronary events in middle age and later life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/17/27930?source=see_link\">",
"     \"Pathogenesis of atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of factors, often acting in concert, are associated with an increased risk for atherosclerotic plaques in coronary arteries and other arterial beds (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78429 \" href=\"mobipreview.htm?24/51/25403\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/28\">",
"     28",
"    </a>",
"    ]. Risk factor assessment is useful in adults to guide therapy for dyslipidemia, hypertension, and diabetes, and multivariate formulations can be used to help estimate risk for coronary disease events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a 12-year follow-up of 14,786 Finnish men and women, age 25 to 64, found that the incidence of CHD was threefold higher in men than women and mortality was fivefold higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/31\">",
"     31",
"    </a>",
"    ]. The relative difference in CHD risk between the sexes was largest among the youngest subjects (25 to 49 years), but the absolute difference was largest in the older age group due to a higher prevalence (60 to 64 years). Almost half of the difference in CHD risk between men and women was associated with the sex differences in cardiovascular risk factors, particularly the",
"    <span class=\"nowrap\">",
"     HDL/total",
"    </span>",
"    cholesterol ratio and smoking. Differences in serum total cholesterol, blood pressure, body mass index, and prevalence of diabetes accounted for about one-third of the age-related increase in CHD prevalence in men and 50 to 60 percent in women.",
"   </p>",
"   <p>",
"    Based upon the absolute, relative, and attributable risks imposed by the various risk factors, concepts of \"normal\" have evolved from usual or average to more optimal values associated with long-term freedom from disease. As a result, optimal blood pressure, blood glucose, and lipid values have been revised downward in the past 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/21,32,33\">",
"     21,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors have asserted that approximately one-half of all patients suffering a manifestation of CHD have no established risk factors other than age and gender, a claim that has contributed to efforts to identify other markers of cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, the accuracy of this assertion has been challenged by the results of several analyses suggesting the prevalence of major risk factors in patients with CHD to be higher than 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study from the National Registry of Myocardial Infarction that enrolled more than 540,000 patients between 1994 and 2006 who presented with a first myocardial infarction with no prior cardiovascular disease, 86 percent had one of five major risk factors (hypertension, smoking, dyslipidemia, diabetes mellitus, or family history of CHD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/38\">",
"       38",
"      </a>",
"      ]. Among the nearly 51,000 patients who died prior to hospital discharge, there was a significant inverse relationship between the risk of death and the number of major risk factors present, with patients having 0 to 2 risk factors significantly more like to die compared to persons with all five risk factors (adjusted odds ratio of death for zero risk factors 1.54, 95% CI 1.23-1.94).",
"     </li>",
"     <li>",
"      A report based upon data from three observational studies (the Framingham Heart Study, the Multiple Risk Factor Intervention Trial [MRFIT], and the Chicago Heart Association Detection Project in Industry) included more than 380,000 subjects, 21,000 of whom died of CHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/36\">",
"       36",
"      </a>",
"      ]. Major CHD risk factors were defined as total cholesterol &ge;240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;6.22",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      systolic blood pressure &ge;140 mmHg, diastolic blood pressure &ge;90 mmHg, smoking, and diabetes. Study subjects were stratified by age and gender. Among subjects dying of CHD, exposure to at least one risk factor ranged from 87 percent (for men aged 40 to 59 in the MRFIT trial) to 100 percent (for women aged 18 to 39 years in the Framingham Heart Study).",
"     </li>",
"     <li>",
"      Another report, based upon 14 randomized clinical trials of CHD, included more than 120,000 subjects with ST elevation MI, non-ST elevation acute coronary syndrome, or percutaneous coronary intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/37\">",
"       37",
"      </a>",
"      ]. Risk factors were defined by information collected at the time of study enrollment, including smoking, diabetes, hypertension, and hyperlipidemia. At least one of these four risk factors was present in 85 percent of women and 81 percent of men. When stratified by age, the lowest prevalence of at least one risk factor was seen among subjects &gt;75 years old (77 percent of women and 65 percent of men).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factor prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;An exact estimate of the prevalence of CVD risk factors remains elusive, but the prevalence of identified risk factors has changed over time with increased awareness and changes in diet and lifestyle. A comparison of results from sequential reports from the National Health and Nutrition Examination Survey (NHANES) has shown that the prevalence of obesity (body mass index &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    increased dramatically in the United States between 1960 and 2000 (15 to 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/39\">",
"     39",
"    </a>",
"    ]. Not surprisingly, there was an associated increase in diagnosed diabetes (1.8 to 5.0 percent) that was most prominent in obese subjects (2.9 to 10.1 percent). (See",
"    <a class=\"local\" href=\"#H4486076\">",
"     'Obesity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, a number of other major cardiovascular risk factors declined substantially between 1960 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum total cholesterol &ge;240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &ndash; 34 to 17 percent",
"     </li>",
"     <li>",
"      Hypertension (blood pressure",
"      <span class=\"nowrap\">",
"       &ge;140/&ge;90",
"      </span>",
"      mmHg) &ndash; 31 to 15 percent",
"     </li>",
"     <li>",
"      Smoking &ndash; 39 to 26 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes occurred in all weight groups, including obese individuals, and were associated with increases in the use of lipid-lowering drugs and antihypertensive medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H5#H5\">",
"     \"Health hazards associated with obesity in adults\", section on 'Trends in cardiovascular risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of established risk factors is associated with CHD, and the achievement and maintenance of good health is being emphasized in programs from The American Heart Association that promote seven ideal cardiovascular health metrics, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Not smoking",
"     </li>",
"     <li>",
"      Being physically active",
"     </li>",
"     <li>",
"      Having a normal blood pressure",
"     </li>",
"     <li>",
"      Having a normal blood glucose level",
"     </li>",
"     <li>",
"      Having a normal total cholesterol level",
"     </li>",
"     <li>",
"      Being normal weight",
"     </li>",
"     <li>",
"      Eating a healthy diet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When these metrics were applied to 15,305 patients (77 percent white, 11 percent black) who participated in NHANES between 1988 and 1994 with follow-up through 2006, only 2 percent achieved all seven metrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/41\">",
"     41",
"    </a>",
"    ]. Significantly lower cardiovascular mortality (adjusted HR 0.24, 95% CI 0.13-0.47) and overall mortality (adjusted HR 0.49, 95% CI 0.33-0.74) were observed in persons who achieved 6 or 7 metrics compared with those achieving 0 or 1 metric. Similar findings have been reported in a more ethnically diverse cohort of 2981 persons in the Northern Manhattan Study (54 percent Hispanic, 25 percent black, 21 percent white), where the risk of myocardial infarction, stroke, or vascular death combined was significantly lower in persons achieving 5 or 6 ideal health metrics (adjust HR 0.41 compared with 0 or 1 ideal health metric, 95% CI 0.26-0.63) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factor prevalence in emerging nations has long been unknown",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    underrepresented in the literature. Among 46,239 Chinese adults age 20 or older (40 percent male) recruited in 2007 and 2008 as a nationally representative cohort, the overall prevalence of CVD was low (1.8 and 1.1 percent in males and females, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/43\">",
"     43",
"    </a>",
"    ]. The prevalence of traditional CVD risk factors was much higher:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overweight or obese &ndash; 36.7 and 29.8 percent in males and females, respectively",
"     </li>",
"     <li>",
"      Hypertension &ndash; 30.1 and 24.8 percent in males and females, respectively",
"     </li>",
"     <li>",
"      Dyslipidemia &ndash; 64 and 67.4 percent in males and females, respectively",
"     </li>",
"     <li>",
"      Hyperglycemia &ndash; 26.7 and 23.6 percent in males and females, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After adjusting for age and sex, the odds of CVD increased with the number of risk factors present (odds ratio 2.4, 4.2, 4.9, and 7.2 for 1, 2, 3, and 4 or more risk factors, respectively, compared with no risk factors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/43\">",
"     43",
"    </a>",
"    ]. These data suggest, in the absence of effective lifestyle and medical interventions, there is likely to be a significant increase in the incidence and prevalence of CVD in China in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4873728\">",
"    <span class=\"h2\">",
"     Risk factors in childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular risk factors are identifiable in childhood and may be predictive of the subsequent development of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The identification of children with risk factors for CVD and the development of atherosclerosis in children are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25352?source=see_link\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=see_link\">",
"     \"Risk factors and development of atherosclerosis in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age and gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular risk factors promote CVD in either gender at all ages but with different relative importance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes and a low high-density lipoprotein",
"      <span class=\"nowrap\">",
"       (HDL)-cholesterol/total",
"      </span>",
"      cholesterol ratio operate with greater power in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"       \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The incidence of a myocardial infarction is increased sixfold in women and threefold in men who smoke at least 20 cigarettes per day compared to subjects who never smoked [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=see_link\">",
"       \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systolic blood pressure and isolated systolic hypertension are major CHD risk factors at all ages and in both genders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/32\">",
"       32",
"      </a>",
"      ]. The Framingham study found that the relative importance of systolic, diastolic, and pulse pressure (the difference between the systolic and diastolic blood pressures) changes with age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/51\">",
"       51",
"      </a>",
"      ]. In patients &lt;50 years of age, diastolic blood pressure was the strongest predictor of CHD risk; in those 50 to 59 years of age, all three blood pressure indices were comparable predictors of CHD risk, while in those &ge;60 years of age, pulse pressure was the strongest predictor. (See",
"      <a class=\"local\" href=\"#H4874043\">",
"       'Hypertension'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=see_link\">",
"       \"Cardiovascular risks of hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some risk factors, such as dyslipidemia, impaired glucose tolerance, and elevated fibrinogen have a diminished impact with advancing age, but a lower relative risk is offset by the high absolute risk in older adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Thus, all of the major risk factors continue to be relevant in older persons.",
"     </li>",
"     <li>",
"      Obesity or weight gain promotes or aggravates all the atherogenic risk factors and physical inactivity worsens some of them, predisposing subjects of all ages to CHD events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"       \"Health hazards associated with obesity in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=see_link\">",
"       \"Role of physical activity and exercise in obese adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Male gender alone may contribute to the risk of CHD, although the potential mechanisms for such risk are not well understood. Several population studies have identified male gender as a risk factor for higher rates of CHD and CHD-related mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Among 31,000 patients from the ONTARGET and TRANSCEND study populations (9378 females, 22,168 males) who were followed for an average of 56 months, females had approximately 20 percent lower risk than males for all major cardiovascular endpoints including cardiovascular death (adjusted RR 0.83, 95% CI 0.75-0.92), myocardial infarction (MI) (adjusted RR 0.78, 95% CI 0.68-0.89), and a combined endpoint of death, MI, stroke, and heart failure hospitalization (adjusted RR 0.81, 95% CI 0.76-0.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of CHD in men has been associated with variations in the Y chromosome. Among 3233 biologically unrelated British men who underwent genotyping of their Y chromosome, with 13 apparent ancient lineages (haplogroups) identified based on the genotype results, those descendent from one particular haplogroup (haplogroup I, almost entirely unique to Europeans) had significantly more CHD than men from other haplogroups (odds ratio 1.56, 95% CI 1.24-1.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/60\">",
"     60",
"    </a>",
"    ]. These results suggest that differences in CHD risk within the male gender are associated with inherited variations in sex chromosomes, which may contribute to the importance of family history as a risk factor for CHD. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Family history'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H1267867#H1267867\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Genetic markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family history is an independent risk factor for CHD, particularly among younger individuals with a family history of premature disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/61-66\">",
"     61-66",
"    </a>",
"    ]. The definition of what constitutes a family history of premature atherosclerosis has been somewhat variable in different studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/67\">",
"     67",
"    </a>",
"    ]. However, there is general agreement that a myocardial infarction (MI) or death from CHD in a first degree relative (ie, parent or sibling) prior to age 50 (males) or 60 (females) denotes a significant family history. A wider definition of a significant family history of CVD might also include other manifestations of atherosclerosis beyond MI or CHD death, including stroke or transient ischemic attack, CHD requiring revascularization in the absence of MI, peripheral artery disease, and abdominal aortic aneurysm (",
"    <a class=\"graphic graphic_table graphicRef71096 \" href=\"mobipreview.htm?7/57/8091\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of family history has been shown in several large cohort studies (Physician's Health Study, Women's Health Study, Reykjavik Cohort Study, Framingham Offspring Study, INTERHEART Study, and Cooper Center Longitudinal Study) that collectively followed over 163,000 patients, and all showed that a positive family history is associated with greater risk of developing CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/61,62,64,65,68,69\">",
"     61,62,64,65,68,69",
"    </a>",
"    ]. The risk of developing CHD in the presence of a positive family history has ranged from 15 to 100 percent in various cohorts, with most cohorts showing a 40 to 60 percent increase.",
"   </p>",
"   <p>",
"    The importance of a family history of premature CVD death appears to be magnified in families with multiple premature deaths. Using data from the Danish Family Relations Database (3,985,301 persons born between 1950 and 2008 followed for nearly 90 million person-years), persons from families with two or more premature cardiovascular deaths among first-degree relatives had a threefold greater risk of developing CVD before age 50 (incidence risk ratio 3.30, 95% CI 2.77-3.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/70\">",
"     70",
"    </a>",
"    ]. Similar findings have been noted among 185,810 cases of hospitalization or death due to CHD in the Swedish Multi-Generation Registry, in which the risk of hospitalization or death due to CHD was increased six- to sevenfold in persons with two or three siblings with CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite multiple studies showing that family history of CHD in a first degree relative increases one's risk of developing CHD, the incremental predictive value of adding family history to an established risk score appears to be small, ranging from 2 to 5 percent upward reclassification of risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/66,72\">",
"     66,72",
"    </a>",
"    ]. In the EPIC-Norfolk prospective cohort of 22,841 patients (45 percent male) aged 40 to 79 years who were followed for a mean of 10.9 years, a family history of CHD in a first degree relative was significantly associated with increased risk of future CHD independent of the Framingham Risk Score (FRS) estimate (adjusted HR 1.74, 95% CI 1.56-1.95) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/66\">",
"     66",
"    </a>",
"    ]. Despite this significant increased risk, the addition of family history to the FRS estimate resulted in minimal reclassification of patients into different risk groups (only 2 percent of patients deemed intermediate risk by FRS were reclassified to high risk because of family history). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Reliability of self-reported family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy and reliability of a self-reported family history may be difficult to ascertain. A 2009 report from the National Institutes of Health reviewed the accuracy of self-reported family history of several common disease states (asthma and allergies, diabetes mellitus, major depression and mood disorders, stroke, CVD, and five common types of cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/67\">",
"     67",
"    </a>",
"    ]. The probability that an unaffected family member was correctly identified as disease-free was high (90 to 95 percent), but for family members with one of the diseases, the probability that they were correctly identified as having the disease was generally lower and far more variable (as low as 6 percent correct identified as having a mood disorder, up to 95 percent correct for some types of cancer). Generally, patients more accurately identified healthy family members as being healthy and were less accurate in correctly identifying family members with specific diseases.",
"   </p>",
"   <p>",
"    The reliability of a self-reported family history of CHD or of risk factors for CHD was explored in an analysis from the Framingham Offspring Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/73\">",
"     73",
"    </a>",
"    ]. A group of 1628 children of study participants completed a questionnaire regarding parental medical history. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predictive value of an affirmative statement was above 75 percent for family histories of hypertension, diabetes, and hypercholesterolemia.",
"     </li>",
"     <li>",
"      For cardiac death the positive predictive value was only 66 percent for fathers and 47 percent for mothers.",
"     </li>",
"     <li>",
"      The predictive value of a negative statement was above 90 percent for family history of cardiac death or for diabetes, but below 60 percent for family history of hypertension or hypercholesterolemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings concerning validated and self-reported family history from Framingham suggest that there is some value in obtaining family history information, but that self-reported information might not be accurate. They also suggest that the additional contribution of family history to CHD risk estimation after inclusion of other traditional risk factors is relatively modest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4874043\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a well established risk factor for adverse cardiovascular outcomes, including mortality from CHD and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/22,74\">",
"     22,74",
"    </a>",
"    ]. In the INTERHEART study, hypertension accounted for 18 percent of the population-attributable risk of a first myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The determination of what blood pressure constitutes hypertension has long been the subject of debate, with various committees and professional societies publishing statements or guidelines attempting to define categories of hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/32,75\">",
"     32,75",
"    </a>",
"    ]. While there is little debate that patients with a blood pressure greater than 140 mmHg and a diastolic blood pressure greater than 90 mmHg are considered hypertensive, there are groups of patients at higher risk in whom lower blood pressure goals have been suggested. An extensive discussion of the definition of hypertension and treatment recommendations for various patient groups is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of hypertension in adults\", section on 'Definitions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although blood pressure at the time of risk assessment (current blood pressure) is typically used in most prediction algorithms, this does not accurately reflect an individual's past blood pressure experience. Two analyses demonstrate the importance of inclusion of past blood pressure into risk prediction models since the duration as well as the degree of hypertension are both risk factors. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiovascular risks of hypertension\", section on 'Current risk versus prior risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ambulatory blood pressure measurements may be more predictive in patients with office or white coat hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The excess coronary risk associated with hypertension is primarily evident in subgroups with other risk factors or underlying target organ damage, and individuals in these subgroups benefit the most from antihypertensive therapy (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"     figure 3",
"    </a>",
"    ). The recommendations of the Seventh Joint National Committee provide guidelines for therapy according to stratifications based upon blood pressure level and the presence or absence of underlying conditions (",
"    <a class=\"graphic graphic_table graphicRef81993 graphicRef72683 \" href=\"mobipreview.htm?36/12/37069\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is the goal blood pressure in patients who already have or are at high risk for cardiovascular disease. This issue is discussed in great detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lipids and lipoproteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipids, principally cholesterol and triglycerides, are the water insoluble compounds that require larger protein containing complexes called lipoproteins to transport them in blood. The protein components of the lipoprotein are known as apolipoproteins or apoproteins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The determination of what cholesterol level constitutes dyslipidemia has long been the subject of debate, with professional societies publishing statements or guidelines attempting to delineate risk levels and when to consider drug therapy for dyslipidemia (",
"    <a class=\"graphic graphic_table graphicRef70489 \" href=\"mobipreview.htm?31/39/32379\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82504 \" href=\"mobipreview.htm?11/4/11340\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67460 \" href=\"mobipreview.htm?10/46/10989\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of dyslipidemia is increased in patients with premature CHD, being as high as 75 to 85 percent compared with approximately 40 to 48 percent in age-matched controls without CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/63,77\">",
"     63,77",
"    </a>",
"    ]. In the INTERHEART study, dyslipidemia (defined as a raised apo B to apo A-1 ratio) accounted for 49 percent of the population-attributable risk of a first MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disturbances in lipoprotein metabolism are often familial. As an example, 54 percent of all patients and 70 percent of those with a lipid abnormality in one reported series had a familial lipid disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/77\">",
"     77",
"    </a>",
"    ]. The most common familial disturbances were Lp(a) excess (alone or with other dyslipidemia), hypertriglyceridemia with hypoalphalipoproteinemia, and combined hyperlipidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence for the pathogenic importance of serum cholesterol has largely come from randomized trials which showed that reductions in total and LDL-cholesterol levels (almost entirely with statins) reduce coronary events and mortality when given for primary and secondary prevention (",
"    <a class=\"graphic graphic_figure graphicRef59494 \" href=\"mobipreview.htm?21/5/21598\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82485 \" href=\"mobipreview.htm?23/30/24045\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. Factors other than LDL-cholesterol lowering also may contribute to the observed benefit from statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for the treatment of hypercholesterolemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following lipid and lipoprotein abnormalities are associated with increased CHD risk. The supportive data are presented elsewhere as noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated total cholesterol (",
"      <a class=\"graphic graphic_figure graphicRef60146 \" href=\"mobipreview.htm?0/19/317\">",
"       figure 6",
"      </a>",
"      ) and elevated LDL-cholesterol (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=see_link&amp;anchor=H3#H3\">",
"       \"Screening guidelines for dyslipidemia\", section on 'Association between dyslipidemia and coronary risk'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Low HDL-cholesterol (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link&amp;anchor=H7#H7\">",
"       \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\", section on 'Low HDL-C as a risk factor for coronary heart disease'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypertriglyceridemia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"       \"Approach to the patient with hypertriglyceridemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased non-HDL-cholesterol (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link&amp;anchor=H14#H14\">",
"       \"ATP III guidelines for treatment of high blood cholesterol\", section on 'Non-HDL-cholesterol'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased Lp(a) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40248?source=see_link\">",
"       \"Lipoprotein(a) and cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased apolipoprotein C-III (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"       \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Small, dense LDL particles (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H22#H22\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Small dense LDL (LDL phenotype B)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Different genotypes of apolipoprotein E (apoE) influence cholesterol and triglyceride levels as well as the risk of CHD (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H20#H20\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Genetics'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The abnormalities discussed above require measurement of lipids or lipoproteins. Proton nuclear magnetic resonance (NMR) spectroscopy of lipoprotein particles has been proposed as an alternative method for predicting cardiovascular disease risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/81\">",
"     81",
"    </a>",
"    ]. In a study of over 27,000 women, this technique was comparable in predictive accuracy to, but not better than, standard measurement of lipids or apolipoproteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lifestyle factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of lifestyle factors impact the risk of cardiovascular disease:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4872547\">",
"    <span class=\"h3\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is an important and reversible risk factor for CHD. The incidence of a myocardial infarction (MI) is increased sixfold in women and threefold in men who smoke at least 20 cigarettes per day compared with subjects who never smoked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The risk of MI is proportional to tobacco consumption in both men and women and is higher in inhalers compared with non-inhalers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/50\">",
"     50",
"    </a>",
"    ]. In the INTERHEART study, smoking accounted for 36 percent of the population-attributable risk of a first MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, the risk of recurrent infarction in a study of smokers who had an MI fell by 50 percent within one year of smoking cessation and normalized to that of nonsmokers within two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/82\">",
"     82",
"    </a>",
"    ]. The benefits of smoking cessation are seen regardless of how long or how much the patient has previously smoked. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4872729\">",
"    <span class=\"h3\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diets with a high glycemic index (GI) or glycemic load (GL) may contribute to the risk of CHD. In a 2012 meta-analysis of eight prospective cohort studies involving 220,050 persons, incident CHD (4826 cases) was more likely in women with the highest GL (RR 1.69 compared to lowest GL, 95% CI 1.32-2.16) and highest GI (RR 1.26 compared to lowest GI, 95% CI 1.12-1.43), but this association was not seen in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/83\">",
"     83",
"    </a>",
"    ]. Similar results have been reported in a second 2012 meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/84\">",
"     84",
"    </a>",
"    ]. Further studies are needed prior to recommending any specific diets to reduce CHD risk based on GL or GI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=see_link&amp;anchor=H3#H3\">",
"     \"Dietary carbohydrates\", section on 'Glycemic index'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=see_link&amp;anchor=H9#H9\">",
"     \"Dietary carbohydrates\", section on 'Glycemic load'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is growing evidence suggesting that fruit and vegetable consumption is inversely related to the risk of CHD and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11,85-91\">",
"     11,85-91",
"    </a>",
"    ]. In a meta-analysis of seven prospective cohorts that included over 230,000 men and women, the risk of stroke was reduced by 11 percent for each additional daily portion of fruit; there was no such effect with vegetable intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/90\">",
"     90",
"    </a>",
"    ]. The INTERHEART study found that lack of daily consumption of fruits and vegetables accounted for 14 percent of the population-attributable risk of a first MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher intake of red meat and high-fat dairy products has also been associated with higher risks of CHD. Among 84,136 female nurses from the Nurses&rsquo; Health Study who were followed for 26 years, those who ate two or more servings of red meat daily had a 29 percent higher risk of developing CHD compared with those who ate 0.5 servings daily (adjusted RR 1.29, 95% CI 1.12-1.49) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/92\">",
"     92",
"    </a>",
"    ]. In the same Nurses' Health Study of women as well as the Health Professionals Follow-up Study of 37,698 men, total mortality was linearly associated with increased red meat consumption, with a 15 to 20 percent increase in total mortality for each additional daily serving of red meat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High fiber intake is also associated with a reduction in the risk of CHD and stroke compared to low fiber intake. In two studies of male and female health professionals, a 10 g increase in total daily dietary fiber intake was associated with a reduced risk for MI (relative risk 0.81, 95% CI 0.66 to 0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coffee consumption, both caffeinated and non-caffeinated, appears to have a neutral effect on the development of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17498?source=see_link\">",
"     \"Benefits and risks of caffeine and caffeinated beverages\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High serum concentrations of enterolactone, a putative biomarker of a diet high in fiber and vegetables, have been inversely correlated with the risk of acute coronary events and with CHD mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\", section on 'Healthy diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise of even moderate degree has a protective effect against coronary heart disease and all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11,56,95-97\">",
"     11,56,95-97",
"    </a>",
"    ]. Exercise may have a variety of beneficial effects including an elevation in serum HDL-cholesterol, a reduction in blood pressure, less insulin resistance, and weight loss. In addition to the amount of exercise performed, the degree of cardiovascular fitness (a measure of physical activity), as determined by duration of exercise and maximal oxygen uptake on a treadmill, is also associated with a reduction in coronary heart disease risk and overall cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/98-103\">",
"     98-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who engaged in moderately vigorous sports activity have been reported to have a 23 percent lower risk of death than those who were less active [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/95\">",
"       95",
"      </a>",
"      ]. Persons with mild to moderate levels of physical activity as part of their occupation appear to have lower risk of MI compared with sedentary workers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the INTERHEART study, lack of regular physical activity accounted for 12 percent of the population-attributable risk of a first myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiovascular fitness has been assessed in several studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/102,103,105\">",
"       102,103,105",
"      </a>",
"      ]. In a prospective study of 6213 men referred for exercise testing who were followed for a mean of 6.2 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/102\">",
"       102",
"      </a>",
"      ]. Peak exercise capacity, measured in metabolic equivalents (METs), was a stronger predictor of mortality than other established cardiovascular risk factors among men with and without cardiovascular disease. In a separate study of 11,190 persons deemed \"low-risk\" by Framingham risk score and without diabetes mellitus who underwent treadmill exercise testing and were followed for an average of 27 years, all-cause mortality was significantly higher among individuals in the lowest quintile of exercise capacity at baseline (15 versus 6 percent mortality in the highest quintile) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Heart Association prepared a listing of the most effective strategies to promote exercise, as well as a healthy diet, based on a systematic review of studies published in English between 1999 and 2009 (",
"    <a class=\"graphic graphic_table graphicRef59899 \" href=\"mobipreview.htm?20/23/20861\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4872925\">",
"    <span class=\"h3\">",
"     Lack of moderate alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data indicate that moderate alcohol intake has a protective effect on coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4486076\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with a number of risk factors for atherosclerosis, cardiovascular disease, and cardiovascular mortality, including hypertension, insulin resistance and glucose intolerance, hypertriglyceridemia, reduced HDL-cholesterol, and low levels of adiponectin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/106-109\">",
"     106-109",
"    </a>",
"    ]. However, in an analysis of data from 4780 adults in the Framingham Offspring Study, obesity as measured by body mass index (BMI) significantly and independently predicted the occurrence of CHD and cerebrovascular disease after adjusting for traditional risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/110\">",
"     110",
"    </a>",
"    ]. These relationships are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3641?source=see_link&amp;anchor=H2#H2\">",
"     \"Obesity, weight reduction, and cardiovascular disease\", section on 'Definition of obesity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Psychosocial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial factors may contribute to the early development of atherosclerosis as well as to the acute precipitation of myocardial infarction and sudden cardiac death. The link between psychologic stress and atherosclerosis may be both direct, via damage of the endothelium, and indirect, via aggravation of traditional risk factors such as smoking, hypertension, and lipid metabolism. Depression, anger, stress, and other factors have been correlated with cardiovascular outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25528?source=see_link\">",
"     \"Psychosocial factors in coronary and cerebral vascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Inflammatory markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous inflammatory markers have been reported to be associated with increased risk of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/111\">",
"     111",
"    </a>",
"    ]. C-reactive protein (CRP) is both the most extensively studied marker of inflammation and the marker most widely used in clinical practice. Its precise role in the assessment of cardiovascular risk continues to evolve. While the precise role of CRP remains uncertain, epidemiologic studies have suggested that interleukin-6 (IL-6) has a direct causal role in the development of CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4482486\">",
"    <span class=\"h3\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;A person's baseline level of inflammation, as assessed by the plasma concentration of CRP, predicts the long-term risk of a first myocardial infarction, ischemic stroke, or peripheral artery disease (",
"    <a class=\"graphic graphic_figure graphicRef69135 \" href=\"mobipreview.htm?33/43/34493\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. The relationship between CRP and cardiovascular disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of CRP levels improves risk stratification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Several professional societies have issued statements or guidelines suggesting a role for the measurement of high sensitivity CRP in patients at intermediate risk for coronary heart disease, in whom measurement may help direct further evaluation and therapy for primary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/117-119\">",
"     117-119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=see_link&amp;anchor=H579113#H579113\">",
"     \"Screening for cardiovascular risk with C-reactive protein\", section on 'Recommendations of others'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H835935\">",
"    <span class=\"h3\">",
"     Interleukin-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the association between inflammation and the development of atherosclerotic disease is well-known, proving causation for any particular biomarker of inflammation has been difficult. Interleukin-6 (IL-6) signals a downstream proinflammatory response by activating membrane-bound IL-6 receptors (IL-6R) on the cell surface. IL-6 and IL-6R appear to have a direct causal role in the development of CHD and may be a future target for therapeutic interventions to prevent CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/17/27930?source=see_link&amp;anchor=H27901126#H27901126\">",
"     \"Pathogenesis of atherosclerosis\", section on 'Inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of Asp358Ala (rs2228145, formerly rs8192284), a variant allele of the",
"    <em>",
"     IL6R",
"    </em>",
"    gene encoding IL-6R, is associated with reduced membrane-bound IL-6R, resulting in decreased IL-6R signalling and less inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/120\">",
"     120",
"    </a>",
"    ]. Two large meta-analyses have confirmed the crucial role played by IL-6 and IL-6R in the generation of inflammation and the associated risk of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a collaborative meta-analysis incorporating genetic and biomarker data from over 200,000 persons, each inherited copy of the Asp358Ala allele was independently associated with significantly increased soluble IL-6R levels, significantly decreased CRP levels, and significantly decreased risk of CHD (3.4 percent, 95% CI 1.8-5.0) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Mendelian randomization analysis of over 133,000 persons analyzed for the single nucleotide polymorphisms (SNP) rs7529229, which has strong linkage disequilibrium with Asp358Ala, each allele that contained the SNP rs7529229 was independently associated with significantly increased soluble IL-6R levels, significantly decreased CRP levels, and significantly decreased risk of CHD (5 percent decrease, 95% CI 3 to 7 percent decrease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both studies demonstrate an association between IL-6 and IL-6R levels and CHD that is dose dependent (two variant alleles provided more benefit than one variant allele which provided more benefit than no variant alleles). Increased soluble (ie, circulating) IL-6R levels led to reduced membrane-bound IL-6R, thereby reducing signaling and downstream inflammation (reduced CRP levels). Taken together, these results provide evidence supporting a direct causal role of IL-6 and IL-6R in the development of CHD and suggest a future target for therapeutic interventions to prevent CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4240764\">",
"    <span class=\"h3\">",
"     Myeloperoxidase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher levels of the leukocyte enzyme myeloperoxidase, which is secreted during acute inflammation and promotes oxidation of lipoproteins, are associated with the presence of coronary disease and may be predictive of the presence of acute coronary syndrome in patients with chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/123-126\">",
"     123-126",
"    </a>",
"    ]. As an example, in a nested case-cohort study from the",
"    <span class=\"nowrap\">",
"     MONICA/KORA",
"    </span>",
"    Augsburg involving 333 cases with CHD and 1727 controls followed for an average of nearly 11 years, patients with elevated myeloperoxidase levels had significantly greater likelihood of developing CHD after adjusting for traditional major cardiovascular risk factors (hazard ratio 1.70 for top tertile versus bottom two tertiles, 95% CI 1.25-2.30) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with chronic systolic heart failure, elevated plasma myeloperoxidase levels have been associated with an increased likelihood of more advanced HF and may be predictive of a higher rate of adverse clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/127\">",
"     127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=see_link&amp;anchor=H13#H13\">",
"     \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\", section on 'Myeloperoxidase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4482589\">",
"    <span class=\"h3\">",
"     Other inflammatory markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular risk has also been associated with a variety of other markers of inflammation, though to a lesser extent than CRP. Elevated levels of white blood cells, erythrocyte sedimentation rates, interleukin-18, tumor necrosis factor alpha, soluble intercellular adhesion molecule-1, P-selectin, cathepsin S, and lipoprotein-associated phospholipase A2 have been reported as markers of increased CHD risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/59/39866/abstract/123-125,127-148\">",
"     123-125,127-148",
"    </a>",
"    ]. While this adds further support to the role of inflammation in the development of atherosclerosis and CVD, most of these are not routinely used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9708405\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread use of effective antiretroviral therapies in the treatment of human immunodeficiency virus (HIV) infection has led to increased longevity, exposing HIV-positive patients to many common medical conditions seen in an aging population, such as CVD. The risk of CVD in HIV-positive patients is predominantly influenced by the presence of traditional CVD risk factors. However, studies correcting for traditional CVD risk factors have shown higher rates of coronary heart disease and myocardial infarction (MI) in HIV-positive patients compared to HIV-negative controls. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29702838\">",
"    <span class=\"h2\">",
"     Mediastinal radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to mediastinal or chest wall radiation during treatment for malignancy (eg, Hodgkin lymphoma, breast cancer) has been linked to subsequent development of cardiac disease, including pericardial disease, valvular disease, cardiomyopathy, and coronary heart disease (CHD). CHD following radiation tends to involve the ostia of the left main and right coronary arteries and may manifest as either angina or acute myocardial infarction potentially requiring revascularization. Furthermore, the risk of cardiac disease may be further increased by treatment with systemic anticancer agents (eg, anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ). More information on the cardiac toxicity of mediastinal radiation and systemic anticancer therapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link&amp;anchor=H13#H13\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Incidence of cardiovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4485836\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the constellation of abdominal obesity, hypertension, diabetes, and dyslipidemia are considered to have the metabolic syndrome (also called the insulin resistance syndrome or syndrome X). Individuals with the metabolic syndrome have a markedly increased risk of coronary artery disease. This disorder is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4482421\">",
"    <span class=\"h2\">",
"     Microalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microalbuminuria reflects vascular damage and appears to be a marker of early arterial disease. While microalbuminuria is accepted as an important risk factor for CVD and early cardiovascular mortality, the mechanism by which microalbuminuria is associated with CVD remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2628519\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular disease (CVD) is the leading cause of death in most developed countries, with a prevalence that is rapidly increasing in developing countries as well. Many risk factors for cardiovascular disease are modifiable by specific preventive measures, therein offering an opportunity to reduce the burden of CVD worldwide. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients without known coronary heart disease (CHD) have a risk of subsequent cardiovascular events that is equivalent to that of patients with established coronary disease. Examples of such high-risk patients include patients with noncoronary atherosclerotic arterial disease, diabetes mellitus, and chronic kidney disease. All patients with a CHD risk equivalent should be managed as aggressively as those with prior CHD. (See",
"      <a class=\"local\" href=\"#H4873132\">",
"       'CHD risk equivalents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family history is a significant independent risk factor for CHD, particularly among younger individuals with a family history of premature disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Family history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypertension and dyslipidemia are well established risk factors for CVD. Effectively treating both hypertension and dyslipidemia can significantly reduce the risk of future CVD events. (See",
"      <a class=\"local\" href=\"#H4874043\">",
"       'Hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Lipids and lipoproteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of lifestyle factors, including cigarette smoking, diet, exercise, alcohol intake, and obesity, significantly impact the risk of developing CVD. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Lifestyle factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/1\">",
"      Laslett LJ, Alagona P Jr, Clark BA 3rd, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 2012; 60:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/2\">",
"      Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/3\">",
"      Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012; 366:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/4\">",
"      Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000; 102:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/5\">",
"      Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ 2012; 344:d8059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/6\">",
"      Schmidt M, Jacobsen JB, Lash TL, et al. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 2012; 344:e356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/7\">",
"      Bandosz P, O'Flaherty M, Drygas W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ 2012; 344:d8136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/8\">",
"      Hajat C, Harrison O. The Abu Dhabi Cardiovascular Program: the continuation of Framingham. Prog Cardiovasc Dis 2010; 53:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/9\">",
"      Reddy KS, Satija A. The Framingham Heart Study: impact on the prevention and control of cardiovascular diseases in India. Prog Cardiovasc Dis 2010; 53:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/10\">",
"      Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010; 39:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/11\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/12\">",
"      Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/13\">",
"      Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/14\">",
"      Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/15\">",
"      Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/16\">",
"      Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/17\">",
"      Singer DE, Nathan DM, Anderson KM, et al. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/18\">",
"      Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol 1999; 33:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/19\">",
"      Al-Delaimy WK, Merchant AT, Rimm EB, et al. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 2004; 116:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/20\">",
"      Vaccaro O, Eberly LE, Neaton JD, et al. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med 2004; 164:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/21\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/22\">",
"      Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/23\">",
"      Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/24\">",
"      Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/25\">",
"      Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/26\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/28\">",
"      Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/29\">",
"      Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/30\">",
"      Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999; 130:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/31\">",
"      Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/32\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/33\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/34\">",
"      Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998; 97:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/35\">",
"      Canto JG, Iskandrian AE. Major risk factors for cardiovascular disease: debunking the \"only 50%\" myth. JAMA 2003; 290:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/36\">",
"      Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/37\">",
"      Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/38\">",
"      Canto JG, Kiefe CI, Rogers WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA 2011; 306:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/39\">",
"      Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/40\">",
"      Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010; 121:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/41\">",
"      Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA 2012; 307:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/42\">",
"      Dong C, Rundek T, Wright CB, et al. Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study. Circulation 2012; 125:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/43\">",
"      Yang ZJ, Liu J, Ge JP, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J 2012; 33:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/44\">",
"      Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003; 290:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/45\">",
"      Raitakari OT, Juonala M, K&auml;h&ouml;nen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/46\">",
"      Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/47\">",
"      Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/48\">",
"      Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008; 31:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/49\">",
"      Nj&oslash;lstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996; 93:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/50\">",
"      Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/51\">",
"      Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/52\">",
"      Harris T, Cook EF, Kannel WB, Goldman L. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. The Framingham Heart Study. J Am Geriatr Soc 1988; 36:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/53\">",
"      Wilson PW, Kannel WB. Hypercholesterolemia and Coronary Risk in the Elderly: The Framingham Study. Am J Geriatr Cardiol 1993; 2:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/54\">",
"      Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnoea with myocardial infarction in men. Lancet 1990; 336:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/55\">",
"      Dannenberg AL, Keller JB, Wilson PW, Castelli WP. Leisure time physical activity in the Framingham Offspring Study. Description, seasonal variation, and risk factor correlates. Am J Epidemiol 1989; 129:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/56\">",
"      Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987; 8:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/57\">",
"      Tunstall-Pedoe H, Kuulasmaa K, M&auml;h&ouml;nen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/58\">",
"      D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/59\">",
"      Kappert K, B&ouml;hm M, Schmieder R, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation 2012; 126:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/60\">",
"      Charchar FJ, Bloomer LD, Barnes TA, et al. Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet 2012; 379:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/61\">",
"      Sesso HD, Lee IM, Gaziano JM, et al. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation 2001; 104:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/62\">",
"      Andresdottir MB, Sigurdsson G, Sigvaldason H, et al. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J 2002; 23:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/63\">",
"      Roncaglioni MC, Santoro L, D'Avanzo B, et al. Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. Circulation 1992; 85:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/64\">",
"      Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004; 291:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/65\">",
"      Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 2005; 294:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/66\">",
"      Sivapalaratnam S, Boekholdt SM, Trip MD, et al. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart 2010; 96:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/67\">",
"      Berg AO, Baird MA, Botkin JR, et al. National Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health. Ann Intern Med 2009; 151:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/68\">",
"      Bachmann JM, Willis BL, Ayers CR, et al. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation 2012; 125:3092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/69\">",
"      Chow CK, Islam S, Bautista L, et al. Parental history and myocardial infarction risk across the world: the INTERHEART Study. J Am Coll Cardiol 2011; 57:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/70\">",
"      Ranthe MF, Carstensen L, Oyen N, et al. Family history of premature death and risk of early onset cardiovascular disease. J Am Coll Cardiol 2012; 60:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/71\">",
"      Z&ouml;ller B, Li X, Sundquist J, Sundquist K. Multiplex sibling history of coronary heart disease is a strong risk factor for coronary heart disease. Eur Heart J 2012; 33:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/72\">",
"      Qureshi N, Armstrong S, Dhiman P, et al. Effect of adding systematic family history enquiry to cardiovascular disease risk assessment in primary care: a matched-pair, cluster randomized trial. Ann Intern Med 2012; 156:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/73\">",
"      Murabito JM, Nam BH, D'Agostino RB Sr, et al. Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study. Ann Intern Med 2004; 140:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/74\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/75\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/76\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/77\">",
"      Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/78\">",
"      Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/79\">",
"      Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/80\">",
"      Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/81\">",
"      Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009; 119:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/82\">",
"      Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet 1975; 1:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/83\">",
"      Dong JY, Zhang YH, Wang P, Qin LQ. Meta-analysis of dietary glycemic load and glycemic index in relation to risk of coronary heart disease. Am J Cardiol 2012; 109:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/84\">",
"      Mirrahimi A, de Souza RJ, Chiavaroli L, et al. Associations of glycemic index and load with coronary heart disease events: a systematic review and meta-analysis of prospective cohorts. J Am Heart Assoc 2012; 1:e000752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/85\">",
"      Rimm EB, Ascherio A, Giovannucci E, et al. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996; 275:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/86\">",
"      Wolk A, Manson JE, Stampfer MJ, et al. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women. JAMA 1999; 281:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/87\">",
"      Law MR, Morris JK. By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease? Eur J Clin Nutr 1998; 52:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/88\">",
"      Vanharanta M, Voutilainen S, Lakka TA, et al. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet 1999; 354:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/89\">",
"      Vanharanta M, Voutilainen S, Rissanen TH, et al. Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2003; 163:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/90\">",
"      Dauchet L, Amouyel P, Dallongeville J. Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. Neurology 2005; 65:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/91\">",
"      Dehghan M, Mente A, Teo KK, et al. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation 2012; 126:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/92\">",
"      Bernstein AM, Sun Q, Hu FB, et al. Major dietary protein sources and risk of coronary heart disease in women. Circulation 2010; 122:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/93\">",
"      Pan A, Sun Q, Bernstein AM, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med 2012; 172:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/94\">",
"      Floegel A, Pischon T, Bergmann MM, et al. Coffee consumption and risk of chronic disease in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany study. Am J Clin Nutr 2012; 95:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/95\">",
"      Paffenbarger RS Jr, Hyde RT, Wing AL, et al. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/96\">",
"      Leon AS, Connett J, Jacobs DR Jr, Rauramaa R. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. JAMA 1987; 258:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/97\">",
"      Lee DC, Sui X, Artero EG, et al. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study. Circulation 2011; 124:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/98\">",
"      Sandvik L, Erikssen J, Thaulow E, et al. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993; 328:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/99\">",
"      Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989; 262:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/100\">",
"      LaMonte MJ, Eisenman PA, Adams TD, et al. Cardiorespiratory fitness and coronary heart disease risk factors: the LDS Hospital Fitness Institute cohort. Circulation 2000; 102:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/101\">",
"      Laukkanen JA, Lakka TA, Rauramaa R, et al. Cardiovascular fitness as a predictor of mortality in men. Arch Intern Med 2001; 161:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/102\">",
"      Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/103\">",
"      Barlow CE, Defina LF, Radford NB, et al. Cardiorespiratory fitness and long-term survival in \"low-risk\" adults. J Am Heart Assoc 2012; 1:e001354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/104\">",
"      Held C, Iqbal R, Lear SA, et al. Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. Eur Heart J 2012; 33:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/105\">",
"      Berry JD, Willis B, Gupta S, et al. Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study. J Am Coll Cardiol 2011; 57:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/106\">",
"      Eckel RH, York DA, R&ouml;ssner S, et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004; 110:2968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/107\">",
"      Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/108\">",
"      Wolk R, Berger P, Lennon RJ, et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007; 28:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/109\">",
"      Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011; 364:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/110\">",
"      Wilson PW, Bozeman SR, Burton TM, et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008; 118:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/111\">",
"      Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/112\">",
"      Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/113\">",
"      Koenig W, Sund M, Fr&ouml;hlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/114\">",
"      Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/115\">",
"      Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/116\">",
"      Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/117\">",
"      Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/118\">",
"      U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/119\">",
"      Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/120\">",
"      Reich D, Patterson N, Ramesh V, et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet 2007; 80:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/121\">",
"      IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/122\">",
"      Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/123\">",
"      Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/124\">",
"      Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/125\">",
"      Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/126\">",
"      Karakas M, Koenig W, Zierer A, et al. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med 2012; 271:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/127\">",
"      Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007; 49:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/128\">",
"      Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/129\">",
"      Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/130\">",
"      Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/131\">",
"      Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/132\">",
"      Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/133\">",
"      Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/134\">",
"      Tiret L, Godefroy T, Lubos E, et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005; 112:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/135\">",
"      Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005; 111:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/136\">",
"      Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/137\">",
"      Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/138\">",
"      Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. J Am Coll Cardiol 2002; 39:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/139\">",
"      Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/140\">",
"      Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/141\">",
"      Rold&aacute;n V, Mar&iacute;n F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 2003; 90:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/142\">",
"      Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/143\">",
"      Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/144\">",
"      Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/145\">",
"      Koenig W, Khuseyinova N, L&ouml;wel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/146\">",
"      Blake GJ, Dada N, Fox JC, et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001; 38:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/147\">",
"      Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007; 82:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/59/39866/abstract/148\">",
"      Jobs E, Ingelsson E, Ris&eacute;rus U, et al. Association between serum cathepsin S and mortality in older adults. JAMA 2011; 306:1113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1506 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39866=[""].join("\n");
var outline_f38_59_39866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2628519\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4873132\">",
"      CHD RISK EQUIVALENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4874544\">",
"      Noncoronary atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4873275\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4873282\">",
"      - Hyperglycemia without overt diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4873605\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESTABLISHED RISK FACTORS FOR ATHEROSCLEROTIC CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factor prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4873728\">",
"      Risk factors in childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age and gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Reliability of self-reported family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4874043\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lipids and lipoproteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lifestyle factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4872547\">",
"      - Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4872729\">",
"      - Diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4872925\">",
"      - Lack of moderate alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4486076\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Psychosocial factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Inflammatory markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4482486\">",
"      - C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H835935\">",
"      - Interleukin-6",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4240764\">",
"      - Myeloperoxidase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4482589\">",
"      - Other inflammatory markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9708405\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29702838\">",
"      Mediastinal radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4485836\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4482421\">",
"      Microalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2628519\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1506\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1506|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/26/37294\" title=\"figure 1\">",
"      Age adjusted death rates for CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/58/14254\" title=\"figure 2\">",
"      Deaths from cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25086\" title=\"figure 3\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/5/21598\" title=\"figure 4\">",
"      Pravastatin prevents CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/30/24045\" title=\"figure 5\">",
"      Pravastatin CARE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/19/317\" title=\"figure 6\">",
"      Increasing plasma cholesterol and coronary risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/43/34493\" title=\"figure 7\">",
"      CRP risk future MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1506|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/51/25403\" title=\"table 1\">",
"      Risk factors coronary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/57/8091\" title=\"table 2\">",
"      Risks for common diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/25/18844\" title=\"table 3A\">",
"      Components cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/41/35484\" title=\"table 3B\">",
"      Classification and management of blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/39/32379\" title=\"table 4\">",
"      ATPIII classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/4/11340\" title=\"table 5\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/46/10989\" title=\"table 6\">",
"      Proposed ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/23/20861\" title=\"table 7\">",
"      AHA recs for exercise and diet counseling",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17498?source=related_link\">",
"      Benefits and risks of caffeine and caffeinated beverages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=related_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=related_link\">",
"      Management of asymptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3641?source=related_link\">",
"      Obesity, weight reduction, and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/17/27930?source=related_link\">",
"      Pathogenesis of atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25352?source=related_link\">",
"      Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25528?source=related_link\">",
"      Psychosocial factors in coronary and cerebral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_59_39867="Psychosocial factors LBP";
var content_f38_59_39867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Psychosocial factors associated with persistent low back pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General or work-related beliefs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Belief that pain and activity are harmful",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fear avoidance behavior (avoidance of activities due to fear of increased pain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catastrophizing (excessive focus on pain and feeling of helplessness to control pain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expectation that passive treatments/rehabilitation will work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expectation of increased pain with return to work or activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Work-related factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor control of one's job environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low job satisfaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short job attachment (recent hire)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limited work skills/experience",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior workers' compensation claim or time off work due to injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Litigation case (attorney involved)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physically demanding work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other affective factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression or mood symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Socially withdrawn (lack of family/social support)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39867=[""].join("\n");
var outline_f38_59_39867=null;
var title_f38_59_39868="Diagnostic imaging in acute aortic dissection";
var content_f38_59_39868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guidelines: diagnostic imaging in acute aortic dissection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Transthoracic echocardiography followed by transesophageal echocardiography",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        2. Computed tomography",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        if detection of tears is crucial",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        3. Contrast angiography &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        to define anatomy in visceral malperfusion and to guide percutaneous interventions",
"       </td>",
"       <td class=\"sublist_other\">",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        in stable patients",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        routine preoperative coronary angiography",
"       </td>",
"       <td class=\"sublist_other\">",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        in hemodynamically unstable patients",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Magnetic resonance imaging",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        in hemodynamically unstable patients",
"       </td>",
"       <td class=\"sublist_other\">",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        5. Intravascular ultrasound",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        to guide percutaneous interventions",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence",
"of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        &nbsp;Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that",
"the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from Erbel, R, Alfonso, F, Boileau, C, et al, Eur Heart J 2001; 22:1642.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39868=[""].join("\n");
var outline_f38_59_39868=null;
var title_f38_59_39869="Immediate release preparations";
var content_f38_59_39869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immediate-release stimulant preparations for children with attention deficit hyperactivity disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication (how supplied)",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;US trade name (generic availability)",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;Duration of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose advancement*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dose (per day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Methylphenidate",
"        </p>",
"        <p>",
"         (5, 10, 20 mg tablets; 2.5, 5, 10 mg chewable tablets; 5 mg/5 mL flavored oral solution, 10 mg/5 mL flavored oral solution)",
"        </p>",
"       </td>",
"       <td class=\"indent1\">",
"        <p>",
"         Ritalin",
"         <sup>",
"          &reg;",
"         </sup>",
"         (generic available)",
"        </p>",
"        <p>",
"         Methylin",
"         <sup>",
"          &reg;",
"         </sup>",
"         chewable tablets (generic available)",
"        </p>",
"        <p>",
"         Methylin",
"         <sup>",
"          &reg;",
"         </sup>",
"         oral suspension (generic available)",
"        </p>",
"       </td>",
"       <td class=\"indent1\">",
"        3 to 5 hours&nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         5 mg/day x 1 day; then",
"        </p>",
"        <p>",
"         5 mg 2 times per day",
"        </p>",
"        <p>",
"         Children &le;25 kg may be started with 2.5 mg per day.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Increments of 5 mg per day every 3 to 7 days",
"        </p>",
"        <p>",
"         Children &le;25 kg may be increased by 2.5 mg per day every 3 to 7 days.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &le;25 kg: 35 mg",
"        </p>",
"        <p>",
"         25 kg: 60 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Dexmethylphenidate",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         (2.5, 5, 10 mg tablets, non-scored)",
"        </p>",
"       </td>",
"       <td class=\"indent1\">",
"        Focalin",
"        <sup>",
"         &reg;",
"        </sup>",
"        (generic available)",
"       </td>",
"       <td class=\"indent1\">",
"        5 to 6 hours",
"       </td>",
"       <td>",
"        2.5 mg 2 times per day (patients not taking methylphenidate). For patients taking methylphenidate dose is half current daily dose up to 10 mg twice per day.",
"       </td>",
"       <td>",
"        Increments of 2.5 to 5 mg&nbsp;per day every 3 to 7 days",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        <p>",
"         Dextroamphetamine",
"        </p>",
"        <p>",
"         (5, 10 mg scored tablets; 5 mg/5mL flavored oral solution)",
"        </p>",
"       </td>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Dexedrine",
"        <sup>",
"         &reg;",
"        </sup>",
"        ,",
"        <p>",
"         DextroStat",
"         <sup>",
"          &reg;",
"         </sup>",
"         (generic available), ProCentra",
"         <sup>",
"          &reg;",
"         </sup>",
"         oral solution",
"        </p>",
"       </td>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        4 to 6 hours",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        3 to 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         2.5 mg/day x 1 day",
"        </p>",
"        <p>",
"         2.5 mg 2 times/day",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increments of 2.5 mg per day every 3 to 7 days",
"       </td>",
"       <td class=\"sublist_other\">",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        &ge;6 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         5 mg x 1 day",
"        </p>",
"        <p>",
"         5 mg 2 times/day",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increments of 5 mg per day every 3 to 7 days",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         &le;50 kg: 40 mg",
"        </p>",
"        <p>",
"         &gt;50 kg: 60 mg",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        <p>",
"         Amphetamine-dextroamphetamine",
"        </p>",
"        <p>",
"         (5, 7.5, 10, 12.5, 15, 20, 30 mg scored tablets)",
"        </p>",
"       </td>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        <p>",
"         Adderall",
"         <sup>",
"          &reg;",
"         </sup>",
"         (generic available)",
"        </p>",
"       </td>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        4 to 6 hours",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        3 to 5 years",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         &le;50 kg: 40 mg",
"        </p>",
"        <p>",
"         &gt;50 kg: 60 mg",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         2.5 mg/day x 1 day",
"        </p>",
"        <p>",
"         2.5 mg 2 times/day",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increments of 2.5 mg per day every 3 to 7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        &ge;6 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         &ge;5 mg x 1 day",
"        </p>",
"        <p>",
"         5 mg 2 times/day",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increments of 5 mg per day every 3 to 7 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Doses of immediate-release preparations are given in morning on rising and at lunch time 4 to 6 hours later. Three times per day dosing is an option for children needing control of symptoms in late afternoon or early evening.",
"     <br>",
"      &bull; Dexmethylphenidate may not be an appropriate choice for children aged &lt;6 years due to its relatively higher potency and lack of commercially available chewable tablets or flavored oral solution.",
"      <br>",
"       &Delta; Doses above 40 mg per day total are rarely needed and warrant close monitoring for adverse effects.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      References:",
"     </p>",
"     <ol>",
"      <li>",
"       Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"      </li>",
"      <li>",
"       Subcommittee on attention-deficit/hyperactivity disorder, Steering committee on quality improvement and management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Supplemental information. Pediatrics 2011.",
"      </li>",
"      <li>",
"       Drugs for treatment of ADHD. Treat Guidel Med Lett 2011; 9:24.",
"      </li>",
"      <li>",
"       Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 2001; 22:183.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39869=[""].join("\n");
var outline_f38_59_39869=null;
var title_f38_59_39870="Confirmation of the triggers of anaphylaxis";
var content_f38_59_39870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Confirmation of the triggers of anaphylaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 273px; height: 439px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Proceed with caution. Allergen challenge tests should only be conducted in well-equipped medical facilities staffed with physicians and nurses who are trained in patient selection, in patient assessment on the day of challenge, and in prevention and treatment of anaphylaxis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39870=[""].join("\n");
var outline_f38_59_39870=null;
var title_f38_59_39871="SEER incidence of thyroid cancer in both sexes by race";
var content_f38_59_39871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    SEER incidence rates*, cancer of the thyroid, both sexes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 522px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).",
"    <div class=\"footnotes\">",
"     API: Asian/Pacific Islander; AI/AN: American Indian/Alaska Native.",
"     <br>",
"      * Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).",
"      <br>",
"       Regression lines are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2008 period allow a maximum of 5 joinpoints. Analyses for other ethnic groups during the period 1992-2008 allow a maximum of 3 joinpoints.",
"       <br>",
"        &sect; Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.",
"        <br>",
"         &yen; Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Howlader N, Noone AM, Krapcho M, et al (Eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Full report available at:",
"     <a href=\"file://seer.cancer.gov/csr/1975_2008/\" target=\"_blank\">",
"      file://seer.cancer.gov/csr/1975_2008/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_59_39871=[""].join("\n");
var outline_f38_59_39871=null;
            